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ABSTRACT 
c-Met is a tyrosine receptor kinase which is activated by its only ligand, the hepatocyte 
growth factor (HGF). Activation of c-Met leads to a wide spectrum of biological 
activities such as motility, angiogenesis, morphogenesis, cell survival and cell 
regeneration. c-Met and HGF knock-out mice are embryonic lethal. During 
embryogenesis, c-Met is required for liver, kidney and skeletal muscles development. In 
adult tissues, c-Met is involved in wound healing and hepatocyte regeneration. 
c-Met is abnormally activated in many tumours types. Aberrant c-Met activation was 
found to induce tumour development, tumour cell migration and invasion, and the worst 
and final step in cancer progression, metastasis. In addition, c-Met activation in cells 
was also shown to confer resistance to apoptosis induced by UV damage or 
chemotherapeutic drugs. c-Met is thus an attractive target for drug development. 
This study describes the development of monoclonal antibodies against c-Met as 
therapeutic molecules in cancer treatment/diagnostics. Antibodies were raised against 
the α-chain of c-Met. 21 hybridoma clones were single-cell cloned and subjected to 
preliminary monoclonal antibody characterisation. 11 monoclonal antibodies were 
finally selected for ascites production and antibody purification. These purified 
antibodies were characterised by Western blotting, immunofluorescence staining, 
functional assays (ERK phosphorylation and cell scatter) and for their ability to 
recognise native c-Met by flow cytometry. Some of the anti-α-chain c-Met antibodies 
perform better in Western blotting and immunofluorescence staining than the presently-
available commercial antibodies. The Mab 2.1 and 13.1 bind strongly to native c-Met in 
flow cytometry and may be potential candidates for antibody therapy and cancer 
diagnostics. 
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CHAPTER 1: INTRODUCTION 
Protein phosphorylation is required in signalling transduction pathways to relay 
messages within the cell. Tyrosine kinases, characterised by their ability to 
phosphorylate tyrosine residues in cellular proteins, play a role in signalling pathways 
resulting in the activation of cellular activities such as proliferation, differentiation and 
motility. Tyrosine kinases are grouped into two groups: cellular tyrosine kinases and 
receptor tyrosine kinases. Cellular tyrosine kinases, such as c-Src and c-Abl, are soluble 
intracellular proteins that are activated by ligand binding followed by receptor 
oligomerisation. Receptor tyrosine kinases contain an extracellular ligand binding 
domain, a transmembrane domain and an intracellular kinase domain. Similar to the 
cellular tyrosine kinases, receptor tyrosine kinases are activated upon ligand binding 
which will result in receptor oligomerisation and activation of catalytic domain. 
Examples of receptor tyrosine kinases are epidermal growth factor receptor (EGFR), 
vascular endothelial growth factor receptor (VEGFR) and hepatocyte growth factor 
receptor (HGFR/c-Met).  
1.1: Tyrosine kinases 
Tyrosine kinases are tightly regulated due to their importance in the regulation of 
cellular processes. Constitutive activation of receptor tyrosine kinases caused by 
receptor overexpression or mutation often led to cancer progression in human. Tyrosine 
kinases inhibitors aimed to block abnormal activation of tyrosine kinases have been 
developed for cancer therapy. The majority of anti-cancer drugs presently approved for 
therapy are monoclonal antibodies and small molecules inhibitors. Therapeutic 
monoclonal antibodies have been particularly successful against target receptor tyrosine 
kinases where the monoclonal antibodies exert their anti-cancer effect by competition 
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binding to the ligand with the receptor. This is followed by inhibition of receptor 
oligomerisation. Binding of therapeutic antibodies to the receptor then causes the 
induction of receptor down-regulation to eliminate receptor signalling or recruitment of 
host’s immune system to eliminate aberrant cells. Herceptin (trastuzumab) is an 
example of a monoclonal antibody that has been very successful in the treatment of 
metastatic breast cancer. Herceptin is a humanised murine monoclonal antibody 
developed against Her2. It binds to the Her2 on the cell surface and results in receptor 
internalisation (Shawver et al., 2002). Small molecules inhibitors are effective against 
both receptor and cellular tyrosine kinases. Most small molecule inhibitors are ATP 
analogs which targets the catalytic domain of tyrosine kinases. Due to the structural 
similarity among the catalytic domain of kinases, small molecule inhibitors can have an 
effect on multiple kinases. Imatinib mesylate (STI571) was developed against Bcr-Abl 
in the treatment of CML while, gefitinib (Iressa) and erlotinib (Tarceva) were developed 
against EGFR to treat non-small cell lung cancer.   
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1.2: The c-Met tyrosine kinase receptor 
1.2.1: Identification of c-met as an oncogene 
 c-met was first identified as an oncogene nearly two decades ago when a human 
osteogenic sarcoma (HOS) cell line was treated with the chemical carcinogen N-methyl-
N’-nitro-N-nitrosoguanidine (MNNG) (Park et al., 1986; Rong et al., 1992). Hence the 
name ‘Met’. Treatment with MNNG caused a gene rearrangement resulting in the 
fusion of DNA sequences from translocated promoter region (tpr) in chromosome 1 
with c-met in chromosome 7 (Peruzzi and Bottaro, 2006). This gave rise to a chimeric 
protein (TPR-Met) consisting of an N-terminal leucine-zipper protein-protein 
dimerisation motif and a C-terminal kinase domain expressed from tpr and c-met 
respectively. TPR-Met was found to have constitutive kinase activity with transforming 
abilities (Jeffers, 1999). Further work then identified c-Met as a tyrosine kinase receptor 
that is responsible for a wide spectrum of biological activities in the cell. The c-Met 
ligand was later identified as a cytokine known as hepatocyte growth factor (HGF) or 
scatter factor (SF) (Naldini et al., 1991). While c-Met is mostly expressed in cells of 
epithelial origin like hepatocytes, it is also expressed in endothelial cells and neurons. 
HGF/SF is expressed in mesenchymal cells. This receptor-ligand pair allows 
communication between mesenchymal and epithelial cells that is important for 
regulating the interactions between these two groups of cells. c-Met is required for liver 
and placental development during embryogenesis. In adult tissues, c-Met is required for 
tissue repair and hepatocyte regeneration (Birchmeier and Gherardi, 1998).   
In vitro experiments show that c-Met activation can cause epithelial cell scattering, 
proliferation and epithelial tubulogenesis. In vivo, c-Met de-regulation induces tumour 
development, tumour cell migration and invasion, metastasis and angiogenesis 
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(Birchmeier et al., 2003). c-Met is expressed in a wide variety of human cancers and is 
believed to play a critical role in the advanced, metastatic phase of the disease (Migliore 
and Giordano, 2008). Aberrant expression of c-Met correlates with poor disease 
prognosis (Appendix 1) and recently, has been demonstrated to cause acquired 
resistance to epidermal growth factor receptor (EGFR) inhibitors (Engelman et al., 
2007; Migliore and Giordano, 2008). c-Met’s role in a wide spectrum of activities, 
involvement in tumour progression and main role in tumour metastatic progression 
makes c-Met an attractive target for the development of cancer therapeutics. 
 
1.2.2: The structure of c-Met 
c-Met is a 190 kD tyrosine kinase receptor made up of an extracellular α-chain which is 
linked by a disulphide bond to a transmembrane β-chain (Figure 1.1). c-Met is 
synthesised as a 170 kD single polypeptide that is proteolytically cleaved to form the α-
chain and the β-chain (Tempest et al., 1988). Cleavage of c-Met occurs in the post-
Golgi compartment by the endoprotease, furin (Mondino et al., 1991). The α-chain is 50 
kD and constitutes part of the sema domain. The sema domain is a conserved domain 
shared by semaphorins and plexins. This domain adopts a seven-bladed beta-propeller 
structure which is important for homo-dimerisation. In c-Met, both the α-chain and the 
β-chain form the sema domain that is necessary and sufficient for receptor dimerisation 
and ligand binding (Kong-Beltran et al., 2004).  
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Figure 1.1: Schema of c-Met protein structure.  
c-Met is a tyrosine kinase receptor made up of an α-chain and a β-chain. The sema domain (green box), 
PSI domain (pink octagon) and four IPT domains (orange box) are displayed on the cell surface. The α-
chain is disulphide-linked to the β-chain (yellow line). The cytoplasmic domain of c-Met is made up of 
the juxtamembrane (purple diamond), kinase domain (blue box) and a C-terminal docking site for c-Met 
downstream signalling. Two negative regulatory sites (S985 and Y1003) are present in the 
juxtamembrane region. Activation of c-Met leads to autophosphorylation of Y1234 and Y1235. This 
results in a conformational change which will expose and transphosphorylate Y1349 and Y1356. pY1349 
and pY1356 are then available for downstream signalling proteins to bind.   
 
The β-chain is a 140 kD peptide consist of an extracellular domain, a transmembrane 
domain and a cytoplasmic domain (Figure 1.1). The extracellular portion of the β-chain 
makes up the reminder of the sema domain. Adjacent to the sema domain, lies the 
Plexin, Semaphorin, Integrin (PSI) domain, also known as the Met-related sequence 
(MRS) (Corso et al., 2005; Kong-Beltran et al., 2004). The PSI domain is a cysteine-
rich motif made up of 80 amino acids which can also be found in plexins, semaphorins 
and integrins. Four IPT (Immunoglobulin-like regions in Plexin and Transcription 
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factors) repeats follow after the PSI domain (Kong-Beltran et al., 2004). It is proposed 
that the IPT repeats might form a ‘stalk’ structure that supports the sema domain for 
ligand binding (Birchmeier et al., 2003). The cytoplasmic portion of c-Met β-chain 
contains the juxtamembrane region followed by a kinase domain and a carboxyl-
terminal tail. The carboxyl-terminal tail is essential for c-Met downstream signalling as 
it contains the docking site for signalling and adapter proteins that bind to c-Met. 
 
1.2.3: The c-Met ligand 
The only known ligand for c-Met is the soluble cytokine hepatocyte growth factor 
(HGF). HGF was independently identified as a hepatocyte growth factor and a cell 
motility inducer and has been called both hepatocyte growth factor and scatter factor 
(SF). Further experiments subsequently proved HGF and SF to be the same molecule 
(Naldini et al., 1991). HGF is a large glycoprotein that is closely related to the blood 
protease precursor, plasminogen. HGF is first translated into a 92 kD inactive pro-
polypeptide that is secreted into the extracellular environment. Upon secretion, HGF is 
cleaved to form an active heterodimer made up of an α-chain and a β-chain linked by 
disulphide bridges (Figure 1.2). Site-directed mutagenesis of amino acid 494 in HGF 
produces an uncleavable HGF. Interestingly, single chain pro-HGF is still able to bind 
to c-Met with the same affinity (Hartmann et al., 1992), but is unable to elicit c-Met 
biological responses (Bardelli et al., 1994; Naka et al., 1992). 
The α-chain of HGF contains an N-terminal hair-pin loop (N) followed by four kringle 
domains (K1 to K4) (Figure 1.2). The α-chain alone, containing the N-terminal hair-pin 
loop with the first kringle up to the third kringle, is sufficient to bind to the sema 
domain of c-Met. As mentioned above, the sema domain of c-Met is both necessary and 
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sufficient for HGF binding and dimerisation of c-Met (Kong-Beltran et al., 2004; 
Tolbert et al., 2007). HGF β-chain contains a typical serine protease domain (SPH) 
devoid of serine protease activity due to point mutations in the catalytic domain 
(Birchmeier and Gherardi, 1998). This smaller β-chain, when expressed separately, is 
unable to bind to c-Met, but is crucial for optimal c-Met activation (Cao et al., 2001).  
 
 
Figure 1.2: Schema of HGF protein structure.  
Hepatocyte growth factor (HGF) is the only know ligand for c-Met. Pro-HGF is translated as a single 
chain molecule and is activated by amino acid cleavage at residue 494. This forms a heterodimer made up 
of an α-chain and a β-chain linked by disulphide bridges (yellow line). The α-chain is consists of an N-
terminal (N) hairpin loop (orange box) and four kringle (K) domains (red octagon). A serine protease 
domain (SPH) devoid of serine protease activity lies in the β-chain. Adapted from Birchmeier et al., 2003. 
 
Naturally occurring splice variants, NK1 (HGF N-terminal domain with the first kringle 
domain) and NK2 (HGF N-terminal domain with the first two kringle domain), 
generated from alternative splicing of the original transcript were found to bind to c-Met 
(Cioce et al., 1996; Hartmann et al., 1992). These splice variants were shown to 
partially activate/block c-Met biological activities and further work has been performed 
to convert these molecules into therapeutic drugs that contained full antagonist activity 
towards c-Met (Tolbert et al., 2007). 
Although the mechanism of HGF binding to c-Met remains unclear, dimerisation of 
HGF has been thought to promote binding to c-Met and induce c-Met dimerisation on 
the cell surface leading to the activation of c-Met. Dimerisation of c-Met was reported 
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to be required, but not sufficient, for c-Met activation by Tolbert et al. (2007).  In vitro 
studies of the NK1 isoform binding to the sema domain of c-Met suggests that HGF 
binds to c-Met in a 2:2 stoichiometry, thus forming a uniform dimer complex (Tolbert et 
al., 2007).  Mutations in the four main residues (Y124, K85, D123 and N127) that lie in 
the NK1-NK1 dimer interface were shown to abolish c-Met dimerisation activity 
(Tolbert et al., 2007). The details of Met-HGF interaction are still not clear and 
although the crystal structure has been solved, the structures are of poor quality (low 
resolution). In addition, the crystal structures only represent part of Met-HGF 
interaction as truncated proteins were used in the crystallisation. More work is thus 
required to fully understand the activation of c-Met by HGF. 
 
1.2.4: Activation of c-Met 
Binding of HGF/SF to c-Met activates a cascade of downstream signalling events which 
induce cell motility, metastasis, angiogenesis, morphogenesis, cell survival and cell 
regeneration. HGF/SF binds to c-Met in the presence of Mg2+ ions and ATP (Bardelli et 
al., 1994; Stella and Comoglio, 1999). Upon ligand binding the c-Met receptor 
dimerises which results in autophosphorylation of tyrosine residues in the kinase 
domain (Figure 1.1). Tyrosine residues Y1230, Y1234 and Y1235 are part of a ‘three 
tyrosine motif’ that is conserved in other tyrosine kinase receptors (Bardelli et al., 
1994). Phosphorylation of Y1234 and Y1235 are essential for full kinase activity. In 
vitro experiments show that substitution of either Y1234 or Y1235 with phenylalanine 
results in as significant reduction of c-Met kinase activity. Substitution of both tyrosine 
residues renders the receptor completely incapable of transphosphorylation and 
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activation. However, substitution of Y1230 alone has no effect on c-Met kinase activity 
(Bardelli et al., 1994).    
Autophosphorylation of Y1234 and Y1235 is thought to induce a conformational 
change in c-Met, exposing the docking site (Y1349VNVXXXY1356VHV) in the carboxyl-
terminal tail of c-Met (Birchmeier et al., 2003). This results in transphosphorylation of 
tyrosine residues Y1349 and Y1356. The c-Met docking site is both necessary and 
sufficient to mediate c-Met signal transduction and biological activities (Rosario and 
Birchmeier, 2003). Mutation of both Y1349 and Y1356 results in loss of c-Met 
biological functions (Ponzetto et al., 1994). Once Y1349 and Y1356 are 
phosphorylated, the docking site becomes available for recruitment of adaptor and 
signalling molecules. Most of these signalling and adaptor proteins contain a SH2 (Src 
Homology 2) domain that recognises and binds to regions containing either pY1349 or 
pY1356.  
Recruitment of proteins to the c-Met docking site results in the activation of various 
signalling pathways including the AKT/PI3K, RAS/MAPK and STAT pathways. The 
AKT/PI3K pathway is activated by the binding of the subunit of p85, a subunit of PI3K, 
to the docking site of c-Met. This results in a downstream signal that leads to the 
inhibition of protein molecules like caspase-9 and Bad, promoting cell survival and 
resistance to apoptosis (Birchmeier et al., 2003). c-Met is also able to induce cell cycle 
progression and proliferation by signalling through the RAS/MAPK pathway. 
Activation of the ERK/MAPK pathway occurs via the binding of the adaptor proteins 
Grb2/SOS complex to the c-Met docking site (Christensen et al., 2003). The Grb2/SOS 
complex activates Ras and Raf which are part of the MAPK signalling cascade. The 
ERK/MAPK pathway is also capable of inducing cell migration and invasion by 
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activating matrix metalloproteinases and urokinase plasminogen activators. Finally, the 
ERK/MAPK pathway is able to induce alterations in cytoskeleton functions that are 
essential for cell migration. The invasive properties of c-Met are also induced through 
the STAT pathway. STAT3 is activated by binding to the docking site of c-Met. Once 
activated, STAT3 translocates to the nucleus as a transcription factor to initiate 
transcription of genes involved in cell invasion. 
Of the many different proteins that are recruited to the docking site of c-Met, the most 
crucial and unique protein is the Gab1 (Growth factor receptor bound protein 2-
Associated Binder 1). Gab1 null mice display the same phenotypic defects as HGF/SF 
null and c-Met null mice, demonstrating the importance of Gab1 in c-Met signalling 
(Rosario and Birchmeier, 2003). Gab1 is an adaptor protein. The direct mode of 
interaction between c-Met and Gab1 is through the unique Met-binding site (MBS) in 
Gab1. This 13 amino acid site does not resemble any classical SH2 or phospho-
tyrosine-binding (PTB) domains (Birchmeier et al., 2003). The MBS is not shared with 
other family members of the Gab family and allows direct interaction with c-Met, but 
not with other receptors. It is thought that the MBS site allows a more stable and 
prolonged interaction with c-Met, thus resulting in a prolonged Gab1 phosphorylation 
and activation (Birchmeier et al., 2003; Rosario and Birchmeier, 2003). Alternatively, 
Gab1 activation by c-Met may also occur indirectly by binding to Grb2. Grb2 can only 
bind to the region containing pY1356 of c-Met through its SH2 domain. Gab1 then 
binds to the SH3 domain of Grb2 to be activated. Both ways of Gab1 activation (direct 
or indirect activation) creates multiple binding sites for signalling molecules to bind. 
Such molecules include PI3K, PLCγ, SHP2 and Shc.  
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Aberrant c-Met activation causes a normal cell to acquire malignant phenotype. Such 
cells lose its adheren properties, attain fibroblast-shape and increase its motility – a 
behaviour characterised as epithelial-mesenchymal transition (EMT). EMT is an 
important morphological process during embryonic development and is recognised as a 
mechanism for cancer progression. Given the complex and vast number of cytoplasmic 
protein recruited to activated c-Met, it is a challenge to dissect the signalling pathways 
employed by c-Met to induce EMT. Molecular studies have shown that recruitment of 
PI3K and Src to activated c-Met is necessary for EMT to occur during embryonic 
development (Thiery, 2002). Activation of PI3K by c-Met activation leads to down 
regulation of E-cadherin in epithelial cells. E-cadherin is a component of adheren 
junction complex and is required for stable cell-cell contact. PI3K was found to activate 
the Rho family GTPase which causes alterations in actin polymerisation and cellular 
adhesion. Two Rho family GTPase, RacI and Cdc42, are required for adheren junction 
assembly, lamellipodia formation and cell movement (Rosario and Birchmeier, 2003). 
Activation of c-Met also phosphorylates β-catenin at the cell membrane. Phosphorylated 
β-catenin is translocated to the nucleus where it acts as a transcription factor. The Ras-
ERK pathway is activated upon HGF stimulation. Activation of Ras via Grb2 (Figure 
1.3), which in turn activates the PI3K and MAPK pathways, was also shown to promote 
cell motility by disassembling adherent junctions.    
c-Met activation leads to the induction of a wide array of signalling pathways and a 
detailed discussion on all the signalling pathways involved is outside the scope of this 
report. Very often, these complex pathways interact to bring about the pleiotropic 
functions of c-Met. The final biological outcome of c-Met signalling depends on the 
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type of cells, duration and strength of signalling and interaction with other proteins on 
the cell surface.  
 
Figure 1.3: Simplified diagram of c-Met induced signalling pathways.  
Adapted from Abounader and Laterra (2005). 
 
1.2.5: Negative regulation of c-Met 
The juxtamembrane region of c-Met contains two negative regulatory sites for c-Met. 
Protein kinase C or Ca2+/calmodulin-dependent kinase phosphorylate c-Met at serine 
residue 985 to inhibit c-Met function (Birchmeier et al., 2003; Corso et al., 2005; 
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Gandino et al., 1994). The other negative regulatory site lies on tyrosine residue 1003. 
The E3 ubiquitin ligase, Cbl, recognises and binds to pY1003 (Peschard et al., 2001). 
Upon HGF/SF binding, c-Met is rapidly poly-ubiquitinated by Cbl. This induces 
endocytosis of c-Met, followed by transportation to the lysosome for degradation 
(Hammond et al., 2001). c-Met has also been reported to be degraded via the ubiquitin-
proteosomal pathway (Jeffers et al., 1997b) which was verified further by Hammond et 
al. (2001). However, Hammond et al. (2001) suggested the c-Met is being degraded by 
both the lysosomal and proteosomal pathways, with the former being the main route for 
c-Met degradation. Removal of c-Met from the cell surfaces is thus a mechanism to 
terminate and control c-Met signalling. The Y1003 regulatory site was found to be 
absent in the constitutive active c-Met mutant, Tpr-Met. 
Recently, shedding of the c-Met extracellular domain has been demonstrated to down 
regulate c-Met expression. Cells treated with the anti-Met monoclonal antibody, DN30, 
were reported to shed the c-Met extracellular domain. This results in the loss of the 
HGF-binding domain of c-Met from the cell surface, thus reducing c-Met signal 
transduction and releasing a 130 kD fragment into the cell media. This 130 kD c-Met 
fragment was capable of blocking HGF-induced signal transduction most probably by 
acting as a decoy to sequester unbound HGF in the extracellular matrix (Petrelli et al., 
2006). 
 
1.2.6: c-Met activation in adults and development 
During development, c-Met is expressed in epithelial cells of various organs, while 
HGF/SF is expressed in the adjacent mesenchyme. Through the secretion of HGF/SF, 
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mesenchymal cells are able to communicate to the epithelial cells which will ‘interpret’ 
the message to bring about changes in physiological processes, such as cell 
proliferation, cell migration, tubulogenesis and cell invasion, required for proper 
embryonic development and tissue organisation. Through such physiological processes, 
c-Met is involved in muscle development, nervous system formation, hematopoietic 
differentiation, bone remodelling and angiogenesis.  
c-Met and HGF/SF knock-out mice are embryonic lethal (Stella and Comoglio, 1999). 
Examination of the knock-out mouse embryos shows that they have severe defects in 
liver and placental development. HGF/SF and c-Met are required during development to 
control cell survival and proliferation of hepatocytes, as well as the formation of the 
placenta. Further examination of the mutant embryo showed that the liver is present, but 
small in size with extensive loss of parachymal cells. However, it is the failure of the 
developing placenta to support the developing embryo that causes the eventual death of 
the embryo. The placental labyrinth layer, formed by the epithelial trophoblast, is found 
to be greatly reduced. The defective placental is thus unable to supply sufficient oxygen 
and nutrients to the developing embryo. c-Met and HGF/SF null mice also show defects 
in limb muscle formation. Migration of myoblast precursors from the dermomyotome to 
the limb, where skeletal muscles are formed, requires c-Met-HGF/SF signalling. c-Met 
is expressed by the myoblast precursors. Cells adjacent to the dermomyotome and along 
the route to the limb guide the migrating myoblast precursors to their final destination 
by expressing HGF/SF (Birchmeier et al., 2003). 
c-Met signalling is also crucial for normal establishment of tissue patterning during 
development (Corso et al., 2005). In the adult, when tissue patterning has been well-
established, c-Met function becomes dispensable. c-Met is only required in the adult for 
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wound healing (Chmielowiec et al., 2007), hepatocyte regeneration and during post-
natal physiology. In fact, when c-Met expression is turned off in adult mice containing 
inducible c-Met expression, the mice have almost no defects except for the inability to 
regenerate tissue after an injury.  
 
1.2.7: c-Met in Cancer 
In normal physiological conditions, c-Met activation is only a transient event. However, 
in tumour cells, c-Met is often constitutively active. Constitutive activation of c-Met 
signalling pathways correlates with hyperproliferation, tumour cell invasion, tumour 
angiogenesis and poor prognosis in various human cancers. In addition, c-Met 
signalling protects the tumour cell by inhibiting apoptosis and inducing resistance 
towards cancer therapy, thus hampering the efforts of tumour treatment.  
The oncogenic role of c-Met has been documented in numerous cancers and examined 
in many in vitro studies. Xenograft models have also convincingly demonstrated the 
reduction of tumour size and tumour angiogenesis upon c-Met inhibition (Abounader 
and Laterra, 2005). A list, containing c-Met and HGF expression levels obtained from 
human cancer biopsies and the disease prognosis, is available in Appendix 1. 
Overexpression of c-Met, often discovered in gastric cancers, is the most common cause 
of aberrant c-Met signalling in human cancers. Linkage analysis revealed that germline 
activating mutations in the kinase domain of c-Met result in hereditary forms of cancers 
such as hereditary papillary renal carcinomas, childhood hepatocellular carcinomas and, 
head and neck squamous-cell carcinomas (Giordano et al., 2005). Autocrine expression 
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of HGF is often observed in glioblastoma. HGF promotes endothelial cell proliferation, 
migration and blood vessel formation in glioblastoma (Abounader and Laterra, 2005).   
c-Met activation in cancer may be grouped into two categories, ligand-independent and 
ligand-dependent. In the absence of HGF/SF, overexpression of c-Met leads to 
spontaneous receptor dimerisation and activation of c-Met. Overexpression of c-Met 
could be due to gene amplification caused by chromosomal duplication, or by 
increasing c-Met gene transcription by oncogenes such as Ras and ETS (Furlan et al., 
2008). c-Met gene amplification is one of the most common causes of aberrant c-Met 
expression in cancers. Fluorescence in situ hybridisation (FISH) analysis of c-Met gene 
amplification in gastric cell lines indicates that the c-Met locus is a result of targeted 
amplification rather than chromosomal aneuploidy (Smolen et al., 2006). 
Environmental stimuli such as hypoxia may also induce and increase c-Met 
transcription by acting on the c-Met promoter region. Hypoxia increases c-Met 
expression by 3-fold which is sufficient to activate c-Met and induce branching 
morphogenesis (Pennacchietti et al., 2003). Another ligand-independent mechanism of 
c-Met activation is caused by mutation. Mis-sense mutations in c-Met have been 
identified in both hereditary and sporadic forms of renal papillary carcinoma (Jeffers et 
al., 1997a). These activating mutations were mostly in the tyrosine kinase domain of c-
Met, which resulted in the constitutive and abnormal activation of c-Met kinase activity 
leading to tumour malignancies. The fully active c-Met mutant containing both 
mutations in L1213V and M1268T was found to activate c-Met and cause a full range 
of c-Met biological changes without autophosphorylation of Y1234, Y1235 and Y1349, 
Y1356 (Jeffers et al., 1997a). These mutations were thought to alter and stabilise c-Met 
conformation in the active state thus bypassing the requirements for 
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autophosphorylating at Y1234 and Y1235. Interestingly, Jeffers et al. (1997) 
demonstrated that dimerisation of mutant c-Met is an absolute necessity for these 
activating mutations to cause c-Met activation. As mentioned earlier, the Tpr-Met 
chimeric protein caused by chromosomal translocation in vitro contains the N-terminal 
dimerising motif of TPR gene fused to the C-terminal kinase domain of c-Met. As the 
regulatory juxtamembrane domain of c-Met was found to be absent in Tpr-Met protein. 
The lack of a regulatory domain and the effects of the dimerisation motif from TPR, 
cause Tpr-Met self-dimerisation and a strong constitutive activation of c-Met tyrosine 
kinase activity. However, Tpr-Met protein in cancers was observed to be very rare 
(Corso et al., 2005). Finally, Mondino et al. reported the activation of c-Met due to 
defects in the post-translational processing of c-Met. A colon carcinoma cell line 
(LoVo) lacks the ability to cleave single chain c-Met precursor into the mature α and β 
chains due to defects in furin activity. Single-chain c-Met is expressed onto the cell 
surface and is self-activated. The mechanism whereby single-chain c-Met is able to self-
induce its tyrosine kinase activity remains unknown (Mondino et al., 1991). 
Ligand-dependent activation of c-Met in cancer may occur in an autocrine or paracrine 
manner. Autocrine activation of c-Met occurs when a cell expresses both HGF/SF and 
c-Met, thus self-activating c-Met signal transduction resulting in abnormal cellular 
processes. In certain tumours such as glioblastoma, autocrine activation of c-Met has 
been found occurring in the tumour cells. Paracrine activation occurs when surrounding 
stroma cells secrete high levels of HGF/SF constitutively. Abnormal secretion of 
HGF/SF into the extracellular matrix is detected by normal c-Met expressing cells. The 
abnormal amount of HGF/SF in the extracellular matrix thus results in abnormal and 
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constitutive activation of c-Met in the cells, which will lead to enhanced 
tumourigenicity and malignant progression of the normal cell into a cancer cell. 
Recent studies have emerged highlighting c-Met ability to crosstalk with cell surface 
receptors such as adhesive receptors (CD44 and integrins) and signalling transducing 
receptors (EGF family, FAS and B plexins). The molecular mechanisms of these 
interactions are not well-define and the physiological purpose is unclear. Individually, 
each c-Met crosstalk partner has a role in cancer progression and cooperate with c-Met 
to promote tumour growth and development (Corso et al., 2005) by reinforcing cMet 
signalling.  CD44v6, an isoform of CD44, was reported to form a complex with c-Met 
and HGF. While CD44v6 extracellular domain is involved in promoting c-Met and 
HGF interaction on the cell surface, the intracellular domain acts to amplify c-Met 
downstream signalling. c-Met anti-apoptotic activity is enhanced by the interaction with 
the death receptor FAS receptor. In a HGF-independent manner, c-Met binds to FAS 
receptor and is inhibits its activation. c-Met thus have a dual role by encouraging 
tumour cell survival through its own activated signalling pathway and inhibiting 
apoptosis via interaction with FAS. Enhanced cell invasion was observed in c-Met 
interaction with plexins. Plexins are receptors of semaphorins and are involved in 
cytoskeleton remodelling and cell adhesion. Both plexins and c-Met interact through 
their own sema domain which is a protein-protein interaction motif (Gherardi et al., 
2004). Finally, c-Met was demonstrated to crosstalk with members of the EGFR family 
to acquire drug resistance against EGFR drugs (e.g. gefitinib) in human cancer. 
Inhibition of c-Met activity using c-Met specific small molecules inhibitor (PHA-
665752) sensitise tumour cells to gefitinib (Engelman et al., 2007) and combine 
treatment of PHA-665752 and gefitinib showed tumour cell killing. 
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 1.2.8: c-Met and cancer therapy 
Aberrant c-Met expression was found in many cancers and the levels of c-Met 
expression often correlate with tumour aggression. While tumour cell lines containing 
amplification of c-Met were shown to be sensitive to the small molecule inhibitor PHA-
665752, non c-Met amplified tumour cell lines showed no sensitivity (Smolen et al., 
2006). This indicates dependence of the cancer cells on c-Met expression and by 
blocking c-Met activation, tumour cells were sensitised. In addition, c-Met function in 
adult human is largely dispensable. Results from adult mice that have c-Met gene 
expression turned off suggested that inactivation of c-Met would have few side effects. 
These makes c-Met is an attractive target for drug therapy and many groups have 
employed different strategies in attempts to block c-Met signalling for cancer therapy. 
They include c-Met/HGF competitive inhibitors, c-Met small molecule inhibitors and 
antibodies directed against c-Met/HGF. 
c-Met/HGF competitors 
NK4 molecule and decoy-Met are examples of competitive inhibitors of the Met-HGF 
interaction. NK4 is a synthetic, truncated variant of HGF α-chain containing the N-
terminal hair-pin loop and the four kringle domain. NK4 is able to compete with HGF 
for c-Met binding, but does not activate c-Met. It was shown to inhibit HGF-induced 
proliferation and angiogenesis in cell lines and to inhibit tumour growth and metastasis 
in xenograft models (Brockmann et al., 2003). Another promising molecule is decoy-
MET which is a soluble variant of c-Met, consisting of the entire extracellular domain 
of c-Met. Decoy-Met is able to bind to c-Met to prevent receptor dimerisation as well as 
to HGF thus preventing HGF from activating c-Met (Michieli et al., 2004). Compared 
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to NK4 molecule, decoy-Met has a higher affinity towards HGF and was also able to 
block tumour cell growth and metastasis in mice.  
Small molecule inhibitors 
Small molecule inhibitors of c-Met were found to be effective in inhibiting the c-Met 
signalling cascade by competing with ATP for the catalytic domain of c-Met, thus 
preventing c-Met from activation and phosphorylation of cytoplasmic proteins. AM7, 
SU11274 and PHA-665752 were separately identified as c-Met small molecule 
inhibitors, shown to block HGF-induced c-Met activity at nanomolar concentrations 
(Bellon et al., 2008; Christensen et al., 2003; Sattler et al., 2003; Wang et al., 2003). 
Interestingly, due to the differential binding of AM7 to c-Met, compared to SU11274, 
SU11274 was only effective on M1268T and H1112Y c-Met mutants while AM7 
showed inhibition against both wild-type and mutant c-Met (Bellon et al., 2008). Small 
molecules c-Met inhibitors show promising results. However, the likelihood of an ATP 
inhibitor having complete specificity towards the c-Met kinase is extremely small and 
there are concerns about the toxicity of these molecules if used as therapeutic molecules 
(Migliore and Giordano, 2008). XL880 (from Exelixis) and ARQ197 (from ArQule 
Inc.) are kinase inhibitors that have successfully gone into phase II of clinical trials 
(Migliore and Giordano, 2008). Other than c-Met, XL880 targets other tyrosine kinases. 
ARQ197 is a non-ATP-competitive molecule that binds outside of the c-Met ATP 
binding site. Clinical studies have demonstrated that these drugs have been well 
tolerated with anti-tumour activity (Migliore and Giordano, 2008). 
Monoclonal antibodies and their variants 
Monoclonal antibodies have been extremely successful as therapies against receptor 
protein kinases. The best known examples are Trastuzumab and Rituximab that target 
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HER-2 and CD20 respectively. Monoclonal antibodies function as receptor inhibitors 
by blocking the ligand from binding to the receptor or by preventing receptor 
oligomerisation. Currently, AMG102 from Amgen, is the only therapeutic antibody 
targeted at the Met-HGF axis that has gone through into clinical trials. AMG102 is a 
fully human IgG2 monoclonal antibody directed against HGF. It was shown to increase 
the cell growth inhibition of tumour cells in combination treatment with docetaxel or 
temozolomide compared with treatments with docetaxl or temozolomide alone (Jun et 
al., 2007). AMG102 was well tolerated in initial trials and is in the process of entering 
the second clinical phase. 
Other than AMG102, there are reports of other bivalent monoclonal antibodies 
developed against c-Met/HGF that can successfully block the receptor-ligand 
interaction. Prat et al. (1998) developed two monoclonal antibodies (DO-24 and DN-30) 
against the extracellular domain of c-Met. Interestingly, both monoclonal antibodies act 
as an agonist rather than an antagonist and activate c-Met signalling in vivo. It is 
hypothesized that the bivalent binding of an antibody could mimic the dimerising effect 
of HGF, thus causing c-Met dimerisation upon antibody binding. Attempts to block 
Met-HGF interaction by developing monoclonal antibodies against HGF were 
performed by Cao et al. (2001). However, none of the antibodies alone were capable of 
blocking HGF-induced c-Met activation. Only when three different monoclonal 
antibodies were used in combination, was c-Met activation blocked. Finally, the 
combination of using two fully human anti-Met antibodies (R13 and R28) was more 
effective in inhibiting c-Met binding to HGF as compared to using R13 or R28 alone 
(van der Horst et al., 2009).  Binding and activation of c-Met by HGF appears to be a 
complex interaction as more than one Met-HGF interaction site has to be blocked.  
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Despite the dimerisation effects of monoclonal antibodies on c-Met, antibodies were 
able to specifically target c-Met on the cell surface and induce an antagonist/agonist 
effect on c-Met activation. Other variants of antibodies were thus exploited for targeting 
c-Met in drug development. Genetech developed a one-armed (OA) variant of the anti-
human c-Met antibody 5D5 which showed promising results in orthotopic models. OA-
5D5 is a monovalent Fab recombinantly fused to a human Fc region. The heavy and 
light chains in the Fab region are made up of murine variable domains with human IgG1 
constant domains (Martens et al., 2006). OA-5D5 inhibits HGF binding to c-Met and 
showed inhibition of tumour cell proliferation, migration and angiogenesis with no 
signs of toxicity (Martens et al., 2006). OA-5D5 has gone into phase I of clinical trials. 
Novel strategies 
Other strategies have been employed to block Met-HGF interactions. Recently, a Met-
binding peptide (YLFSVHWPPLKA) screened from a phage display library was found 
to compete with HGF for binding to c-Met. Zhao et al. (2007) showed that the Met-
binding peptide is internalised by Met-expressing cells and is able to inhibit cell 
proliferation. However, peptides are generally not good therapeutic agents due to 
instability and protease cleavage. Peptides are usually developed to form 
peptidomimetic agents by substituting residues with non-naturally occurring amino 
acids. However, peptides are also useful for forming the starting point for the 
development of small molecule therapeutic agents.  Another strategy employed was to 
down regulate the mRNA levels of a target by the use of U1snRNA/ribozymes. 
U1snRNA/ribozyme chimeric molecule is made up of a hammerhead ribozyme, an 
U1snRNA and an anti-sense mRNA sequence of the target gene. Abounader et al. 
(2001) targeted c-Met and HGF mRNA levels by creating anti-c-Met-U1/ribozyme and 
anti-HGF-U1/ribozyme respectively. These U1/ribozymes were shown to successfully 
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inhibit c-Met activation, c-Met-activated biological activities in cell lines as well as 
inhibit tumour growth in glioma xenograft models. However, this therapeutic strategy 
requires complex delivery system such as virus or liposomes to efficiently deliver the 
molecules to the target site in vivo (Brockmann et al., 2003).      
Although all of these drugs demonstrate anti-tumour activity in xenograft models, their 
clinical activity still remains unknown. The aim of this project is to produce and screen 
for conventional and single chain antibodies that will bind c-Met and inhibit c-Met 
signalling. Promising molecules will be used in xenograft models to determine the 
effectiveness of these molecules in inhibiting tumour progression, tumour migration and 
invasion and angiogenesis. 
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1.3: Antibodies 
1.3.1: Introduction to antibodies 
Antibodies, also known as immunoglobulins (Ig), are glycosylated proteins secreted by 
plasma cells as part of the immune defence against foreign molecules in a body. Plasma 
cells are terminally differentiated B-cells, highly committed to secreting antibodies into 
the blood stream. Antibodies bind to antigens and facilitate their destruction by 
recruiting the host’s immune effector cells. This can either lead to the phagocytosis of 
the antibody-coated antigen or to the initiation of the complement system. Each B-cell 
expresses only one type of antibody that has a unique antigen-binding site. Since B-cells 
exist as clones, the progeny of a particular B-cell will only produce one type of antibody 
with a unique epitope.  
The basic structure of an immunoglobulin is a ‘Y’-shape molecule made up of four 
polypeptides. Two identical heavy chains and two identical light chains of an 
immunoglobulin molecule are held together by non-covalent and covalent bonds. Each 
light chain is paired with a heavy chain, producing a bilaterally symmetric structure. 
There are two types of light chain: the kappa (κ) and the lambda (λ) light chain. Light 
chains are approximately 220 amino acid residues long (~25 kD) and are made up of a 
variable region (VL) and a constant region (CL). In contrast, a heavy chain contain 
approximately 440 amino acid residues (~ 55 kD) and there are five types of heavy 
chains: mu (μ), alpha (α), gamma (γ), epsilon (ε) and delta (δ). Antibodies are 
categorised into classes based on the type of heavy chain they possess (IgM, IgA, IgG, 
IgE and IgD respectively). The different types of heavy chains allow different biological 
molecules to bind to the antibody, producing different immunological responses. In 
addition to the major immunoglobulin classes, there are four subclasses of IgG 
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molecules (IgG1, IgG2, IgG3 and IgG4) based on subtle differences in the γ-heavy 
chain. The subclasses of IgG will be discussed in Section 1.3.2. The γ-heavy chain of an 
IgG molecule is made up of one variable region (VH) and three constant regions (CH1, 
CH2 and CH3). By allelic exclusion, a B-cell expresses only one type of light chain and 
one type of heavy chain. Table 1.1 summaries the characteristic of the different classes 
of immunoglobulins.  
Table 1.1: Characteristics of immunoglobulin (Ig) classes. 
 Ig 
Class 
Type of 
heavy chain 
Type of antibody 
complexes 
Antibody 
valency Function 
IgA α Monomer, dimer or trimer 2, 4 or 6 
Protects mucous 
membranes 
IgD δ Monomer 2 Unknown 
IgE ε Monomer 2 Protects against parasites 
IgG μ Monomer 2 Secondary immune response 
IgM γ Pentamer 10 Primary immune response 
Adapted from Harlow and Lane, 1999. 
The VH and VL regions form the antigen-binding site which can be further restricted to 
three highly variable domains known as CDR (complementarity determining regions) 
(Figure 1.4). CDRs are the main antigen binding site of an antibody. As the antibody 
response matures, somatic hypermutation occurs in the CDR region and fine-tunes the 
antibody specificity to produce higher affinity antibodies. IgG molecules function as 
monomers containing two antigen-binding sites. Cleavage of an IgG molecule by the 
proteolytic enzyme, papain, produces three protein fragments with biological activities: 
two similar Fab (fragment antigen binding) fragments and one Fc (fragment that 
crystallises) fragment. The Fab fragments bind to antigens, but fail to evoke an immune 
response due to the absence of the Fc fragment. The constant regions (CH2 and CH3) of 
the heavy chains make up the Fc fragment (Figure 1.4). The Fc fragment is the main 
region that determines the class and subclass of an antibody. Different Fc fragments are 
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recognised by different Fc receptor (FcR) proteins displayed on the surface of cells such 
as macrophages and neutrophils. Different classes of antibodies are thus able to evoke 
different immune responses by the binding their Fc fragments to the FcR of different 
effector cells. FcR are further discussed in Section 1.3.3. 
 
Figure 1.4: Structure of an immunoglobulin (Ig) G molecule. 
An IgG molecule is made up of two light chains polypeptides linked to two heavy chain polypeptides by 
disulphide bonds (in green). The complementarily determining region (CDR) is located in the Fab 
(fragment antigen binding) region. The variable regions of the heavy and light chains make up the antigen 
binding site. An antibody’s isotype is dependent on the Fc (fragment that crystallises) domain. The CH2 
region, located within the Fc domain, is glycosylated and is involved in FcR binding. The conserved 
glycosylation site (asparagine 297) in the CH2 region is highlighted in pink. The hinge region determines 
the flexibility of the IgG molecule and is varied among the different IgG subclasses. VL: Variable region 
light chain. VH: Variable region heavy chain. CL: Constant region light chain. CH1/2/3: Constant region 
heavy chain 1/2/3.   
 
The κ light chain, λ light chain and the heavy chain of an immunoglobulin are each 
expressed by a collection of gene segments known as a gene pool. A gene pool typically 
contains more than four types of gene segments. During B-cell differentiation, the 
different sets of gene segments, from a gene pool, recombine and are expressed into an 
antibody polypeptide chain. The VH and VL regions of an immunoglobulin are encoded 
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by genes segments known as the variable (V) segment, diversity (D) segment and 
joining (J) segment. The VH region is made up of the V-D-J segments found in the same 
cluster on chromosome 12 while the VL region is made up of the V-J segments found in 
two different gene clusters, the kappa light chain gene cluster on mouse chromosome 6 
and the lambda light chain gene cluster on mouse chromosome 16. There are several 
different copies of each gene segment and only one copy of each gene segment is 
randomly chosen and combined with other gene segments. This mechanism of 
recombination results in an enormous repertoire of possible antibodies. 
Antibody diversity is not only a result of the random recombination of different copies 
of gene segments during B-cell differentiation. The recombination process of the gene 
segments is not precise. Nucleotides are often added on or removed during the process 
which further increases the antibody diversity. In addition, it is possible to pair any 
heavy chain polypeptide to any light chain polypeptide. Finally, affinity maturation (as 
discussed earlier), adds on to this huge antibody repertoire. 
 
1.3.2: IgG subclass 
IgG antibodies constitutes the highest percentage (75%) of total immunoglobulin in the 
blood. In contrast to IgM molecules, IgG antibodies are expressed during secondary 
antibody response, have longer half-lifes and have higher affinity towards foreign 
molecules. The four IgG subclasses, designated IgG1, IgG2, IgG3 and IgG4, are 
enumerated according to their concentration in the blood (Table 1.2). IgG subclasses 
share 95% homology in the constant domain of the heavy chain and the biggest 
difference lies in the antibody’s hinge region. The hinge region links the antibody’s Fab 
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fragments to the Fc fragment and is responsible for the flexibility of the antibody. 
Proline and cysteine make up the main residues in the core hinge region (Table 1.3). As 
length and number of disulphide bonds differs among the IgG subclasses, this in turn 
influences the antibody’s flexibility and ability to bind to serum proteins (Table 1.2). 
The IgG subclasses also differ in this ability to recruit effector molecules (by interacting 
with FcγR displayed on the surface of immune cells), ability to induce CDC (by 
interacting with C1q component) and serum half-life (by interacting with FcRn), which 
is mediated through the Fc domain of the IgG. Table 1.2 tabulates the in vitro binding 
properties of IgG subclasses of various effector molecules. Selection of IgG subclasses 
for antibody therapy is very much dependent on the effector function of the antibody. In 
cancer therapy, the therapeutic antibody is required to recruit effector functions and 
destroy the tumour cells, IgG subclasses with strong effector functions is preferred. 
Although IgG1 and IgG3 share similar biological characteristic that are ideal cancer 
therapy (Table 1.2), IgG1 are preferred over IgG3 due to the shorter half-life, extensive 
polymorphism and longer hinge region (thus more susceptible to proteolysis) of IgG3 
(Salfeld J.G., 2007, Jefferis R., 2007). Presently, no IgG3 subclasses have been 
approved for therapy. Both IgG2 and IgG4 are poor mediators of the complement 
pathway and are usually employed when less aggressive activity is required (i.e. when 
neutralisation of the antigen is more relevant than the effector function) (Salfeld J.G., 
2007). IgG2 antibodies are more resistant to proteolysis due to the shorten hinge region. 
Recently, IgG2 molecules were shown to form covalent dimers with identical IgG2 
molecules and different IgG2 molecules (Correia I.R., 2010). The molecular mechanism 
of IgG2 dimer formation has yet been understood and the clinical safety implications 
have not been determined by regulatory bodies. Similar to IgG2, IgG4 subclass have 
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low affinity to C1q component and were initially chosen as a therapeutic molecule as 
the recruitment of effector mechanisms is not desirable (Correia I.R., 2010). 
Natalizumab (Tysabri) is an IgG4 therapeutic molecule used for multiple sclerosis. 
However, the cytokine storm elicited by the anti-CD28 IgG4 molecule during Phase I 
clinical trial caused further investigation of using IgG4 subclasses as therapeutic 
molecules. It was shown that the inter-chain disulphide bonds of IgG4 molecules could 
be broken to form monovalent half-molecules (one heavy chain and one light chain). 
The disulphide bonds of the monovalent half-molecules could be re-created again 
forming a bivalent molecule paired with its original half molecule or a different IgG4 
half-molecule. 
Table 1.2: Characteristics of IgG subclasses. 
  IgG1 IgG2 IgG3 IgG4 
Percentage of total IgG 
concentration (%) 60 25 10 5 
Half-life (days) 21 21 7 21 
Hinge Length (number of 
amino acid residues) 15 12 62 12 
Inter-heavy chain disulphide 
bonds (hinge region) 2 4 11 2 
     
Binding properties     
C1q ++ - +++ - 
FcγRI +++ - +++ ++ 
FcγRII + ± + ? 
FcγRIIIa/b + - + ± 
FcRn + + + + 
Adapted from Salfeld, J.G. (2007). 
IgG subclass binding properties are determined by in vitro assays. As every IgG is different, its in vivo 
activity may not correlate to the above table.  
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Table 1.3: Amino acid sequences of core hinge region of IgG subclasses. 
IgG subclasses Sequence 
IgG1  EPKSCDKTHTCPPCP 
IgG2 ERKCCVECPPCP 
IgG3  ELKTPLGDTTHTCPRCP …… (EPKSCDTPPPCPRCP) x 3 
IgG4  ESKYGPPCPSCP 
Adapted from Correia, I.R. (2010). 
 
1.3.3: Fc receptors and effector function 
Cells of the immune system, such as macrophages, neutrophils and natural killer cells, 
display Fc receptors on their cell surface which recognises the Fc domain of 
immunoglobulins. Aggregation of antibodies on an antigen surface is followed by the 
recognition and binding of FcR to the Fc domain of the immunoglobulin. This triggers 
the activation of immune effector cells to induce various effector functions such as: 1) 
antibody-dependent cell-mediated cytotoxicity (ADCC), 2) antibody-dependent cellular 
phagocytosis (ADCP), and 3) complement-dependent cytotoxicity (CDC) (Chan and 
Carter, 2010). Binding of FcR to immunoglobulin may also inhibit immune cells from 
inducing an immune response. Different antibody isotype classes are recognised by 
specific FcR i.e. FcαR, FcδR, FcεR, FcγR and FcμR which bind to IgA, IgD, IgE, IgG 
and IgM respectively. Different cell types express different FcR on their cell surface. 
An immune response raised against an antigen is thus dependent on the cell type, 
expressing specific FcR that recognises the Fc tail of an antibody class. 
There are three different classes of FcγR in human: FcγRI (CD64), FcγRII (CD32), and 
FcγRIII (CD16). Among the FcγR classes are subclasses (FcγRI, FcγRII and FcγRIII) 
with different affinity and specificity for the various human IgG isotypes (hIgG1, 
hIgG2, hIgG3 and hIgG4). Isoforms exist in these subclasses. In humans, the various 
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FcγR subclasses are encoded from multiple genes: FcγRIA, B and C, FcγRIIA, B and C, 
and FcγRIIIA and B. Most FcγR are transmembrane proteins and contain a cytoplasmic 
tail where the immunoreceptor tyrosine-based activation motif (ITAM) or the 
immunoreceptor tyrosine-based inhibition motif (ITIM) is located. Binding of FcγR to 
the Fc domain of IgG results in the activation of a signal transduction pathway carried 
out by the immunoreceptor tyrosine-based motifs (ITAM or ITIM). This eventually 
leads to the activation or inhibition of the cell immune activity (Schmidt and Gressner, 
2005). 
Human FcγRI (hFcγRI) is a high affinity receptor. As mentioned earlier, there are three 
FcγRI genes (FcγRIA, B and C), however only hFcγRIA is being expressed. hFcγRIa is 
expressed on monocytes and macrophages. hFcγRIa has high affinity for hIgG1 and 
hIgG3 while its affinity for hIgG4 and hIgG2 is lower, with hIgG2 being the lowest. 
The murine homologue of human FcγRIa is murine FcγRI (mFcγRI). hFcγRIa binds to 
murine IgG2a and mIgG3 but not IgG2b (Gessner et al., 1998). 
The hFcγRII is a low affinity receptor with affinity for hIgG1 and hIgG3 (Gessner et al., 
1998). Members of hFcγRII do not bind to hIgG4 and are widely expressed in various 
immune cells such as eosinophils, monocytes, leukocytes and macrophages. The ITIM 
motif only exists in the hFcγRII subclass (namely hFcγRIIb1, hFcγRIIb2 and 
hFcγRIIb3). FcγRII proteins bind well to mIgG2a and mIgG2b. Like hFcγRII, hFcγRIII 
is a low affinity receptor. It has affinity for hIgG1 and hIgG3 but low affinity for hIgG4 
and hIgG2. hFcγRIII class of FcR are constitutively expressed on macrophages and NK 
cells. hFcγRIIIa is the human homolog of mFcγRIII (Schmidt and Gessner, 2005). 
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1.3.4: Antibody therapy 
Hybridoma antibody fusion technology, developed by Kohler and Milstein in the mid-
1970s, was the main driving force that initiated the use of antibodies for therapy. The 
fusion of a B-cell to an immortal cell line resulted in a hybrid cell that not only retains 
its antibody producing ability, but is also immortal. Antibodies produced from a 
hybridoma clone are called monoclonals, exhibiting specificity to a single epitope. 
Hybridoma fusion technology has enabled antibodies from different clones to be 
individually studied and characterised, thus, the most useful and potent antibody could 
be selected for therapeutic purposes.  
With an enormous antibody repertoire and the ability to produce highly specific 
antibodies, it is possible exploit the antibody-mediated immune system to create an 
antibody against any cell surface protein, carbohydrate or synthetic molecule. It is thus 
very attractive to develop antibodies against novel targets for the treatment of human 
diseases. The first US Food and Drug Administration (FDA) approved therapeutic 
antibody was Orthclone OKT3, an IgG2a CD3 mouse monoclonal antibody, used as an 
organ transplant rejection drug in 1986. Antibody therapy has since been very 
successful in the treatment of human diseases such as inflammation, autoimmune 
disease and organ transplantation where the antibody interacts and blocks specific cell 
receptors, ligands and cytokine molecules. Conversely, the use of antibodies for cancer 
treatment has not been as successful as the other non-cancer illness. This is because the 
antibody not only has to interact with the cancer cell, it also has to induce the 
destruction of the cancer cell. The mechanism by which an antibody, upon binding, 
efficiently targets a cancer cell for destruction is still unclear. While there have been 
successful therapeutic antibodies (for example Herceptin that targets human epidermal 
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growth factor 2) in the market, further studies are required to better understand the use 
of antibodies as cancer therapies, advances in antibody engineering has greatly 
improved the success of antibodies for clinical purposes.  The outlook of using 
antibodies for cancer treatment is promising. 
 
1.3.5: Antibody engineering 
Advances in antibody engineering have allowed the modification and optimisation of an 
antibody’s shape, molecular size, binding affinity, specificity, pharmacokinetics and 
effector function for the use of antibody in the clinical field. The first generation of 
antibody therapy used mouse monoclonal antibodies which were not as successful in 
clinical trials due to their murine origin. The failure was also due to insufficient 
knowledge required for antibody therapy e.g. the amount of antibodies required to elicit 
a therapeutic activity (milligrams of antibodies were required) (Glennie and van de 
Winkel, 2003). Mouse monoclonal antibodies had short half-lifes, failed to efficiently 
recruit immune effector functions and were highly immunogenic, thus evoking human 
anti-mouse antibody (HAMA) responses. Binding of human anti-mouse antibodies to 
murine therapeutic antibodies prevented the antibodies from attaining their therapeutic 
effectiveness. Attempts were thus made to humanise the murine antibodies which led to 
the generation of chimeric antibodies. A chimeric antibody is generated by engineering 
the variable region (containing the epitope binding region) of the mouse monoclonal 
antibody into the constant regions of a human antibody (VH and VL) (Figure 1.5) 
(Glennie and van de Winkel, 2003). The constant regions were often taken from the 
kappa light chain and the IgG1 heavy chain subclass. Among the various IgG 
subclasses, IgG1 have the best ability to recruit effector function in the immune system 
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as they can efficiently engage receptors on cytotoxic effector cells. This leads to the 
elimination of the antigen-antibody complex through the activation of the complement 
cascade or mediation of ADCC. Chimeric antibodies had improved serum half-lifes and 
reduced immunogenicity, therefore, human anti-chimeric antibody (HACA) responses 
were still observed in patients (Glennie and van de Winkel, 2003). To further reduce 
immunogenicity of the chimeric antibodies, humanised antibodies were thus created by 
engineering the CDR of a murine antibody into a human antibody framework (Figure 
1.5). Humanised antibodies greatly reduced the immunogenicity of the antibody 
molecule, though human anti-human antibody (HAHA) responses could still be elicited. 
In addition, it was frequently observed that the binding affinity for the target antigen, 
compared to the parental mouse antibody, was greatly reduced (Glennie and van de 
Winkel, 2003). Genetic engineering in the CDR region was thus required to improve the 
binding efficiency. Currently, most of the therapeutic antibodies approved for use in 
human diseases are chimeric and humanised antibodies. The more successful 
therapeutic antibodies used in human cancer are bevacizumab (Avastin), cetuximab 
(Erbitux) and trastuzumab (Herceptin) (Adams and Weiner, 2005). 
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Figure 1.5: Engineering mouse monoclonal antibodies. 
Engineering of mouse monoclonal antibodies, for human therapeutic purposes, led to the generation of 
chimeric and humanised antibodies. Chimeric antibodies contain the variable regions of the mouse 
monoclonal antibody (in yellow) fused to the constant regions of a human antibody (in blue). The whole 
framework of a humanised antibody is made of human origin except for the CDR (complementarily 
determining regions) which is of mouse origin. Disulphide bonds are in green. 
 
Further advances in technology have led to the development of fully human monoclonal 
antibodies. Human monoclonal antibodies can be generated from transgenic mice which 
had their murine immunoglobulin genes replaced by the human counterpart (Glennie 
and van de Winkel, 2003). Panitumumab, a recently approved antibody directed against 
EGFR, is an example of a fully human monoclonal antibody generated by transgenic 
mice (Xenomouse by Abgenix). A different approach to generate human monoclonal 
antibodies is through phage display. Human antibody cDNA libraries cloned into phage 
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particles are expressed and displayed as fusion proteins on the coat surface of the 
viruses. One virus will only express and display a single unique cDNA construct and 
this allows the screening, panning, amplification and isolation of the antibody that binds 
to the target of interest (Glennie and van de Winkel, 2003). To date, many different 
variations of human antibody libraries have been created in phage display technology. 
Naive and immunised libraries were obtained by isolating lymphocytes from non-
immunised or immunised individuals respectively. Synthetic human antibody libraries 
were constructed from random arrangement of the antibody gene segments obtained 
from germ line cells. Single-chain variable fragment (scFv) and Fab antibody library 
fragments were also constructed. Successfully selected scFv or Fab fragments could be 
further engineered to contain a Fc domain that contains appropriate effector functions. 
Antibody engineering has also led to the production of various variations of antibody 
fragments. Depending on the clinical application, antibody fragments can be engineered 
to be multivalent, smaller in size and have increased stability. Antibody fragments can 
also be engineered to generate an antibody which can recognise two different epitopes 
through two distinct Fab arms termed a bispecific antibody (Bsab). With advancing 
technology and understanding, Bsab molecules are emerging to be promising 
therapeutic drugs as they have the ability to simultaneously cause dual inhibition (Jain 
et al., 2007). Other forms of antibody engineering, such as alteration of antibody amino 
acid sequence, have been focused on enhancing antibody interaction with FcR which 
led to the improved recruitment of effector functions (Jain et al., 2007). Glycosylation 
of the antibody’s Fc domain also affects the recruitment of effector functions (Figure 
1.6). Depending on the type of sugar molecules attached to the core sugar group, the 
mode and efficacy of the effector function is affected. Sugar moieties, attached to the 
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single site at asparagine 297, affects the conformation of the IgG Fc domain which in 
turn, influences the binding of FcγR or C1q to the antibody (Jefferis, 2009). 
Aglycosylated or deglycosylated antibodies have demonstrated reduced efficacy in the 
recruitment of effector functions. Additional of certain sugar moieties, such as fucose, 
to the core sugar group also reduces an antibody’s therapeutic activity. Many efforts 
have thus been focused on engineering cell lines to produce homogenous production of 
therapeutic antibodies with increased ADCC and CDC (e.g. by engineering CHO cell 
that add bisecting N-acetylglucosamine residues or are deficient in adding fucose 
residues) (Jefferis R., 2007). 
 
Figure 1.6: Glycosylation on IgG Fc domain. 
Glycosylation at asparagine 297, located in the CH2 domain, of an IgG molecule is important for the 
recruitment of effector functions. The core sugar group is shown in blue. Additional sugar molecules 
could be added to the core group and are shown in red. Circle: N-acetylglucosamine. Triangle: mannose. 
Star: fucose. Rectangle: galactose. Diamond: N-acetylneuraminic acid. Adapted from Jefferis R., 2009. 
 
In this work, we describe the development and characterisation of mouse monoclonal 
antibodies against the α-chain of c-Met. Purified c-Met α-chain was used as an 
immunogen to raise antibodies in mice. Hybridoma cell lines were created and 39 were 
identified to stably express antibodies against the α-chain of c-Met. 21 hybridoma cell 
lines were single cell-cloned and the monoclonal antibodies produced were 
characterised for their isotype subclass and epitope binding region. Mouse ascites were 
developed from 11 of these hybridoma clones. Antibodies were purified from the ascites 
and further characterised by Western blotting, immunofluorescence staining, functional 
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assays (ERK phosphorylation and cell scatter) and for their ability to recognise native c-
Met by flow cytometry. 
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CHAPTER 2: MATERIALS AND METHODS 
All cells were maintained at 37 ˚C in 5 % CO 2 humidified incubator. HaCaT, U-87MG 
and NIH3T3 cells, cultured in Dulbecco’s Modified Essential Medium (DMEM) high 
glucose with sodium pyruvate, were generous gifts from Birgit Lane (Institute of 
Medical Biology (IMB), Singapore), Nick Leslie (Division of Cell Signalling and 
Immunology, University of Dundee) and Axel Ullrich (Institute of Medical Biology 
(IMB), Singapore) laboratories respectively. SNU-5 cells were purchased from Korean 
Cell Line Bank. T47D and SNU-5 cells were cultured in RPMI 1640 media. DMEM 
and RPMI were obtained from Invitrogen (Clarlsbad, U.S.A). All tissue culture medium 
was supplemented with 10% heat-inactivated fetal calf serum (FCS) obtained from 
HyClone Laboratories/Thermo Scientific (Waltham, U.S.A.). Tissue culture plates and 
dishes were obtained from TPP (St. Louis, U.S.A). 
Cell lines and reagents 
Recombinant human HGF (#294-HG) and anti-human HGF (#MAB294) were 
purchased from R&D Systems (Minneapolis, U.S.A.) and were resuspended in 
phosphate-buffered saline (PBS), according to the manufacturer’s instructions. 
SU11274, the c-Met small molecule inhibitor, was purchased from Calbiochem/Merck 
(Darmstadt, Germany, #448101) and was dissolved in DMSO to obtain a stock 
concentration of 5 mM. HGF, anti-HGF and SU11274 were used at a final 
concentration of 10 ng/ml, 5 μg/ml and 5 μM respectively. 
 
The entry vector, containing full length human c-Met cDNA in pENTR221 vector 
(#IOH36570), was obtained from Invitrogen. Using the LR clonase II kit (Invitrogen 
Cloning c-Met for mammalian cell expression 
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#11791-020), human c-Met cDNA in pENTR221 was recombined into the following 
Gateway destination vectors listed on Table 2.1. Briefly, the entry clone was incubated 
with a destination vector in the presence of LR clonase II at 25oC for an hour. 
Proteinase K, provided by the kit, was added to the recombination mixture and 
incubated at 37oC for 10 mins. The recombination mixture was transformed into 
appropriate strains of commercially-available chemically-competent E. coli cells 
(Invitrogen). Transformed cells were then plated on LB plates (10 g Bacto-tryptone/5 g 
yeast extract/5 g NaCl /20 g agar per litre) containing antibiotic. Bacteria strains and 
antibiotic selection used are listed in Table 2.1.   
Table 2.1: Mammalian vectors used for transient c-Met expression. 
Gateway vectors Promoter Tag Antibiotic selection 
Competent 
cells 
Approximate 
molecular weight  
Mature 
c-Met β-
chain 
c-Met 
precursor 
protein 
pcDNA3-GW-
DEST CMV TATA NIL Ampicillin TOP10 145 kD 170 kD 
pcDNA3-GFPc-
GW-DEST CMV TATA 
C-terminal 
GFP Ampicillin TOP10 172 kD 197 kD 
pcDNA3-SBPc-
GW-DEST CMV TATA 
C-terminal 
SBP Ampicillin TOP10 149 kD 174 kD 
pCMV-SCP-EFI-
FRT-GW-DEST 
Super Core 
Promoter 
(SCP) 
C-terminal 
V5 Ampicillin TOP10 
146 kD 171 kD 
pLenti6.3-GW-
DEST 
Super Core 
Promoter 
(SCP) 
C-terminal 
V5 
Ampicillin 
& 
blasticidin 
STBL3 
pCMV-SCP-EFI-
SBPc-GW-DEST 
Super Core 
Promoter 
(SCP) 
C-terminal 
SBP Ampicillin TOP10 149 kD 174 kD 
Blasticidin (Invitrogen) and ampicillin (Sigma-Aldrich), was used at a final concentration of 50 μg/ml and 
100 μg/ml respectively. 
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Cloning c-Met for prokaryotic expression 
Four constructs containing different regions of human c-Met (Figure 2.1) were each 
cloned, without the c-Met membrane localisation signal, into pET19b vector 
(Novagen/Merck) for prokaryotic expression. The plasmids map of pET19b vector is 
shown in Figure 2.2. Primer sequences used to amplify the different c-Met regions are 
listed in Table 2.2. iProof PCR mix (Bio-Rad, Hercules, U.S.A.) which contains proof 
reading polymerase was used for the amplification. An ‘A’ tail was added to the 3’ end 
of the PCR product by incubating with Taq polymerase at 72oC for 30 mins. The PCR 
product was gel purified and cloned into pCR2.1 vector (Invitrogen) using the TOPO 
TA cloning kit (Invitrogen). Commercially-available TOP10 chemically-competent 
cells (Invitrogen) was used for bacterial transformation. Transformed cells were plated 
on LB plates containing ampicillin and X-gal (5-bromo-4-chloro-3-indolyl- -D-
galactoside, from Invitrogen). 40 μl of X-gal (stock concentration of 40 mg/ml) was 
spread onto each LB plates before use. White colonies were picked for plasmid 
extraction and these plasmids were screened using restriction enzyme digestion. 
Restriction enzymes used are listed in Table 2.3. Positive clones were sequenced using 
M13 forward and M13 reverse primers as well as c-Met internal primers listed in Table 
2.4. c-Met encoding regions were then sub-cloned from pCR2.1 into pET19b vectors. c-
Met constructs in pET19b were transformed into seven different bacteria strains listed 
on Table 2.5 for protein expression. All plasmid extraction, gel extraction and PCR 
product purification protocols were performed using Qiagen (West Sussex, United 
Kingdom) kits, according to manufacturer’s protocol. 
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Figure 2.1: Diagram of human c-Met precursor protein and the four c-Met protein expressed in 
prokaryotes (not drawn to scale). 
c-Met precursor is a 1390 amino acid residue protein made up of a membrane localisation signal (green), 
an alpha chain (pink) and beta chain (blue). The localisation signal, which directs newly synthesised c-
Met to the plasma membrane, lies in the first 24 amino acid residues. Furin, an ubiquitous endoprotease, 
cleaves c-Met precursor at R307/S308 which divides the protein into the α-chain and β-chain. The orange 
box represents the transmembrane region of c-Met which spans amino acid residues 933 – 955. Four c-
Met constructs, with different regions of c-Met, were cloned into pET19b vector for prokaryotic 
expression. The c-Met proteins were expressed with an N-terminal histidine tag (black-checked box) that 
that is used for protein purification. The molecular weight of each construct is noted. 
 
 
Figure 2.2: Plasmid map of pET19b.  
Plasmid map was obtained from Novagen. Proteins expressed from pET19b vector contain an N-terminal 
histidine tag (10 histidine residues) which could be used for future protein purification or detection by 
Western blotting.  
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Table 2.2: Primer sequences used for cloning c-Met into pET19b for prokaryotic protein 
expression. 
Primer Sequence ( 5' - 3') Restriction Sites 
Alpha01F GGAATTCcatatgGAGTGTAAAGAGGCACTAGC NdeI 
Alpha02R GCggatccCTATCTCTTTTTTCTCTTTTCTGTGAG BamHI 
Beta03F CCGctcgagTCCACAAAGAAGGAAGTG XhoI 
Beta04R CCGctcgagCTATGATGTCTCCCAGA XhoI 
Beta05R ctcgagCTATGTGAAATTCTGATCTGGTTGAACTATTAC XhoI 
AB06F ctcgagGAGTGTAAAGAGGCACTAGCAAAG XhoI 
Restriction sites are in lower case letters. 
 
Table 2.3: Primers used for c-Met amplification. 
c-Met constructs Forward primer 
Reverse 
primer Template Tm (
oC) Restriction enzyme 
α-chain Alpha01F Alpha02R 
IOH36570 
65 NdeI / BamHI 
Extracellular β-chain Beta03F Beta05R 65 XhoI / XhoI 
c-Met extracellular αβ-
chain AB06F Beta05R 65 XhoI / XhoI 
Full length β-chain Beta03F Beta04R 65 XhoI / XhoI 
 
Table 2.4: c-Met sequencing primers. 
No. Sequence (5’ → 3’) Nucleotide number 
JS01 GATCAACTCATTAGCTGTGGC 382 - 402  
JS02 GCGTATGTCAGCAAGCCT 958 - 975  
JS03 CTGCAGACATTTCCAGTCC 1557 - 1575  
JS04 CAGTTACCGTGAAGATCCCAT 2208 - 2228  
JS05 GAGTGGAAGCAAGCAATTTC 2728 – 2747 
JS06 GGTTGTGTATATCATGGGACTTTG 3268 – 3291 
JS07 GACATGTCGCTGGCAGG  419 - 435 (c) 
JS08 CGGGTTGTAGGAGTCTTCTC 3897 - 3916 (c) 
JS11 GAGAAGACTCCTACAACCCG 3897 - 3916 
(c): complementary sequence. 
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Table 2.5: Bacteria characteristic used in this study for protein expression. 
Bacteria 
strain 
lacY 
mutation1 
Ion2 and 
ompT3 
mutations 
Rare 
tRNA 
codon4 
trxB5 and 
gor6 
mutations 
T7 
lysozyme7 
rne131 
mutation8 
BL21 DE3   *         
BL21 Star   *       * 
BL21 pLysS   *     *   
RG2 DE3     * *     
RG2 pLysS     * * *   
RGB DE3 * * * *     
RGB DE3 
pLysS * * * * *   
Table was adapted from pET System Manual (11th Edition). Other than BL21 star (Invitrogen), all 
bacteria strains were obtained from Novagen/Merck. 
1) Mutation in lac permease provides homogenous uptake of IPTG into all cells in the population, thus 
facilitating concentration-dependent induction of protein expression. 
2) Mutation in cytoplasmic Ion protease. 
3) Mutation of ompT membrane protease prevents cleavage of some membrane proteins during 
purification. 
4) Provides either six or seven tRNAs codons that rarely occur in E. coli thus increasing the expression 
level of proteins limited by codon usage. 
5) Mutation in thioredoxin reductase facilitates disulphide bonds formation in the cytoplasm. 
6) Mutation in glutathione reductase, when combined with trxB mutation, greatly facilitates formation of 
disulphide bonds in the cytoplasm.  
7) Provides T7 lysozyme to reduce basal expression of target genes thus stabilising plasmids that express 
proteins toxic to E. coli. 
8) Encodes for defective RNaseE gene thus increasing mRNA stability. 
  
Prokaryotic expression of c-Met constructs  
As mentioned earlier, pET19b constructs containing the various c-Met constructs were 
chemically transformed into seven bacteria strains (gifts from Jeffrey Hill, Experimental 
Therapeutics Centre, Singapore). The bacteria strains used are BL21 DE3, BL21 star, 
BL21 pLysS, Rosetta-gami 2 DE3 (RG2 DE3), Rosetta-gami 2 pLysS (RG2 pLysS), 
Rosetta-gami B DE3 (RGB DE3) and Rosetta-gami B DE3 pLysS (RGB DE3 pLysS) 
(listed in Table 2.5). BL21 pLysS was used for large-scale protein expression of c-Met 
α-chain. BL21 star was used for large-scale expression of c-Met extracellular β-chain, 
extracellular αβ-chain and full length β-chain. Transformed cells were grown in a 500 
ml culture until an OD600 0.4 to 0.6 was reached. Protein expression was induced by 
adding IPTG (isopropyl-β-D-thio-galactoside) to a final concentration of 1 mM. 
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Cultures were then further allowed to grow for 3 hrs. Cells were recovered by 
centrifugation at 6,000 xg for 15 mins and resuspended in 12 ml of lysis buffer (0.3 M 
KCL, 50 mM KH2PO4, pH 8.0). Cells were incubated in lysis buffer for 30 mins at 4oC, 
with constant swirling before sonication. The resulting cell lysate was centrifuged at 
maximum speed 33,000 xg for 30 mins. The cell pellet obtained after centrifugation was 
resuspended in lysis buffer containing 6 M urea and incubated overnight with gentle 
stirring. The resulting suspension was centrifuged at 33,000 xg for 30 mins and the 
supernatant (pre-purified supernatant) obtained was used for protein purification. 
 
Protein purification 
Various c-Met protein constructs expressed by bacteria was affinity purified on a 1 ml 
IMAC (immunobilised metal affinity chromatography) Bio-Scale Mini Cartridge (Bio-
Rad), using the automated Profinia protein purification system (Bio-Rad). Purified 
protein was eluted in 4 ml of elution buffer. Purified protein was used to immunise mice 
for monoclonal antibody production. 
 
Construction of c-Met adenoviral plasmids 
Construction of c-Met adenoviral plasmids were performed with reference to 
AdEasyTM XL Adenoviral Vector System (Stratagene/Agilent Technologies, Santa 
Clara, U.S.A.) and He et al. (1998). c-Met and cMet-SBP were amplified using Expand 
Long Template PCR System (Roche Applied Science, Mannheim, Germany). An 
outline of adenoviral plasmid construction is illustrated in Figure 2.3. Primer sequences 
used for the amplification are listed in Table 2.6. Amplification conditions were 
performed according to the PCR conditions in Table 2.7 and 2.8. c-Met and cMet-SBP 
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PCR fragments were ligated into the shuttle vector,  pAD.Track.CMV. Ligation mixture 
was transformed into commercially-available DH5α cells (Invitrogen) and cells were 
selected on kanamycin (Sigma-Aldrich, St. Louis, U.S.A.) LB plates.  Plasmids 
extracted from these clones were screened using KpnI and HindIII restriction enzyme 
digest. Positive plasmids were sequenced using c-Met internal primers listed in Table 
2.4. pAD.Track.CMV positive constructs were then linearised using PmeI enzyme 
before phenol/chloroform purification. Purified constructs were electroporated into 
BJ5183-AD-1 cells (Stratagene) which contained the adenoviral plasmid, pADEasy1. 
This allows DNA recombination to take place between the linerised pAD.Track.CMV 
constructs and pADEasy1 vector within BJ5183-AD-1 cells. Transformed cells were 
plated on LB plates containing kanamycin. Plasmids were extracted from these clones 
and screened using PacI restriction enzyme digest. Digested plasmids were analysed on 
0.8% low melting agarose gels (Invitrogen). Digestion of pADEasy1 constructs, 
containing c-Met or cMet-SBP, with PacI will produce two DNA bands (one of >10 kb 
and one ~4 kb). 
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Figure 2.3: An outline of cloning c-Met constructs for adenoviral expression. 
 
Table 2.6: Primer sequences used for cloning c-Met constructs into pAD.Track.CMV vector. 
Primer Sequence ( 5' - 3') Restriction Sites 
JD09 GggtaccGCCACCATGAAGGCCCCCGCTGTGCTTG KpnI 
JD10 CCCaagcttCTATGATGTCTCCCAGAAGGAGGC HinDIII 
JD11 CCCaagcttTCAGGGTTCACGCTGACCCTGC HinDIII 
 
Table 2.7: Conditions used for cloning c-Met for adenoviral expression. 
c-Met 
constructs  
Forward 
primer 
Reverse 
primer Template 
Restriction 
enzyme 
c-Met JD09 JS10 pENTR221-cMet 
KpnI / HindIII 
cMet-SBP JD09 JD11 pcDNA3-cMet-SBPc 
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Table 2.8: PCR cycle used for c-Met and cMet-SBP amplification. 
 
 
Amplification of functional c-Met viral particles 
AD293 cells were grown in DMEM supplemented with 10% heat-inactivated FCS. 
During the maintenance of AD293 cell culture, care was taken to not allow cell 
confluence to exceed >50%. To produce viral particles, 1 x 105 AD293 cells were 
seeded in a 6-well plate before transfection. pADEasy1 constructs were linearised with 
PacI enzyme and transfected into AD293 cells. 2 μg of linearised pADEasy1 constructs 
were used for the lipofectamine transfection. Cells and media were harvested by 
centrifugation at 2 krpm for 3 mins at 4oC (Heraeus Accuspin 1R, rotor #3041), once 
the cells circularise and detach from the plate. 
To test if the viral particles are infectious and express c-Met/cMet-SBP, AD293 cells 
were seeded in 10 cm plates. AD293 cells were allowed to grow to 90% confluence 
before the viral particle containing extracts (freeze-thawed for three times) were added 
to the cells. Cells and media were harvested as described above. Half of the cells 
collected were lysed in RIPA lysis buffer containing complete protease inhibitor (150 
mM NaCl, 1% NP40, 0.5% DOC, 0.1% SDS, 50 mM Tris pH 8.0) and probed for c-Met 
expression by Western blotting. The other half was frozen at -80oC and used for bulk 
Step Tm Time No. of cycle 
1 92oC 1 min 1 
2 
92oC 10 sec 
10 60oC 30 sec 
68oC 2 min 40 sec 
3 
92oC 15 sec 
15 
60oC 30 sec 
68oC 
2 min 40 sec 
(Increase 20 sec 
every cycle) 
4 68oC 7 min 1 
5 4oC - 1 
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amplification of viral particles. Bulk amplification of the viral particles was performed 
by seeding AD293 cells in forty plates of 15 cm dishes. Viral particles collected from 
the 10 cm plates (described above) were freeze-thawed three times before infecting the 
cells. Cells and media were harvested as described above. Infected cells were pooled 
together by centrifugation at 4 krpm for 10 mins at 4oC (Heraeus Accuspin 1R, rotor 
#3360). Finally, the infected cells were resuspended in 10 mM Tris-Cl, pH 8.0 (0.5 ml 
of Tris-Cl per every 15 cm dish harvested). Viral particles obtained were freeze-thawed 
three times. 0.5 ml of viral particles (resuspended in Tris-Cl) was used to infect T47D 
cells grown to 90% confluence in a 10 cm plate. 
  
Transfection 
Lipofectamine 2000 (Invitrogen) was used to transfect NIH3T3 cells. Transfection was 
performed according to an optimised protocol for NIH3T3 cells. Briefly, 0.9 x 106 cells 
were seeded on a 10 cm plate. 9 μg of DNA and 45 μl of lipofectamine, both diluted in 
Optimem Reduced Serum Medium (Invitrogen), were added to cells. Media was 
replaced after 4 hrs and cells were left to grow for 48 hrs before harvest. Amount of 
cells, DNA, lipofectamine and Optimem were scaled proportionally according to size of 
the tissue culture plates/dishes. 
  
Cell harvest and cell lysis 
Cell culture plates/dishes were rinsed three times with cold PBS before the cells were 
scraped off. Cells were collected by spinning in a microcentrifuge for 5 mins at 233 xg, 
at 4oC. PBS was removed before quick freezing the cell pellet on dry ice. The frozen 
cell pellet was lysed on ice using NP40 lysis buffer (1% NP40, 150 mM NaCl, 50 mM 
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Tris-HCL pH 8.0) containing complete protease inhibitor (Roche, West Sussex, United 
Kingdom, #11 697 498 001) for 30 mins. Cell debris was spun down at 10,000 xg for 10 
mins, at 4oC. The supernatant was recovered for analysis. Protein quantification was 
performed using a BCA kit (Pierce/Thermo Scientific), according to the manufacturer’s 
protocol. 
 
Western blots and antibodies 
Protein samples were mixed with 4X LDS sample buffer (Invitrogen) and 10X sample 
reducing agent (Invitrogen) before analysing on a 4 -12% Bis-Tris gradient gels 
(Invitrogen) using MOPs buffer (Invitrogen). SeeBlue Plus2 protein ladder (Invitrogen) 
was used as molecular weight ladder. Transfer of proteins onto a nitrocellulose 
membrane (0.45 μm pore size, Whatman, Kent, United Kingdom) was performed using 
Bio-Rad wet transfer system for 2 hrs, at a constant current of 100 V. Transfer buffer 
contains 25 mM Tris, 192 mM and 20% methanol. Blocking buffer was made up of 5% 
Marvel in PBST (1% Tween20 in PBS) (w/v). Non-specific sites on the membrane were 
blocked in blocking buffer for 1 hr before incubating with primary antibodies. The 
membrane was washed three times and secondary antibodies were added at 1:10 000 
dilutions in blocking buffer. The working dilutions and information of primary 
antibodies can be found in Table 2.9. Secondary antibodies conjugated to horseradish 
peroxidise (HRP) were obtained from Jacksons Laboratory/Stratech Scientific Ltd. 
(Suffolk, United Kingdom). Enhanced chemiluminescence (ECL) (Amersham/G.E. 
Healthcare) was used for the detection of Western blots. 
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 Table 2.9: Primary antibodies used in this study for Western blotting. 
Antibody Company / Catalogue number Origin Specificity Monoclonal / Polyclonal 
Incubatio
n time 
Working 
dilution 
Anti-cMet (C-12) Santa Cruz  / #SC-10 Rabbit Peptide located in c-Met cytoplasmic domain Polyclonal 12 - 24 hrs 1:10 000 
Anti-cMet (AF276) R&D systems / #AF276 Goat Extracellular domain of c-Met Polyclonal 12 - 24 hrs 1:10 000 
Anti-cMet (EY1454Y) Abcam / #EY1454Y Rabbit N-terminus of c-Met Monoclonal 12 - 24 hrs 1:10 000 
Anti-α-Met (Mab 18.1) In house Mouse α-chain of c-Met Monoclonal 12 - 24 hrs 1 μg/ml 
Anti-phospho-cMet Invitrogen / #44888G Rabbit Phospho-cMet (pYpYpY1230/1234/1235) Polyclonal 12 - 24 hrs 1:500 
Anti-GFP (Clone 7.1 and 13.1) Roche Diagnostic / #11 814 460 001 Mouse GFP Monoclonal 1 hr 1:5 000 
Anti-His-Peroxidase (BMG-His-1) Roche Diagnostic /  #11 965 085 001 Mouse 6 constitutive histidine residues Monoclonal 1 hr 1:5 000 
Streptavidin Peroxidase Polymer Sigma-Aldrich / #S2438 - Biotinylated biomolecules - 1 hr 1:2 000 
Anti-V5 (Clone 336) Gift from Dimitri Xirodimas Mouse V5 tag Monoclonal 1hr 1:5 000 
Anti-β-actin (AC-15) Sigma-Aldrich / #A5441 Mouse β-Actin Monoclonal 1 hr 1:10 000 
Anti-PCNA (PC10) Moravian Biotechnology Mouse PCNA Monoclonal 1 hr 1:5 000 
Anti-α-tublin (B-5-1-2) Sigma-Aldrich / #T5168 Mouse α-Tublin Monoclonal 1 hr 1:8 000 
Anti-ERK Cell Signalling / #9102 Rabbit ERK 1/2 Polyclonal 12 - 24 hrs 1:1 000 
Anti-phospho-ERK Cell Signalling / #9101 Rabbit Phospho-ERK 1/2 (Thr 202 / Tyr 204) Polyclonal 12 - 24 hrs 1:1 000 
Anti-AKT Cell Signalling / #9272 Rabbit AKT Polyclonal 12 - 24 hrs 1:1 000 
Anti-phospho-AKT Thr308 Cell Signalling / #9275 Rabbit Phospho-AKT (Thr 308) Polyclonal 12 - 24 hrs 1:1 000 
Anti-phospho-AKT Ser473 Cell Signalling / #9271 Rabbit Phospho-AKT (Ser 473) Polyclonal 12 - 24 hrs 1:1 000 
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Immunoprecipitation 
Cells lysates were obtained by lysing cells in NP40 lysis buffer as described above. 1 µg 
of purified antibody was incubated with cell lysate (200 μg – 500 μg of total protein in 
approximately 500 μl) at 4oC, overnight. 20 μl of washed protein G beads (Sigma-
Aldrich) were added to the cell lysate and incubated for 45 mins at 4oC, with rotation. 
Beads were collected by spinning at 18,000 xg for 5 mins at 4oC. Beads were washed 
several times with NP40 lysis buffer. Bound proteins were eluted by adding 60 μl of 2X 
LDS sample buffer (Invitrogen) and the samples heated at 100oC for 5 mins. Beads 
were removed from eluate by centrifugating at 10,000 xg for 1 min. The eluate was 
analysed by SDS-PAGE gel. 
  
SBP pull down experiments 
Cells, grown to 90% confluency in a 10 cm plate, were harvested and lysed in NP40 
lysis buffer (as described above). Cell lysate was pre-cleared with 10 μl of avidin-
conjugated agarose beads (Pierce/Thermo Scientific, #20219). The avidin-conjugated 
beads were removed from the cell lysate by centrifugation before the addition of 40 μl 
of streptavidin-conjugated magnetic beads (Dynal/Invitrogen, #112.06). Streptavidin-
conjugated beads were incubated with the pre-cleared cell lysate for 2 hrs at 4oC, with 
rotation. Beads were washed several times with wash buffer (0.1% Tween 20, 150 mM 
NaCl, 10 mM HEPES) before elution with PBS containing 1 mM of biotin. Eluted 
proteins were analysed by SDS-PAGE gel. 
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Antibody production 
Antibody production was performed by Dr. Borek Vojtesek from Moravian 
Biotechnology (Czech Republic). A brief overview of monoclonal antibody production 
is described in Figure 2.4  
 
Figure 2.4: Overview of monoclonal antibody production. 
Various c-Met constructs were expression in bacteria and purified. The α-chain and the extracellular β-
chain were selected for mouse immunisation. Tail bleeds of these mice were obtained to test the 
immunological response raised against the immunogen. Only mice immunised with the α-chain were 
sacrificed for hybridoma fusion. Hybridoma cells obtained were grown in selection medium containing 
hypoxanthine, aminopterin and thymidine. Hybridoma cells that survived in the selection media were 
screened (primary and secondary screening) for production of anti-α-chain antibodies. Positive hybridoma 
lines were single-cell cloned and the monoclonal antibodies produced were characterised. Finally, 
hybridoma clones were selected for ascites production. Antibodies obtained from ascites were purified 
and characterised further. 
 
Immunisation   
Four BALB/c mice were immunised with either purified human c-Met alpha chain or 
extracellular beta chain. Each injection contained 40 μg of purified protein. The first 
three injections were done monthly with either complete Freund’s Adjuvant (first 
injection) or incomplete Freund’s Adjuvant (second and third injection). Mouse serum 
was taken after the second injection to test for immunological response against the 
immunogen. Two mice that gave the highest specific immune response were given the 
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fourth and fifth injection which was three days and five days, respectively, before the 
fusion. The fourth and fifth injections did not contain Freund’s Adjuvant. 
Fusion   
Two mice were sacrificed for hybridoma fusion. Spleen cells of the mice were fused 
with SP2./0-Ag14 cells which are mouse immortal myeloma cells. Hybridoma cells 
were grown in selection media containing hypoxanthine, aminopterin and thymidine 
and only hybridoma cells which have been successfully fused between a spleen cell and 
an immortal cell will survive and grow in the selection media. 
  
Antibody screening 
An outline of monoclonal antibody screening is shown in Figure 2.5. 
Primary hybridoma screen  
Hybridoma cells were screened for anti-α-chain antibody production ten days after cell 
fusion. This was performed in collaboration with Moravian Biotechnology. Hybridoma 
supernatants were screened for immunoglobulin (Ig) production and recognition of 
purified c-Met alpha chain using dot blot technique. Briefly, rabbit anti-mouse antibody 
(DAKO (Denmark), #Z0109, diluted 1:100), or purified c-Met alpha chain (20 μg/ml) 
was incubated on nitrocellulose membrane for 2 hrs before rinsing off with PBS. The 
membrane was blocked in 10% FCS/DMEM then hybridoma supernatants were added. 
Hybridoma supernatants (~2 μl) were incubated on the nitrocellulose membrane for 1 
hr, at room temperature, in a humidity chamber. The supernatants were then rinsed off 
with PBS and HRP-conjugated anti-mouse antibody (DAKO, P0161, diluted 1:100) was 
added to the nitrocellulose membrane.  The secondary antibody was rinsed off in PBS 
and a substrate solution was added. This was made up by dissolving a 4-chloro-1-
naphthol tablet (Sigma-Aldrich) in 10 ml methanol. 30 ml of PBS was then added and 
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the solution was filtered. 200 μl of hydrogen peroxide was added before the substrate 
solution was added onto the dot blot. The reaction was stopped by rinsing the blot in tap 
water. 
Hybridoma supernatants were also screened by Western blotting and cell staining. The 
Western blotting protocol was mainly performed as described above, except that 
purified α-chain was resolved on a single well SDS-PAGE gel before the proteins were 
transferred onto a nitrocellulose membrane. The membrane was cut into strips and neat 
hybridoma cell supernatant were incubated directly on it. HRP-conjugated anti-mouse 
secondary antibody (DAKO) was added at 1:1000 dilution for the detection of mouse 
monoclonal antibodies. For cell staining, NIH3T3 cells were transfected in a 6 cm dish, 
as described above, with constructs expressing c-Met or Met-V5 (pcDNA3-Met or 
pCMV-Met-V5). Cells were washed twice with cold PBS and fixed with cold 1:1 
acetone/methanol for 6 mins. Acetone/methanol was aspirated off and the plates were 
left to dry. Grids (0.5 cm x 0.5 cm) were drawn on the opposite side of the tissue culture 
dish.  Approximately 2 μl of supernatant was added in each grid (cell surface side) and 
incubated in a humidity chamber overnight at 4oC. Cell supernatant was rinsed off three 
times with PBS and HRP-conjugated anti-mouse secondary antibody, diluted 1:100 in 
DMEM containing 10% FCS, was added to the fixed cells for 1 hr at room temperature. 
Cells were rinsed in PBS three times. DAB (Diaminobenzidine, Vector Labs, CA, 
U.S.A.) substrate was freshly made up and added to cells for approximately 2 mins or 
until the desired staining intensity develops. The reaction was stopped by rinsing in 
water (Lane and Lane, 1981). 57 hybridoma cells lines were identified to produce 
antibodies against c-Met α-chain. 
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Secondary antibody screening 
57 antibodies identified in the primary screen were expanded and tested again for their 
reactivity against c-Met in the secondary antibody screen. We tested our monoclonal 
antibodies by Western blotting. Dot blot and cell staining screens were carried out by 
Moravian Biotechnology. We characterised the ability of our antibodies to detect 
transfected c-Met and endogenous c-Met from whole cell lysates by Western blot. 
NIH3T3 cells were transfected with c-Met and Met-GFP (as described above).  Whole 
cell lysate of NIH3T3 transfected cells, U-87MG cells and T47D cells were obtained by 
directly lysing the cells in boiling 2X LDS. Protein concentration was determined using 
the BCA kit and 50 μg of whole cell lysates were analysed on SDS-PAGE gel. Western 
blotting technique was performed as described above with the exception that hybridoma 
cell supernatants were diluted 1:1 in 5% Marvel/PBST (w/v).  
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Figure 2.5: Outline of monoclonal antibody screening. 
768 cell lines were screened for the production of anti-α-chain antibodies after hybridoma fusion. 57 lines were found to express anti-α-chain antibodies in the primary 
screen. These lines were expanded and tested again for the production of anti-α-chain antibodies in the secondary screen. 39 lines were observed to stably express anti-α-
chain antibodies. 21 lines were selected for single-cell cloning with advice from Moravian Biotechnology. These antibodies were then characterised for region of binding, 
isotype subclasses, functional assays (ERK phosphorylation and cell scatter), ability to cause cell cluster and functionality on Western blots. Based on these assays, 11 clones 
were selected for ascites production. Monoclonal antibodies were purified from ascites and characterised further. 
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Isotyping 
Mouse monoclonal antibodies isotype were characterised using the commercially-
available IsoQuick™ strips (Sigma-Aldrich). Isotyping strips were incubated in 
hybridoma cell supernatant for 5 mins. A red test line will develop on the strip. The 
position of the red test line is dependent on the antibody’s isotype, thus by referencing 
to the manufacturer’s isotyping chart, the antibody’s isotype is determined. 
 
Pepscan 
Peptides that span the entire alpha chain of c-Met was synthesised by Mimotopes 
(Australia). Peptides were linked to biotin by an SGSG linker sequence at the N-
terminus. A total of fifty-five peptides with consecutive, overlapping sequences were 
synthesised. Each peptide consists of 15 amino acid residues and overlapped the 
previous peptide by 10 amino acid residues. Streptavidin-coated plates (Pierce/Thermo 
Scientific, #15520) were blocked with 3% BSA/PBS (w/v) (200 μl per well) for 2 hrs at 
room temperature. The peptides were dissolved in DMSO and stored according to 
manufacturer’s recommendation. Streptavidin-coated plates were coated with each 
peptide (5 μg/ml) overnight at room temperature, in a humidity chamber. Wells were 
washed with 200 μl of 1% NP40/PBS (v/v). 100 μl of hybridoma supernatant (diluted 
1:10 in 1% BSA/PBS (w/v)) was added to the each well and the plate was incubated at 
room temperature for 2 hrs in a humidity chamber. The wells were washed again in 1% 
NP40/PBS. HRP-conjugated anti-mouse antibody (DAKO, diluted 1:1000 in 1% 
BSA/PBS) and incubated at room temperature for 2 hrs. The wells were washed again 
in 1% NP40/PBS. 50 μl of ELISA substrate (Bio-Rad #172-1067) solution was prepared 
freshly according to the manufacturer’s instructions and added to the wells. Colour 
change was monitored by eye and the reaction was stopped by adding 50 μl of 100 mM 
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sulphuric acid. Absorbance was read at 450 nM in a microplate reader (SPECTRAmax 
PLUS384, Molecular Device, CA, U.S.A.). The crystal structure of c-Met extracellular 
domain, 1SHY, was obtained from Protein Data Base (PDB). Computer imaging of the 
epitopes were analysed by PyMol (DeLano Scientific LLC, Hamilton Avenue, U.S.A.) 
software. 
 
Cell cluster assay 
0.004 x 106 SNU-5 cells/well were seeded in 24-well plates containing the indicated 
dilution of hybridoma cell supernatant. Hybridoma cell supernatant were diluted in 10% 
heat-inactivated FCS/RPMI. Cell clumping were observed 24 - 48 hrs later. Cell 
clumping was observed using Zeiss Axiovert 25 inverted microscope and pictures were 
taken using Canon EOS 1000 D. 
 
Cell scatter assay 
100 - 200 HaCaT cells were seeded in 24-well plates and allowed to grow until small 
colonies were formed (approximately 7 days). Cells were serum-starved for 24 hrs. 
Cells were incubated with hybridoma supernatants (dilutions as indicated) or purified 
monoclonal antibodies (1 μg/ml) for 1 hr before 10 ng/ml of HGF was added. Cells 
were incubated for 24 hrs before rinsing twice in cold PBS and fixing in ice-cold 
methanol for 10 mins. Cells were then stained in 1% crystal-violet (w/v) (Sigma-
Aldrich) solution for 5 mins. Antibody against HGF, anti-HGF, or SU11274 was used 
as a control. 5 μg/ml of anti-HGF was pre-incubated with HGF for 1 hr before adding to 
cells. SU11274 was added to a final concentration of 5 μM for 1 hr before HGF was 
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added to the cells. Cell staining was observed using Zeiss Axiovert 25 inverted 
microscope and pictures were taken using a Canon EOS 1000 D camera. 
 
ERK phosphorylation assay 
HaCaT cells (0.3 x 106 cells/well) were seeded in a 24-well plate and serum starved for 
24 hrs. Cells were incubated with hybridoma supernatants (dilutions as indicated) or 
purified monoclonal antibodies (1 μg/ml) for 1 hr before 10 ng/ml of HGF was added. 
Cells were incubated with HGF for 30 mins. Antibody against HGF, anti-HGF, or 
SU11274 was used as a control. 5 μg/ml of anti-HGF was pre-incubated with HGF for 1 
hr before adding to cells. SU11274 was added to a final concentration of 5 μM for 1 hr 
before HGF was added to the cells. Cells were immediately rinsed three times with cold 
PBS and lysed immediately in 100 μl of boiling 2X LDS loading buffer. The cell lysate 
was sonicated (three times, 10 sec each) and protein concentrations were determined 
using Pierce/Thermo Scientific BCA kit. Cell lysates were analysed by Western blotting 
as described above. The antibodies used for Western blotting are listed in Table 2.9. 
 
Flow cytometry 
Flow cytometry was performed with enormous help from Michael Boylan (Flow 
Cytometry Core Facility, College of Medicine, Dentistry and Nursing, University of 
Dundee, UK).   
T47D were trypsinised to remove them from tissue culture flask. T47D and SNU-5 cells 
(1 x 106 cells) were washed once in cold PBS before blocking in 1% BSA/PBS (w/v) 
for 15 mins at 4oC. Cells were then washed twice in cold 1% BSA/PBS before primary 
antibodies (diluted in 1% BSA/PBS) were added for 30 mins at 4oC, with rotation. 
61 
 
Primary antibodies, AF276 or c-Met monoclonal antibodies, was used at 1:70 dilution 
or 1 μg/ml respectively. Cells were washed in cold 1% BSA/PBS before incubating with 
FITC-conjugated secondary antibodies (diluted 1:500 with 1% BSA/PBS) for 30 mins 
at 4oC, with rotation. FITC-conjugated secondary antibodies were obtained from 
Invitrogen: Alexa Fluor 488 donkey anti-goat IgG (#A11055) and goat anti-mouse IgG 
(#A11029). Cells were finally washed twice in cold 1% BSA/PBS and resuspended in 
500 μl of 1% BSA/PBS. Flow cytometry was performed using Becton Dickinson (New 
Jersey, U.S.A.) FACScan. Cell Quest (Becton Dickinson) and FlowJo (Tree Star Inc., 
Ashland, U.S.A.) software was used for data analysis. 
Immunofluorescence 
SNU-5 cells (0.2 x 106 cells/slide) were washed once with PBS and deposited onto 
polylysine-coated slides (Thermo Scientific, #5991056) using the Thermo Shandon 
Cytospin 3 Cytofuge (Thermo Scientific) at 800 rpm for 5 mins and fixed immediately. 
T47D cells (0.8 x 105 cells/well) were seeded onto 4-well Permanox chamber slides 
(Nunc/Thermo Scientific, #177429) and were washed three times with PBS before 
fixation. 
Cells were fixed at 4oC for 10 mins in 1:1 cold methanol/acetone. Cells were 
permeablised and blocked in PBS containing 0.4% Triton X-100 (v/v) and 5% BSA 
(w/v). Blocking was performed for 30 mins before primary antibody was added and 
incubated overnight at 4oC. Slides were washed twice in PBS before FITC-conjugated 
antibody (1:500 dilution) was added and incubated for 1 hr at room temperature. Cells 
were washed twice again before staining with DAPI (stock concentration of 0.5 μg/ml 
in PBS) for 5 min at room temperature. Slides were washed once with PBS before 
mounting with Hydromount (National Diagnostics, Georgia, U.S.A.) containing 2.5% 
DABCO (1,4- Diazabicyclo-[2.2.2]octane) (Sigma-Aldrich) as an anti-bleaching agent. 
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Primary antibodies, AF276 or c-Met monoclonal antibodies, was used at 1:70 dilution 
or 1 μg/ml respectively. FITC-conjugated secondary antibodies were obtained from 
Invitrogen: Alexa Fluor 488 donkey anti-goat IgG (#A11055) and goat anti-mouse IgG 
(#A11029). Immunofluorescence was observed using Nikon Eclipse E600 microscope. 
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CHAPTER 3: RESULTS 
3.1: Developing and building bio-tools required for the anti-Met monoclonal 
antibody screening and development. 
The original aims of this work were to develop antibodies to native human c-Met by 
expressing human c-Met in a murine fibroblast cell line, NIH3T3, and using whole live 
cells as an immunogen in mice. Our initial attempts to study c-Met were difficult due to 
lack of useful reagents, such as antibodies, and cell lines that are known to be positive 
or negative for c-Met expression. Therefore, we needed to develop constructs 
expressing human c-Met and to analyse expression of both transfected and endogenous 
c-Met in various cell lines.  
3.1.1: Initial analysis of c-Met expression 
Full length human c-Met cDNA, commercially obtained from Invitrogen (IOH 36570), 
came ready-cloned in the Gateway entry plasmid, pENTR221. In order to express 
human c-Met in NIH3T3 cells, c-Met cDNA was cloned into the mammalian expression 
vector, pcDNA3-GW-DEST, using the Gateway LR clonase system. This plasmid was 
then transiently transfected into NIH3T3 cells and cell lysates were prepared for 
Western blot analysis. To compare c-Met expression levels in human cell lines, whole 
cell lysates from various cell lines were analysed on a Western blot using the 
commercial c-Met polyclonal antibodies SC-10 and AF276. These two antibodies were 
identified from a literature search to be specific to human c-Met and to be the most 
commonly-used antibodies for c-Met research. SC-10 is a polyclonal antibody that was 
raised against a peptide within the C-terminal cytoplasmic region of human c-Met and 
would be expected to recognise c-Met precursor and mature c-Met β-chain on Western 
blots. AF276 is a polyclonal antibody raised against the extracellular domain of human 
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c-Met and should recognise c-Met precursor, mature c-Met α-chain and mature c-Met β-
chain on Western blots. Whole cell lysate from NIH3T3 cells expressing human c-Met 
was analysed along with the lysates from the various human cell lines (Figure 3.1).  
c-Met would normally give rise to three protein bands on a Western blot: a 170 kD band 
that represents c-Met precursor, consisting of the α- and β-chain translated together, a 
50 kD band that represents c-Met α-chain, and a 145 kD protein band that represents the 
mature c-Met β-chain. The disulphide bridge between the α-chain and β-chain is 
predicted to be broken as the samples are prepared under reducing conditions. Analysis 
of c-Met expression in these cell lines was difficult to interpret due to multiple bands on 
the Western blot (Figure 3.1). In addition, the rabbit polyclonal commercial antibody, 
SC-10, weakly recognises a protein band of similar molecular weight to c-Met in 
untransfected NIH3T3 cells. The AF276 antibody, goat polyclonal, does not recognise 
the same protein band as SC-10 in the untransfected NIH3T3 sample. Without a cell 
lines to provide positive and negative controls, it is difficult to interpret if the 
commercial antibodies recognise human c-Met and/or also the murine homolog of c-
Met.    
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Figure 3.1: Western blot 
analysis of c-Met from various 
cell lines. 
50 μg of total cell lysate (samples 
provided by P. Robertson) from 
various cell lines were analysed 
for c-Met protein expression. c-
Met was detected using the 
commercial antibodies SC-10 and 
AF276. NIH3T3 transfected with 
human c-Met was used as a 
control. Blue arrows indicate 
predicted precursor c-Met protein 
band (top band) and c-Met β-
chain (bottom band). Actin was 
used as a loading control. Red 
arrows indicate actin band. 
Molecular weights are noted 
aside, in kilodaltons. NIH3T3: 
NIH3T3 cells transfected with 
human c-Met; UT: Untransfected 
NIH3T3 cells. 
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SC-10 and AF276 antibodies were identified during a literature search to identify 
reliable commercial c-Met antibodies used to examine c-Met expression. However, 
these antibodies gave conflicting results in the analysis of c-Met expression from 
various cell lines as shown in Figure 3.1. A third commercial antibody, EP1454Y from 
Abcam, was identified by scanning through commercial c-Met antibodies offered by 
various biotechnology companies. EP1454Y is an anti-peptide human-specific rabbit 
monoclonal antibody. The antibody datasheet describes that EP1454Y epitope lies in 
the N-terminal region of c-Met, but it is not clear if this is the α or β-chain of c-Met. 
According to the datasheet, this antibody should recognise a single band at 
approximately 160 kD using 293 cell lysates. To compare these c-Met commercial 
antibodies (SC-10, AF276 and EP1454Y), endogenous c-Met was immunoprecipitated 
(IP) from H1299 cell lysate (human lung cancer cell line). H1299 cells were used 
because they were easily availability in the laboratory and preliminary results suggest 
that they were positive for c-Met expression (Figure 3.1). Immunoprecipitated proteins 
were analysed by Western blotting using commercial c-Met antibodies (Figure 3.2). 
3.1.2: Analysis of c-Met commercial antibodies 
EP1454Y antibody failed to immunoprecipitate any c-Met (precursor or β-chain) 
protein of the predicted molecular weight that could be detected by SC-10, AF276 
antibodies or by itself. EP1454Y also failed to detect c-Met immunoprecipitated by SC-
10 and AF276 on a Western blot, though it detected a single high molecular weight 
band in the input sample. This protein band is similar to the c-Met protein band shown 
in EP1454Y datasheet. It is very unlikely that this band represents c-Met as the same 
band was not detected by EP1454Y in the samples immunoprecipitated by SC-10, 
AF276 antibodies or by itself. Moreover, the same band was also not 
immunoprecipitated by EP1454Y shown in the SC-10 and AF276 blots. SC-10 and 
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AF276 both successfully immunoprecipitated c-Met and successfully detected 
immunoprecipitated c-Met on a Western blot. EP1454Y was not used for any further 
analysis. 
To investigate further the specificity of SC-10 and AF276 antibodies, the mouse cell 
line, NIH3T3, was transfected with human c-Met tagged to a C-terminal GFP (Met-
GFP). Processing of the full length Met-GFP precursor will result in an un-tagged α-
chain and a GFP-β-chain fusion. Met-GFP was immunoprecipitated by either SC-10 or 
AF276 and the immunoprecipitated proteins were analysed by Western blotting with 
anti-GFP, SC-10 and AF276 antibodies (Figure 3.3). As observed from the anti-GFP 
blot, Met-GFP was clearly detectable. Both SC-10 and AF276 antibodies managed to 
successfully immunoprecipitate Met-GFP from the cell lysate, confirming that these 
antibodies are able to bind to human c-Met. However, the intense Met-GFP band 
detected by the anti-GFP antibody (within a relatively short exposure) suggests that this 
antibody has a much higher affinity for its target that the c-Met commercial antibodies. 
From Figure 3.3, it is observed that SC-10 and AF276 antibodies successfully 
immunoprecipitated transfected c-Met (i.e. Met-GFP), but failed to immunoprecipitate 
and/or detect endogenous murine c-Met. This indicates that either the antibodies do not 
recognise murine c-Met or that NIH3T3 cells do not express c-Met. Finally, in the anti-
GFP antibody blot, it is observed that the protein bands of c-Met in the input samples 
are smaller than the immunoprecipitated samples. The reason causing the molecular 
weight difference is unclear, however, it is possible that the process of 
immunoprecipitating c-Met on a protein bead is similar to the overexpression of c-Met 
on the cell surface of cancer cells. Clustering of c-Met on a surface leads to self-
dimerisation and self-activation of c-Met. c-Met may be phosphorylated which could 
cause an apparent increase in molecular weight. 
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The SC-10 antibody blot had high levels of apparently non-specific bands. As observed 
in the rabbit immunoglobulin sample, non-specific rabbit immunoglobulins which 
bound to the protein beads were eluted together with immunoprecipitated Met-GFP. 
The rabbit immunoglobulins are detected by the secondary antibody (anti-rabbit 
secondary antibody) used in the Western blot analysis, resulting in the protein smear 
observed. SC-10 antibody was able to detect c-Met immunoprecipitated by SC-10 and 
AF276 antibodies.  
The AF276 blot had fewer non-specific bands compared to the SC-10 antibody blot. 
AF276 antibody successfully detected Met-GFP immunoprecipitated by SC-10 and 
AF276 antibodies. The non-specific protein bands observed at approximately 51 kD and 
25 kD correspond to the heavy and light chain of the antibody used for 
immunoprecipitation. 
To compare the efficiency of both commercial antibodies (SC-10 and AF276) to 
immunoprecipitate Met-GFP, cell lysates obtained after immunoprecipitation (depleted 
cell lysate) were collected and analysed on Western blots using anti-GFP antibodies 
(Figure 3.4). Clearly, AF276 antibody is more efficient in immunoprecipitating Met-
GFP compared to SC-10 antibody. This could be due to the different epitopes that the 
antibodies recognise. AF276 epitopes lies in the extracellular region of c-Met (α- and β-
chain) while SC-10 antibody recognises the C-terminal region of c-Met β-chain. The 
epitope for SC-10 could be partially obscured by the GFP tag which is constructed in 
the C-terminus tail of Met-GFP. Finally, AF276 antibody showed stronger band 
intensity in the c-Met precursor band compared to the mature β-chain. This suggests 
that either the main epitopes of AF276 antibody (goat polyclonal antibody) lie in the α-
chain or that AF276 antibody has a higher affinity to c-Met α-chain compared to the β-
chain.    
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Figure 3.2: Western blot analysis of c-Met immunoprecipitation (IP) with various anti-cMet 
antibodies.  
Proteins were immunoprecipitated from H1299 cell lysate using antibodies as shown and detected with 
antibodies shown below each panel. Control immunoprecipitations were performed with rabbit 
immunoglobulin (rabbit Ig) and protein G beads alone. Inputs are whole cell lysate before 
immunoprecipitation. Input samples contain 1/10th of the amount of samples used for 
immunoprecipitation. Arrows indicate c-Met protein bands at 145 kD and 170 kD. Molecular weights are 
noted aside, in kilodaltons. 
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Figure 3.3: Western blot analysis of Met-GFP immunoprecipitation, detected using anti-GFP, SC-10 and AF276 antibodies. 
NIH3T3 cells transfected with Met-GFP were lysed and cell lysate were immunoprecipitated using SC-10 and AF276 antibodies. Control immunoprecipitations were 
performed with rabbit immunoglobulin (rabbit Ig), goat sera and protein G beads alone. Inputs are whole cell lysate before immunoprecipitation. Input samples contain 1/10th 
of the amount of samples used for immunoprecipitation. Red asterisk indicate Met-GFP protein bands at approximately 172 kD and 197 kD. UT: Untransfected. Molecular 
weights are noted aside, in kilodaltons. 
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Figure 3.4: Western blotting of Met-GFP depleted cell lysate using anti-GFP antibodies. 
NIH3T3 cells transfected with Met-GFP were lysed and cell lysate were immunoprecipitated using SC-10 
and AF276 antibodies. Depleted cell lysate (cell lysate left after immunoprecipitation) were collected and 
analysed by Western blotting. Control immunoprecipitations were performed with rabbit immunoglobulin 
(rabbit Ig), goat sera and protein G beads alone. Inputs are whole cell lysate before immunoprecipitation. 
Inputs contain 1/10 of immunoprecipitated proteins. Arrows indicate Met-GFP protein band at 
approximately 172 kD and 197 kD. UT: Untransfected. Molecular weights are noted aside, in kilodaltons. 
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To investigate the possibility of improving c-Met expression in NIH3T3 cells, c-Met 
full length cDNA (from IOH 36570) was cloned into various vectors and transfected 
into NIH3T3 cells. The vectors are grouped into two categories, based on the type of 
promoter they contain. The pcDNA3 vectors (pcDNA3-GW-DEST, pcDNA3-GFPc-
GW-DEST and pcDNA3-SBPc-GW-DEST) are pcDNA3-based vectors that contain a 
CMV TATA promoter and different C-terminal tags i.e. GFP or streptavidin binding 
peptide (SBP) tag.  The SBP is a peptide that binds specifically to streptavidin and can 
be used for protein purification. The pCMV-SCP-based vectors (pCMV-SCP-EFI-FRT-
GW-DEST and pCMV-SCP-EFI-SBPc-GW-DEST) and pLenti vector (pLenti6.3-GW-
DEST) contain an improved version of the CMV promoter, termed Super Core 
Promoter (SCP), which greatly increases gene transcription (Juven-Gershon et al., 
2006). In addition, these vectors also contain an intron, located at the 5’ end of the gene, 
which belongs to the first intron of Elongation Factor I (EFI). Although not true for all 
genes, the presence of introns is reported to help the nuclear export machinery to 
recognise the mRNA of interest and export it out of the nucleus to be translated 
(Brinster et al., 1988; Dreyfuss et al., 2002). 
3.1.3: Improvement of c-Met expression in NIH3T3 
Previously, plasmids used for expressing c-Met (c-Met without tag, Met-GFP and Met-
SBP) were from the pcDNA3-based plasmids containing the CMV TATA promoter. 
Here, we compare c-Met expression from pCMV-SCP-based plasmids, which contains 
the super core promoter and the additional 5’ intron sequences, with and without a C-
terminal V5 tag. We also compare c-Met expression, with and without a C-terminal V5 
tag, from the pLenti-based plasmid which also shares the same super core promoter and 
5’ intron sequences as the pCMV-SCP-based plasmids.  
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Cell lysates obtained from NIH3T3 cells transfected with the various c-Met plasmids 
were analysed on a Western blot (Figure 3.5). The approximate molecular weight of c-
Met and its various constructs are listed in Table 3.1 (below). c-Met protein bands 
(indicated by red asterisks in Figure 3.5) from the pcDNA3-based plasmids were quite 
faint, especially in Met-SBP and Met-GFP samples. There is increased c-Met 
expression in the pCMV-SCP-based and pLenti-based plasmids when compared to the 
pcDNA3-based plasmids. Other than sharing the same promoter and the additional 
intron sequences, pCMV-SCP-based plasmids and pLenti-based plasmids are totally 
different vectors. It is clear that that the increased c-Met expression is due to the effects 
of the promoter and intron sequences. A non-specific band, close to c-Met protein 
bands, is observed in every sample. Lastly, it is unclear why only one c-Met band is 
being observed from the cell extracts. It is uncertain if this c-Met band belongs to the 
mature β-chain or the precursor protein. However, the staggering bands of tagged and 
untagged c-Met further confirms that c-Met is being detected in this Western blot.    
Table 3.1: Molecular weight of c-Met and constructs. 
Constructs 
Approximate molecular weight  
Mature c-Met β-
chain 
c-Met precursor 
protein 
c-Met 145 kD 170 kD 
Met-V5 146 kD 171 kD 
Met-SBP 149 kD 174 kD 
Met-GFP 172 kD 197 kD 
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Figure 3.5: Western blot analysis of c-Met expression in NIH3T3 cells using various expression 
constructs.  
Full length c-Met cDNA was cloned into various mammalian cell expression vectors and transfected into 
NIH3T3 cells. 50 μg of whole cell lysate was analysed for c-Met expression in each sample. c-Met 
expression was detected using the AF276 antibody. Actin was used as a loading control. Red asterisk 
indicate c-Met (see text) and its various tagged constructs. Molecular weights are noted aside, in 
kilodaltons. Various expression constructs were used, as indicated:  
pCMV-Met-V5: c-Met with V5 tag in pCMV-SCP-EFI-FRT-GW-DEST 
pCMV-Met: c-Met in pCMV-SCP-EFI-FRT-GW-DEST (no tag) 
pLenti6.3-Met-V5: c-Met with V5 tag in pLenti6.3-GW-DEST 
pLenti6.3-Met: c-Met in pLenti6.3-GW-DEST (no tag) 
pcDNA3-Met: c-Met in pcDNA3-GW-DEST (no tag) 
pcDNA3-Met-SBP: c-Met with SBP C-terminal tag in pcDNA3-SBPc-GW-DEST 
pcDNA3-Met-GFP: c-Met with GFP C-terminal tag in pcDNA3-GFPc-GW-DEST 
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The aim of this project is to produce therapeutic antibodies against c-Met. An 
understanding of c-Met expression levels in various cell lines is required to develop a 
good antibody screening protocol to select for anti-cMet antibodies. To determine 
endogenous c-Met protein levels and phosphorylation/activation status in different cell 
lines, cell extracts from four cell lines were selected for analysis. U-87MG (human 
glioblastoma cell line), T47D (human breast cancer cell line) and SNU-5 (human gastric 
cell line) cells were selected through a literature search while HaCaT cells (human skin 
keratinocyte cell line) were selected due to their tight colony formation growth 
characteristics. The growth characteristics of HaCaT cells are required for cell motility 
assays which will be discussed later in Section 3.3. Cell extracts from U-87MG, T47D, 
HaCaT and SNU-5 cells were prepared and proteins immunoprecipitated using the 
AF276 antibody. As a control, goat sera were also used for immunoprecipitation. 
Immunoprecipitated samples were analysed on Western blots using SC-10 to detect 
expression of endogenous c-Met. To detect the phosphorylation status of endogenous c-
Met, immunoprecipitated samples were also analysed on the Western blot using anti-
phospho-tyrosine 4G10 antibody (Figure 3.6).  
3.1.4: Further analysis of c-Met expression in selected cell lines 
Consistent with other reports, U-87MG and SNU-5 cells are positive for c-Met protein 
expression, while T47D cells have undetectable levels of c-Met (Bellon et al., 2008; 
Shen et al., 2000; van der Horst et al., 2009). HaCaT cells are positive for c-Met protein 
expression and due to their ability to grow in colonies, they could be used to test our 
monoclonal antibodies in cell motility assays. SNU-5 cells express the highest amount 
of c-Met followed by HaCaT cells, U-87MG cells and finally, T47D cells. Interestingly, 
unlike other cell lines, the precursor band of c-Met (170 kD) from the HaCaT 
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immunoprecipitated sample is not detected by SC-10 antibody, suggesting that 
precursor c-Met is not tolerated in the cell and is rapidly processed into the mature form.  
c-Met is known to be activated and phosphorylated upon binding to its ligand, 
hepatocyte growth factor (HGF). Lysates were also analysed from cells treated with 
HGF. It is difficult to interpret c-Met activation status in SNU-5 cells. Large numbers of 
protein bands were detected by 4G10 antibody in the SNU-5 samples 
immunoprecipitated by both AF276 antibody and by control goat sera. Therefore, it is 
possible that proteins from SNU-5 cell extract were binding non-specifically to the 
beads or the goat antibodies and these are being detected by 4G10 antibody. However, 
two bands corresponding to the predicted molecular weight of c-Met precursor and β-
chain are detected by 4G10 antibody and these show a similar intensity in the presence 
and absence of HGF, suggesting that c-Met is constitutively active in this cell line. 
There is no difference observed in c-Met protein expression levels upon stimulation 
with HGF in HaCaT and U-87MG cells, though c-Met is phosphorylated in these cell 
lines in response to HGF. Interestingly, although U-87MG cells are reported to be 
autocrine (expresses both c-Met and HGF) for c-Met signalling, c-Met is only 
detectably phosphorylated upon incubation with HGF. This might suggest a mechanism 
within the cell that inhibits c-Met’s constant activation in U-87MG cells.   
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Figure 3.6: Western blot analysis of 
endogenous c-Met 
immunoprecipitated with AF276 
antibody. 
U-87MG, T47D, HaCat and SNU-5 
cells were incubated with 10 ng/ml of c-
Met ligand (HGF) for 30 mins to induce 
activation and phosporylation of c-Met. 
Cells incubated with and without HGF 
were lysed in NP40 lysis buffer. 
Proteins were immunoprecipitated using 
AF276 antibody (a, b, c) or goat sera (d 
& e). Immuunoprecipitated samples 
were detected on Western blots using 
SC-10 (a & d) and 4G10 (b, c & e) 
antibodies. b & c) Same blots with 
different exposure time. NIH3T3 cells 
transfected with human c-Met were 
controls. Blue arrows indicate 
endogenous and exogenous c-Met. Red 
arrows indicate activated/phosporylated 
endogenous c-Met. HGF: Hepatocyte 
growth factor. Molecular weights are 
noted aside, in kilodaltons. 
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The Streptavidin Binding Peptide (SBP) was reported by Keefe et al. in 2001 as a 
peptide that binds very specifically to streptavidin, but not to avidin. SBP is made up of 
38 amino acid residues, has a molecular weight of approximately 4.2 kD, and can be a 
useful protein purification tag. Protein purified using the SBP tag was shown to be purer 
than protein purified using maltose-binding protein or histidine tag (Keefe et al., 2001). 
The simplicity of the SBP tag protein purification protocol and the wide range of 
commercially available streptavidin-associated products in the market (i.e. streptavidin-
coated plates) makes the SBP tag a useful tool for high-throughput protein purification. 
3.1.5: Streptavidin binding peptide 
Proteins previously reported to be purified by SBP tag have been tagged at the N-
terminus (Keefe et al., 2001). c-Met contains a plasma membrane localisation signal at 
the N-terminus (Materials and Methods, Figure 2.1), which is cleaved off during protein 
maturation, therefore c-Met can only be tagged at the C-terminus. We made constructs 
expressing GFP tagged with SBP, either at the N- or C-terminus, to determine whether 
this tag could successfully be used in either context. These constructs were transfected 
into NIH3T3 cells. Cell lysates were prepared and pre-cleared with avidin-coated beads 
to remove non-specific proteins. Pull down experiments were then performed with 
streptavidin-conjugated magnetic beads and bound proteins were eluted with biotin. The 
beads were boiled to extract any remaining proteins that bound to the beads. Purified 
proteins were resolved on a SDS-PAGE gel and stained with Coomassie blue dye to 
determine the purity of the pull down experiment (Figure 3.8). Western blotting, using 
an anti-GFP antibody and streptavidin-conjugated peroxidase, was also performed 
(Figure 3.8). Both N-terminally tagged and C-terminally tagged GFP constructs were 
successfully pulled down with high purity as observed in the Coomassie-stained SDS 
gel. The pull down is observed to be very efficient and specific as none of GFP-tagged 
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proteins were observed in the depleted lysate samples or the boiled avidin beads 
samples. There is a difference in the molecular weight of N-terminal tagged GFP and C-
terminal tagged GFP (see shift in molecular weight in Figure 3.8). This difference is due 
to transfer of C-terminal vector sequences incorporated during the Gateway cloning 
process. A band of lower molecular weight can also be detected by the anti-GFP 
antibody in the N-SBP input sample. This band is likely to be untagged GFP which is 
expressed from an alternate initiation codon, downstream of the tag (Figure 3.7). This is 
confirmed by the observation that this protein band is not purified by the streptavidin 
bead pull down and is also not detected by the streptavidin-conjugated peroxidase on 
the Western blot.  
Streptavidin-conjugated peroxidase detects proteins tagged with SBP. Consistent with 
the protein bands observed on the anti-GFP blot, streptavidin-conjugated peroxidase 
detected the same GFP constructs. However, three higher molecular weight bands were 
being purified by the streptavidin-conjugated magnetic beads (in the boiled streptavidin-
conjugated magnetic beads samples).  It is likely that these proteins bind to the magnetic 
beads and not streptavidin as these proteins bands are only observed when the beads are 
boiled and not upon competitive elution by biotin. 
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Figure 3.7: Illustration of GFP N-terminally tagged with SBP (SBP-GFP) construct (not drawn to 
scale).  
The SBP tag is a 4.2 kD protein and GFP is a 26.9 kD protein. The SBP tag is cloned 5’ of GFP gene, 
which also contains its own transcription initiation start codon (red arrows, ATG). Transcription may 
initiate from the SBP tag, producing the 31.1 kD SBP-GFP protein. Alternatively, transcription may also 
initiate from the GFP gene to produce the 26.9 kD GFP protein. 
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Figure 3.8: Coomassie-stained SDS-
PAGE gel and Western blot analysis 
of GFP-SBP pull down using 
streptavidin-conjugated magnetic 
beads. 
Plasmids expressing either N- or C- 
terminally tagged GFP, as indicated, 
were transfected into NIH3T3 cells. 
Cell lysate was initially pre-cleared 
with avidin beads. Proteins binding to 
streptavidin were purified using 
streptavidin-conjugated magnetic 
beads and eluted using biotin. After 
biotin elution, streptavidin-conjugated 
magnetic beads were boiled in loading 
buffer to recover any protein left on 
the beads. SBP pull down is analysed 
by Coomassie blue staining of the 
SDS-PAGE gel and by Western 
blotting using an anti-GFP antibody 
and streptavidin-conjugated 
peroxidase (streptavidin-HRP). Input 
lanes contain 1/10th of the amount 
used for purification are shown as 
controls. Bands representing N- or C- 
terminally tagged GFP can be seen as 
indicated by the red asterisk. Elute: 
Purified protein samples obtained by 
elution with biotin. Boiled beads: 
Purified protein samples obtained 
from boiling streptavidin-conjugated 
magnetic beads in LDS. N-SBP: GFP 
N-terminally tagged with SBP. C-
SBP: GFP C-terminally tagged with 
SBP. UT: Untransfected. Molecular 
weights are noted aside, in kilodaltons. 
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To test if the C-terminal SBP tag can be used to purify c-Met, full length c-Met cDNA 
was Gateway cloned into pCMV-SCP-EFI-SBPc-GW-DEST vector and the resulting 
construct was transfected into NIH3T3 cells. Cell lysate was pre-cleared using avidin-
coated beads and proteins pulled down with streptavidin-conjugated magnetic beads. 
Purified proteins were analysed by Western blotting using AF276 antibody and 
streptavidin-conjugated peroxidase (Figure 3.9). Using streptavidin-conjugated 
peroxidise, the very high number of non-specific bands made it impossible to determine 
if any c-Met proteins were recognised. However, AF276 antibody detected two bands, 
with molecular weights corresponding to those of the Met-SBP precursor (174 kD) and 
the β-chain (149 kD). In the AF276 antibody and streptavidin-conjugated peroxidase 
blots, two protein bands (red asterisks) were observed in the elute lane corresponding to 
c-Met, indicating that Met-SBP was eluted from streptavidin by competition with biotin. 
Unlike SBP-tagged GFP constructs (Figure 3.8), Met-SBP was only partially eluted 
from the beads. The remaining Met-SBP was released by boiling. Finally, two protein 
bands (blue asterisks) are detected by AF276 antibody in the depleted lysate sample. It 
is unclear if these bands belong to c-Met as they are slightly smaller than the other c-
Met bands. The SBP purification is an excellent method of protein purification which 
we have shown to efficiently purify large protein such as c-Met from whole cell lysates, 
produce highly pure proteins, and could potentially yield native protein due to mild 
elution conditions using biotin.  
3.1.6: Purification of c-Met via SBP tag pull down  
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Figure 3.9: Western blot analysis of cMet-SBP purification from NIH3T3 cells. 
The plasmid expressing Met-SBP was transfected into NIH3T3. Cell lysate was prepared and pre-cleared 
using avidin-coated beads. Proteins were purified using streptavidin-conjugated magnetic beads. Purified 
proteins were eluted using biotin and were analysed on a Western blot using streptavidin-conjugated 
peroxidase (streptavidin-HRP), or AF276 antibody. Input samples contain 1/10th of the amount used for 
purification. Depleted cell lysate was analysed to determine the efficiency of SBP pull down. Avidin 
beads used for pre-clearing were boiled and analysed to confirm the specificity of SBP to streptavidin and 
not avidin. Protein bands representing Met-SBP β-chain (149 kD) and Met-SBP precursor (174 kD) are 
both indicated by the red asterisk. Elute: Purified protein samples obtained by elution with biotin. Boiled 
beads: Purified protein samples obtained from boiling streptavidin-conjugated magnetic beads in LDS. 
Met-SBP: c-Met with C-terminal SBP tag. UT: Untransfected. Molecular weights are noted aside, in 
kilodaltons. 
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As shown earlier, human c-Met transient expression in NIH3T3 cells was improved by 
using pCMV-SCP-based vectors (Figure 3.5). However, c-Met expression levels in 
these transfected cells were not significantly higher then untransfected cells. To improve 
expression efficiency, the adenovirus expression system was used to introduce human c-
Met cDNA into mammalian cells. 
3.1.7: Adenoviral expression of human c-Met 
c-Met was successfully purified using the SBP tag (Figure 3.9). SBP purification allows 
high-throughput protein purification which is useful for antibody screening i.e. high 
levels of Met-SBP could be easily purified and used to screen for antibodies against c-
Met or used as an immunogen. c-Met and Met-SBP were thus cloned into the adenoviral 
plasmid pADEasy1. Two plasmids, from different bacterial colonies, were selected and 
purified for each construct. To produce infectious virus particles, plasmids were 
transfected into AD293 cells. A Western blot analysis was performed on infected 
AD293 cell lysates to ensure that c-Met was being expressed (Figure 3.10). Two high 
molecular weight bands were observed from whole cell lysate samples obtained from 
AD293 cells infected with both c-Met constructs. These protein bands are consistent 
with the molecular weight of unprocessed and β-chain of c-Met, indicating that 
adenovirus had successfully infected AD293 cells, and that both constructs were 
successfully expressed by the cell. Expression of c-Met from plasmid #1 is higher as 
compared to plasmid #3. Similarly, expression of Met-SBP from plasmid #4 is higher 
compared to plasmid #5. c-Met #1 and Met-SBP #4 were therefore chosen for bulk 
virus amplification.      
Western blotting of AD293 cells infected with adenovirus was a preliminary test to 
verify that c-Met constructs were expressed by cells. To ensure that c-Met cDNA 
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constructs are being expressed by the adenovirus, viruses were used to infect T47D cells 
(c-Met low expressing cell line). Infected cells were harvested and analysed on a 
Western blot for c-Met expression using AF276 antibody (Figure 3.10). As a loading 
control, a Coomassie-stained SDS-PAGE gel was used. c-Met and Met-SBP were 
expressed, but at very low levels (Figure 3.10). It is unclear why the expressions of the 
constructs were low. As T47D expresses low levels of c-Met, it is possible that T47D 
cells harbour some transcription defects or has a strong negative regulation against c-
Met expression. The failure to achieve high level expression of c-Met in these 
experiments caused us to alter our original strategy of immunising with whole cells and 
led us to pursue the expression of c-Met in prokaryotic system. 
 
Figure 3.10: Expression of c-Met and Met-SBP in mammalian cells using adenovirus infection. 
a) Western blotting of adenovirus expression of c-Met and Met-SBP in Ad293 cells. Two individual 
plasmid isolates were used for each plasmid construct. Plasmids were transfected into Ad293 cells and 
whole cell lysate was obtained. Expression of c-Met constructs was analysed on Western blot using 
AF276 antibody. b) Analysis of c-Met and Met-SBP in T47D cells. Infectious virus particles carrying c-
Met and Met-SBP constructs were used to infect T47D cells. Whole cell lysate was obtained from 
infected cells and c-Met expression was detected on Western blot using AF276 antibody. Black arrows 
indicate various c-Met protein constructs. As a loading control, a Coomassie-stained gel was performed. 
Molecular weights are noted aside, in kilodaltons UI: Uninfected.       
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We demonstrated that the affinity of c-Met commercial antibodies (SC-10 and AF276) 
towards human c-Met was poor and EP1454Y antibodies showed undetectable levels 
human c-Met on Western blots. AF276 antibody was the best commercial antibody 
tested for detecting c-Met from cell lysates in Western blots. However, to use AF276 
antibody to detect c-Met on Western blots, optimisation of blotting protocol, large 
amount of cell lysate and long exposures were still required. The next stage of this 
project was to make antibodies that have higher affinity and specificity towards human 
c-Met than the commercially available ones. These could then be tested for functional 
activity in either suppressing or inducing c-Met activity.  
3.1.8: Prokaryotic expression of c-Met constructs 
Monoclonal antibodies against human c-Met were produced by immunising mice with 
different regions of bacterially expressed, purified, human c-Met. Four regions of 
human c-Met were cloned into the prokaryotic expression vector, pET19b, for protein 
expression. The four c-Met constructs are: α-chain (full length), extracellular β-chain, 
extracellular αβ-chain (the extracellular domain of c-Met) and full length β-chain 
(Figures 3.11A to D). c-Met constructs were transformed into seven different bacteria 
strains: BL21 DE3, BL21 star, BL21 pLysS, Rosetta-gami 2 DE3 (RG2 DE3), Rosetta-
gami 2 pLysS (RG2 pLysS), Rosetta-gami B DE3 (RGB DE3) and Rosetta-gami B DE3 
pLysS (RGB DE3 pLysS). Different bacteria strains have specific characteristics (please 
refer to Table Materials and Methods), such as increased stability of mRNA, enhanced 
disulphide bond formation in the bacterial cytoplasm, and enhanced expression of 
eukaryotic proteins by containing specific tRNA. Any of these characteristics may 
increase the expression and solubility of c-Met constructs.  
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To determine if the bacteria strains are able to express the various c-Met constructs, 
protein expression was induced with IPTG and analysed on a Coomassie blue stained 
SDS-PAGE gel (Figures 3.11A to D). Among the four different c-Met constructs, c-Met 
α-chain was most successfully expressed in all seven bacteria stains. This is followed by 
c-Met extracellular β-chain, full length β-chain and lastly, extracellular αβ-chain. It is 
observed that as the molecular weight of the c-Met construct increases, the ability to 
expresses the protein decreases, hence resulting in the faint band observed in the higher 
molecular weight constructs i.e. full length β-chain (~119 kD) and extracellular αβ-
chain (~100 kD) samples. In addition, the presence of other endogenous protein bands 
near the extracellular αβ-chain protein band on the SDS-PAGE gel made the protein 
difficult to distinguish. BL21 pLysS was chosen for large scale protein expression of the 
α-chain. BL21 star was selected to express the extracellular β-chain, extracellular αβ-
chain and full length β-chain constructs in larger quantities (Figures 3.12A to D). 
Protein expression of the various c-Met constructs was induced for three hours before 
cells were harvested and lysed in lysis buffer (0.3 M KCL, 50 mM KH2PO4, pH 8.0). 
Bacteria lysate was centrifuged to separate soluble (cell supernatant) and insoluble 
proteins (cell debris pellet). To determine if the expressed protein resides in the soluble 
or insoluble fraction after cell lysis, cell supernatant and cell debris pellet samples were 
resolved on a SDS-PAGE gel (Figures 3.11A to D). Total bacterial cell lysate was used 
as a control. Despite the use of various bacteria strains in an attempt to increase the 
solubility of c-Met protein constructs, all four constructs were observed predominantly 
in the insoluble pellet. The insolubility of c-Met constructs does not pose a problem as 
denatured protein samples can be used for the immunisation of mice. Insoluble c-Met 
proteins were extracted from bacterial cell lysate by centrifugation and solubilised in 
6M urea before purification.     
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Figure 3.11A: Prokaryotic expression of human c-Met α-chain. 
a & c) SDS-PAGE gels stained with Coomassie blue dye. c-Met α-chain is indicated by the arrow. 
Molecular weights are noted aside, in kilodaltons. a) Cultures of seven bacteria strains containing c-Met 
α-chain construct were induced with IPTG for 3 hrs. Cells were harvested at 30 mins intervals to check 
for the expression of c-Met α-chain. b) Illustration of c-Met α-chain that is being expressed is highlighted 
in the black oval (not drawn to scale). Predicted molecular weight and number of amino acid residues of 
c-Met α-chain are shown. c) Solubility of c-Met α-chain expressed by the various bacteria strains was 
tested. c-Met α-chain was induced for 3 hrs before cells were harvested. RG2: Rosetta-gami 2. RGB: 
Rosetta-gami B. Whole: Bacteria lysate before centrifugation.   
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Figure 3.11B: Prokaryotic expression of human c-Met extracellular β-chain. 
a & c) SDS-PAGE gels stained with Coomassie blue dye. c-Met extracellular β-chain is indicated by the 
arrow. Molecular weights are noted aside, in kilodaltons. a) Cultures of seven bacteria strains containing 
c-Met extracellular β-chain construct were induced with IPTG for 3 hrs. Cells were harvested at 30 mins 
intervals to check for the expression of c-Met extracellular β-chain. b) Illustration of c-Met extracellular 
β-chain that is being expressed is highlighted in the black oval (not drawn to scale). Predicted molecular 
weight and number of amino acid residues of c-Met extracellular β-chain are shown. c) Solubility of c-
Met extracellular β-chain expressed by the various bacteria strains was tested. c-Met extracellular β-chain 
was induced for 3 hrs before cells were harvested. RG2: Rosetta-gami 2. RGB: Rosetta-gami B. Whole: 
Bacteria lysate before centrifugation. 
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Figure 3.11C: Prokaryotic expression of human c-Met extracellular αβ-chain (or extracellular 
domain of c-Met). 
a & c) SDS-PAGE gels stained with Coomassie blue dye. c-Met extracellular αβ-chain is indicated by the 
arrow. Molecular weights are noted aside, in kilodaltons. a) Cultures of seven bacteria strains containing 
c-Met extracellular αβ-chain construct were induced with IPTG for 3 hrs. Cells were harvested at 30 mins 
intervals to check for the expression of c-Met extracellular αβ-chain. b) Illustration of c-Met extracellular 
αβ-chain that is being expressed is highlighted in the black oval (not drawn to scale). Predicted molecular 
weight and number of amino acid residues of c-Met extracellular αβ-chain are shown. c) Solubility of c-
Met extracellular αβ-chain expressed by the various bacteria strains was tested. c-Met extracellular αβ-
chain was induced for 3 hrs before cells were harvested. RG2: Rosetta-gami 2. RGB: Rosetta-gami B. 
Whole: Bacteria lysate before centrifugation. 
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Figure 3.11D: Prokaryotic expression of human c-Met full length β-chain. 
a & c) SDS-PAGE gels stained with Coomassie blue dye. c-Met full length β-chain is indicated by the 
arrow. Molecular weights are noted aside, in kilodaltons. a) Cultures of seven bacteria strains containing 
c-Met full length β-chain construct were induced with IPTG for 3 hrs. Cells were harvested at 30 mins 
intervals to check for the expression of c-Met full length β-chain. b) Illustration of c-Met full length β-
chain that is being expressed is highlighted in the black oval (not drawn to scale). Predicted molecular 
weight and number of amino acid residues of c-Met full length β-chain are shown. c) Solubility of c-Met 
full length β-chain expressed by the various bacteria strains was tested. c-Met full length β-chain was 
induced for 3 hrs before cells were harvested. RG2: Rosetta-gami 2. RGB: Rosetta-gami B. Whole: 
Bacteria lysate before centrifugation. 
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3.1.9: Purification of c-Met protein 
Cloning into pET19b expression vector allowed the expression of c-Met constructs 
tagged at the N-terminal by ten residues of histidine (Materials and Method, Figure 1). 
c-Met constructs were expressed in large volume bacterial cultures. Bacterial lysates 
were centrifuged to obtain the insoluble c-Met constructs. Insoluble c-Met proteins were 
then re-solubilised in 6M urea before affinity purification using commercially-obtained 
nickel columns (IMAC Bio-scale mini profinity cartridges). Purified proteins were 
resolved on a SDS-PAGE gel and Coomassie stained. Western blot analysis using anti-
Histidine-peroxidase was performed to validate the protein bands seen on the 
Coomassie-stained SDS-PAGE gel (Figures 3.12A to D). All c-Met constructs were 
successfully purified. However, contaminating bands were observed in the purified 
sample of all proteins. It could be that these contaminating bands are degraded or 
truncated products of the c-Met protein constructs. We have obtained sufficient purified 
proteins for immunising the mouse for monoclonal antibody production. The α-chain of 
c-Met and the extracellular β-chain of c-Met were chosen for immunisation as they were 
the most highly expressed compared to the other two c-Met constructs. Antibody 
production in mice was done in collaboration with Moravian Biotechnology. Purified 
protein samples were sent to them as immunogens for the mice. 
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Figure 3.12A: SDS-PAGE gel and Western blot analysis of human c-Met α-chain expression in BL21 pLysS bacteria strain.  
a &b) SDS-PAGE gels stained with Commassie blue dye. a) Bacteria cells containing c-Met α-chain construct were induced with IPTG for 3 hrs. Expression of c-Met α-
chain can be seen (as indicated by the arrow). The insoluble fraction of bacterial lysate was solubilised in 6M urea before purification and loaded in increasing amounts to 
visualize c-Met α-chain (pre-purified suspension). b) c-Met α-chain was affinity purified using a 1 ml Bio-Scale mini cartridge. The flow through, washes (wash I and wash 
II), and elute were collected and analysed on a SDS-PAGE gel. c-Met α-chain has a predicted molecular weight of 31 kD although it runs at a higher molecular weight. 
Arrow indicates purified c-Met α-chain. c) Western blot analysis of c-Met α-chain expression. Half the amount of protein used in a) and b) was used in this Western blot. The 
presence of purified c-Met α-chain was confirmed by detecting the N-terminal histidine tag using an anti-Histidine-peroxidase antibody. 
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Figure 3.12B: SDS-PAGE gel and Western blot analysis of human c-Met extracellular β-chain expression in BL21 star bacteria strain.  
a & b) SDS-PAGE gels stained with Commassie blue dye. a) Bacteria cells containing c-Met extracellular β-chain construct were induced with IPTG for 3 hrs. Expression of 
c-Met extracellular β-chain can be seen (as indicated by the arrow). The insoluble fraction of bacterial lysate was solubilised in 6M urea before purification and loaded in 
increasing amounts to visualize c-Met α-chain (pre-purified suspension). b) c-Met extracellular β-chain was affinity purified using a 1 ml Bio-Scale mini cartridge. The flow 
through, washes (wash I and wash II), and elute were collected and analysed on a SDS-PAGE gel. Arrow indicates purified c-Met extracellular β-chain that has a predicted 
molecular weight of 69 kD. c) Western blot analysis of c-Met extracellular β-chain expression. Half the amounts of protein used in a) and b) was used in this Western blot. 
The presence of purified c-Met extracellular β-chain was confirmed by detecting the N-terminal histidine tag using an anti-Histidine-peroxidase antibody. 
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Figure 3.12C: SDS-PAGE gel and Western blot analysis of human c-Met extracellular αβ-chain expression in BL21 star bacteria strain.  
a) Commassie-stained SDS-PAGE gel. Bacteria cells containing c-Met extracellular αβ-chain construct were induced with IPTG for 3 hrs. Expression of c-Met extracellular 
αβ-chain can be seen (as indicated by the arrow). Whole cell lysate before and after induction were analysed. Insoluble fraction of bacterial lysate before purification (pre-
purified suspension) was solubilised in 6M urea before analysis. c-Met extracellular αβ-chain was affinity purified using a 1 ml Bio-Scale mini cartridge. The flow through, 
washes (wash I and wash II), and elute were collected and analysed on a SDS-PAGE gel. Arrow indicates purified c-Met extracellular αβ-chain that has a predicted molecular 
weight of 100 kD. b) Western blot analysis of a similar gel to that shown in a). Half the amounts of protein used in a) were used in this Western blot. The presence of purified 
c-Met extracellular αβ-chain was confirmed by detecting the N-terminal histidine tag using an anti-Histidine-peroxidase antibody. 
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Figure 3.12D: SDS-PAGE gel and Western blot analysis of human c-Met full length β-chain expression in BL21 star bacteria strain.  
a) Commassie-stained SDS-PAGE gel. Bacteria cells containing c-Met full length β-chain construct were induced with IPTG for 3 hrs. Expression of c-Met β-chain can be 
seen (as indicated by the arrow). Whole cell lysate before and after induction were analysed. Insoluble fraction of bacterial lysate before purification (pre-purified suspension) 
was solubilised in 6M urea before analysis. c-Met β-chain was affinity purified using a 1 ml Bio-Scale mini cartridge. The flow through, washes (wash I and wash II), and 
elute were collected and analysed on a SDS-PAGE gel. Arrow indicates purified c-Met β-chain that has a predicted molecular weight of 119 kD. b) Western blot analysis of a 
similar gel to that shown in a). Half the amounts of protein used in a) were used in this Western blot. The presence of purified c-Met β-chain was confirmed by detecting the 
N-terminal histidine tag using an anti-Histidine-peroxidase antibody. 
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3.1.10: Summary of Section 3.1 
This project aims to produce therapeutic monoclonal antibodies against the tyrosine 
kinase receptor, c-Met. At the beginning of this project, there were limited resources 
and biological reagents to allow us to study c-Met. However, in this section, we have: 1) 
verified the use of AF276 antibody as a positive control antibody, 2) determined the 
expression levels of endogenous c-Met in various mammalian cell lines, thus enabling 
us to have c-Met expressing and low c-Met expressing cells lines for antibody 
screening, 3) improved c-Met expression levels in mammalian cells by using various 
vectors as well as utilising the adenoviral system, and 4)  investigated the use of SBP 
tag for c-Met purification. Armed with these useful tools, we are now able to design an 
antibody screening protocol to select for therapeutic monoclonal antibodies directed 
against c-Met.    
Various c-Met constructs were successfully expressed in prokaryotes and purified. 
Purified c-Met α-chain and c-Met extracellular β-chain were sent to Moravian 
Biotechnology as immunogens for antibody production in mice. Antibody production 
and screening will be described in Section 3.2. 
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3.2: Production, screening and initial characterisation of monoclonal hybridoma 
supernatant 
The aim of this project was to produce therapeutic mouse monoclonal antibodies against 
c-Met. In Section 3.1, c-Met α-chain and extracellular β-chain proteins were 
successfully expressed in bacteria, affinity purified and sent to Moravian Biotechnology 
for mouse immunisation. Four mice were immunised with each protein preparation. 
After several rounds of immunisation, tail-bleeds (blood sera) were collected and 
screened for an immunological response against c-Met. To determine if an immune 
response was evoked, serum obtained from each mouse was diluted successively and 
tested on Western blots for reactivity against the purified protein used for immunisation 
and transiently transfected full length human c-Met from NIH3T3 whole cell lysate 
(Figures 3.13A to B and 3.14A to B). 
3.2.1: Screening of immunised mice by Western blotting 
All four mice immunised with the α-chain of c-Met developed good immunological 
responses against purified α-chain as shown by Western blotting (Figure 3.13A). Since 
the α-chain of human c-Met was used as an immunogen, the mice sera should 
theoretically detect the 170 kD c-Met precursor and the mature 50 kD c-Met α-chain in 
cell lysates. However, AF276 failed to detect the α-chain in samples from transfected 
NIH3T3 cells, it is not known if the α-chain is being stably expressed. Sera from these 
mice successfully detected full length c-Met precursor immunoprecipitated from 
NIH3T3 transfected cells (Figure 3.13B), but failed to detect mature c-Met α-chain in 
the same sample. The mice sera also failed to detect full length c-Met from U-87MG 
and T47D cell lysates which are c-Met expressing and low c-Met expressing cells lines 
respectively. Protein bands, observed at the approximate predicted molecular weights of 
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c-Met, are present at equal intensity in samples from both U-87MG and T47D. This 
suggests that they are non-specific protein bands. Anti-α-chain serum 3 detected two 
bands of approximately 55 kD specifically in U-87MG samples, suggesting that they 
could be modified versions of c-Met α-chain. Serum is a crude mixture containing 
various types of antibodies and proteins. It is possible that the antibodies produced 
against human c-Met were present at a low concentration within the serum, resulting in 
the failure to detect full length endogenous human c-Met in cell lysates.  
Despite going through the same immunisation and screening procedure as with the α-
chain, mice immunised with c-Met extracellular β-chain did not develop good immune 
responses. Only the tail-bleeds obtained from the first and second mice were able to 
detect purified c-Met β-chain by Western blotting (Figure 3.14A). Theoretically, anti-β-
chain chain blood sera should be able to detect c-Met precursor and mature c-Met β-
chain (170 kD and 145 kD respectively) on Western blots using whole cell extracts. 
Consistent with this, the tail-bleed from the first mouse successfully detected both 
precursor and mature c-Met β-chain from immunoprecipitated c-Met protein in NIH3T3 
transfected cells as well as endogenous c-Met from U-87MG cells (Figure 3.14B). 
However, there was a strong cross reactivity band at 170 kD (Figure 3.14B). The second 
mouse immunised with the β-chain developed no response as it failed to detect 
immunoprecipitated c-Met and endogenous c-Met on Western blots. Finally, the last 
two mice developed poor or no response towards purified β-chain. 
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Figure 3.13A: Screening of 
mouse tail-bleeds against c-Met 
α-chain by Western blotting. 
Four mice were immunised with 
purified c-Met α-chain. Tail-bleeds 
(blood sera) obtained from these 
mice (mouse serum 1 to 4) were 
diluted 1:500, 1:1000 1:2000 and 
1:5000, and tested for reactivity 
against purified c-Met α-chain and 
c-Met in lysates of NIH3T3 cells 
transfected with plasmid DNA 
expressing full length human c-
Met (Met). Lysates from 
untransfected cells and purified 
extracellular β-chain protein were 
used as controls.  20 μg of cell 
lysate, 50 ng of purified α-chain 
and 200 ng of purified β-chain was 
used in each case. AF276 antibody 
and secondary antibody only 
(secondary only) were used as 
controls. Blue arrows indicate c-
Met β-chain (145 kD) and 
precursor c-Met (170 kD). Red 
arrows indicate purified c-Met α-
chain which was predicted to be 
31 kD. The observed increase in 
molecular weight may have been 
due its secondary structure. UT: 
Untransfected NIHT3 cells. α-
chain: Purified α-chain used for 
immunisation. β-chain: Purified 
extracellular β-chain. Molecular 
weights are noted aside, in 
kilodaltons. 
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Figure 3.13B: Screening of anti-α-chain mouse tail-bleeds against endogenous c-Met by Western blotting. 
Tail-bleeds (blood sera) obtained from α-chain immunised mice were tested for their reactivity towards immunoprecipitated and endogenous c-Met. 50 μg of whole cell 
lysates were analysed from U-87MG and T47D samples. U-87MG expresses human c-Met while T47D expresses very low levels of human c-Met. c-Met immunoprecipitated 
using AF276 antibody from 500 μg of cell lysate (obtained from NIH3T3 transiently expressing human c-Met) was used as a positive control (IP Met). Since the antibodies 
are directed against the α-chain of c-Met, they should recognise c-Met at 50 kD and 170 kD, but not at 145 kD. Tail-bleeds are used at 1:500 dilutions. AF276 antibody was 
used a positive control. Red asterisks indicate precursor c-Met protein band (top band) and c-Met β-chain (bottom band). IP: Immunoprecipitated. Molecular weights are 
noted aside, in kilodaltons. 
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Figure 3.14A: Screening of mouse 
tail-bleeds against c-Met 
extracellular β-chain by Western 
blotting. 
Four mice were immunised with 
purified c-Met extracellular β-chain. 
Tail-bleeds (blood sera) obtained from 
these mice (mouse serum 1 to 4) were 
diluted 1:500, 1:1000 1:2000 and 
1:5000, and tested for reactivity against 
purified c-Met β-chain and c-Met in 
lysates of NIH3T3 cells transfected 
with plasmid DNA expressing full 
length human c-Met (Met). Lysates 
from untransfected cells and purified 
extracellular β-chain protein were used 
as controls.  20 μg of cell lysate, 50 ng 
of purified α-chain and 200 ng of 
purified β-chain was used in each case. 
AF276 antibody and secondary 
antibody only (secondary only) were 
used as controls. Blue arrows indicate 
c-Met β-chain and precursor c-Met 
(145 kD and 170 kD respectively) 
while red arrows indicate purified c-
Met β-chain. The predicted molecular 
weight of extracellular β-chain was 69 
kD. UT: Untransfected NIH3T3 cells. 
α-chain: Purified α-chain used for 
immunisation. β-chain: Purified 
extracellular β-chain. Molecular 
weights are noted aside, in kilodaltons 
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Figure 3.14B: Screening of anti-β-chain mouse tail-bleeds against endogenous c-Met by Western blotting. 
Tail-bleeds (blood sera) obtained from extracellular β-chain immunised mice were tested for their reactivity towards immunoprecipitated and endogenous c-Met. 50 μg of 
whole cell lysates were analysed from U-87MG and T47D samples. U-87MG expresses human c-Met while T47D expresses very low levels of human c-Met. c-Met 
immunoprecipitated using A276 antibody from 500 μg of cell lysate (obtained from NIH3T3 transiently expressing human c-Met) was used as a positive control (IP Met). 
Since the antibodies are directed against the extracellular β-chain of c-Met, they should recognise c-Met at 145 kD and 170 kD. Tail-bleeds are used at 1:500 dilutions. 
AF276 antibody was used a positive control. Red asterisks indicate precursor c-Met protein band (top band) and c-Met β-chain (bottom band). IP: Immunoprecipitated. 
Molecular weights are noted aside, in kilodaltons. 
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3.2.2: Screening of sera from immunised mice by cell staining 
The immunological responses of immunised mice were also screened by cell staining of 
untransfected NIH3T3 cells, or NIH3T3 cells transiently transfected with either full 
length human c-Met or full length human c-Met tagged with V5 (Met-V5). Sera from all 
α-chain immunised mice were able to detect both c-Met and Met-V5 in cell staining, but 
with low intensity (Figures 3.15A and B). This was probably due to the low levels of 
antibodies present in the mice sera. Consistent with the Western blotting analysis, only 
the first mouse immunised with the β-chain of c-Met showed reactivity against c-Met in 
cell staining. The β-chain of c-Met therefore appears to be a poor immunogen. Only 
mice producing antibodies directed against c-Met α-chain were used for hybridoma 
fusions directed towards making anti-Met monoclonal antibodies. 
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Figure 3.15A: Screening of immunised mouse tail-bleeds by cell staining of NIH3T3 cells 
transfected with human c-Met. 
Tail-bleeds obtained from mice immunised with either c-Met α-chain or extracellular β-chain were used 
to detect c-Met protein in NIH3T3 cells transiently transfected with full length human c-Met. Mouse sera 
were used at a 1:500 dilution. AF276 and SC-10 antibodies were used as positive controls while anti-V5 
and anti-GFP antibodies were used as negative controls. A score, located at the top right of each picture, 
indicates the staining intensity of each antibody. (-): no staining; (+): slight staining; (++): intermediate 
staining; (+++): intense staining.  
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Figure 3.15B: Screening of immunised mouse tail-bleeds by cell staining of NIH3T3 cells 
transfected with human c-Met tagged with V5. 
Tail-bleeds obtained from mice immunised with either c-Met α-chain or extracellular β-chain were used 
to detect c-Met protein in NIH3T3 cells transiently transfected with full length human c-Met with C-
terminus V5 tag. Mouse sera were used at a 1:500 dilution. AF276, SC-10 and anti-V5 antibodies were 
used as positive controls while anti-GFP antibodies were used as a negative control. A score, located at 
the top right of each picture, indicates the staining intensity of each antibody. (-): no staining; (+): slight 
staining; (++): intermediate staining; (+++): intense staining.  
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Figure 3.15C: Screening of immunised mouse tail-bleeds by cell staining of untransfected NIH3T3 
cells.  
Tail-bleeds obtained from mice immunised with either c-Met α-chain or extracellular β-chain were tested 
on untransfected NIH3T3 cells as a negative control. Mouse sera were used at a 1:500 dilution. A score, 
located at the top right of each picture, indicates the staining intensity of each antibody. (-): no staining; 
(+): slight staining; (++): intermediate staining; (+++): intense staining.  
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3.2.3: Hybridoma cell fusion and primary hybridoma supernatant screening 
In order to develop an immortal cell line that secretes a monoclonal antibody, the spleen 
cells of an immunised mouse are fused to the mouse cell line Sp2/0-Ag14. This can 
result in a hybrid cell that contains both the antibody secreting properties of the spleen 
cell and the growth characteristics of the immortal cell line. Antibodies produced from a 
single hybridoma clone are termed monoclonal antibodies. By single cell cloning 
hybridoma cells, cell lines secreting a single monoclonal antibody are created. Due to 
the high specificity of monoclonal antibodies, hybridoma cells and their secreted 
antibodies are extremely useful tools in biomedical science research and have the 
potential to be developed into therapeutic agents. 
Hybridoma cell fusion and monoclonal antibody production were performed by 
Moravian Biotechnology. Briefly, two mice immunised with c-Met α-chain were 
sacrificed and had their spleens removed. Spleen cells obtained from these mice were 
fused with the mouse immortal cell line, SP2/0-Ag14. Immediately after fusion, the cell 
mixture was plated into 96-well plates and fused cells were grown in selection media 
containing hypoxanthine, aminopterin and thymidine. Hypoxanthine and thymidine are 
intermediates in the DNA synthesis pathway. Aminopterin blocks the de novo synthesis 
of DNA causing cells to rely on the salvage pathway for DNA synthesis. Sp2/0-Ag14 
cells are defective in the DNA salvage pathway, therefore are unable to survive in 
aminopterin selection media due to the blockage of both DNA synthesis pathways. 
Spleen cells are functional in both DNA synthesis pathways, however, due to their 
limited propagation capacity under tissue culture conditions, spleens cells fail to 
survive. Only hybridoma cells which have been successfully fused between a spleen cell 
and an immortal cell will survive and grow in the selection media. This is because the 
immortal-spleen hybrid cell will contain the ability of the immortal cell line to 
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proliferate under tissue culture conditions and the functional DNA salvage pathway of 
the spleen cell. To screen for anti-cMet antibody producing hybridoma clones, cell 
supernatant were taken from individual 96-wells (referred here as hybridoma lines to 
avoid confusion) that contained growing hybridoma cells. A flow chart of hybridoma 
screening is shown in Materials and Methods section (Figure 2.5). 
To screen for hybridoma lines secreting immunoglobulin (Ig) antibodies against the α-
chain of human c-Met, we took cell supernatants from growing hybridoma cells and 
tested separately for Ig production (data not shown) and for antibody reactivity against 
c-Met α-chain by dot blot technique. An example of dot blot analysis which was used to 
screen for antibodies against c-Met α-chain is shown in Figure 3.16a. From two separate 
dot blot analyses, 82 hybridoma lines were identified to be both positive for Ig and for 
reactivity against c-Met α-chain. These lines were then screened for their reactivity 
towards purified c-Met α-chain by Western blotting and for their ability to recognise full 
length c-Met by cell staining. Figure 3.16b shows an example of hybridoma cell 
supernatant screening by Western blotting. Antibodies identified from dot blot analysis 
were found to be variable in their reactivity towards c-Met in Western blotting and cell 
staining. This may be due to the varying methods of fixation which can lead to differing 
epitope presentation. For example, antibodies from the 12A12 line detected purified α-
chain in Western blotting, but failed to detect full length human c-Met in cell staining 
(Figure 3.17). Based on the results of the screening procedure using dot blot, Western 
blotting and cell staining, hybridoma cells lines that successfully detected c-Met in the 
screening assays were selected for clonal expansion and further screening. In total, 58 
hybridoma lines were identified. 
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Figure 3.16: An example of hybridoma cell supernatant screening by dot blot and Western blotting. 
a) Dot blot analysis of hybridoma cell supernatant reactivity against purified α-chain. Purified α-chain was coated onto a nitrocellulose membrane. Approximately 2 μl of 
undiluted hybridoma cell supernatant were spotted onto the nitrocellulose membrane, forming a circular droplet. Hybridoma cell supernatant was rinsed away before anti-
mouse secondary antibody conjugated to HRP was added onto the nitrocellulose membrane. HRP activity was detected using 4-chloro-1-naphthol and hydrogen peroxide 
which resulted in a colourmetric reaction. Positive hybridoma lines were identified by the dark purple/black circles developed on the nitrocellulose membrane.  Serum taken 
from the mouse before it was sacrificed was the positive control. Dots on the nitrocellulose membrane are pencil marks to indicate the position of the supernatant sample on 
the membrane. b) A panel of hybridoma lines were tested for the ability to detect purified c-Met α-chain on Western blotting. Purified α-chain was resolved on a single well 
SDS-PAGE gel and proteins were transferred onto a nitrocellulose membrane. Membrane was cut into strips and neat hybridoma cell supernatant were incubated directly on 
it. Again, serum taken from the mouse was used as positive control. Black arrow indicates the α-chain. Molecular weights are noted aside, in kilodaltons. Preparation of dot 
blots in a) and Western blot strips in b) was done in collaboration with Moravian Biotechnology. 
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Figure 3.17: Examples of hybridoma 
lines screening by cell staining and 
Western blotting.  
Hybridoma lines were screened for 
antibody production against c-Met by 
cell staining and Western blotting. Cell 
supernatants were taken from 
hybridoma cells and used to stain 
NIH3T3 cells transfected with full 
length human c-Met and vector alone. 
A score, located at the top right of each 
picture, indicates the staining intensity 
of each antibody. Hybridoma cell 
supernatants were also screened for 
their reactivity against the immunogen, 
purified α-chain, by Western blotting. 
Blue arrow indicates α-chain. (-): no 
staining; (+): staining. Molecular 
weights are noted aside, in kilodaltons. 
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3.2.4: Secondary hybridoma supernatant screening 
To ensure that the hybridoma lines are stably expressing antibodies against c-Met, the 
58 hybridoma lines were expanded and re-tested by dot blot, Western blotting and cell 
staining in a secondary screen. Secondary screen was performed entirely by Moravian 
Biotechnology, thus only an example of the data is shown. Dot blot and cell staining 
screening was performed using the same methods as the primary screening. Hybridoma 
supernatants were analysed on Western blot for the detection of purified α-chain and 
full length human c-Met in cell lysates derived from NIH3T3 transfected cells. 
Examples of this analysis are shown in Figure 3.18a. The ability of these antibodies to 
recognise endogenous human c-Met in extracts from U-87MG cells were also tested by 
Western blotting (Figure 3.18b). 
The hybridoma cell lines used in this screening process were derived from surviving 
cells in a 96-well during hybridoma fusion selection, not from a single cell clone. 
Therefore at this stage, it remained a possibility that they might contain a mixture of 
hybridoma cells secreting two or possibly more antibodies. In addition, it was not 
possible to standardise the antibody concentration in the hybridoma supernatant due to 
the presence of fetal calf serum (FCS). Variation in antibody concentration might affect 
the results obtained in the screen. Although these points must be borne in mind when 
analysing the results shown, the primary screen was designed to identify promising 
clones for further analysis. In the secondary screen, 39 hybridoma lines were observed 
to be stably producing anti-α-chain antibodies and were successful in detecting c-Met 
by dot blotting, Western blotting and cell staining to varying extents (Table 3.2).  
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21 cell lines, identified from the secondary screen, were chosen to be single cell cloned 
for monoclonal antibody production following consultation with Moravian 
Biotechnology (refer to Table 3.2). 
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Figure 3.18: Secondary screening of hybridoma lines by Western blotting. 
a) 58 hybridoma lines identified from primary screening were re-tested for their ability to recognise human c-Met in cell lysates derived from NIH3T3 cells transfected with 
either c-Met or Met-GFP fusion construct. a & b) 50 μg of whole cell lysates was used in the case of untransfected (UT) NIH3T3 cells, and NIH3T3 cells transfected with 
constructs expressing c-Met or Met-GFP as shown. 50 μg of cell lysates dervied from U-87MG or T47D cells was used. 100 ng and 10 ng of purified c-Met α-chain protein 
was analysed in a) and b) respectively. Hybridoma supernatants were diluted 1:1 with 5% milk in PBST. AF276 antibody was used as a positive control. Hybridoma 
supernatants should be tested against murine c-Met to determine the cross-species reactivity of the antibodies. Blue arrows indicate c-Met precursor or c-Met tagged to GFP. 
Red arrows indicate purified α-chain. Molecular weights are noted aside, in kilodaltons.     
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Table 3.2: Screening results of the 21 hybridoma lines selected for monoclonal antibody production. 
Line 
Cell staining Western blot Dot blot 
Met 
transf. 
Met-
V5 
transf. 
α-chain Met transf. 
U-
87MG T47D Ig 
α-
chain 
2C6 ++ +++ +++ +++ +++ NS +++ +++ 
2H8 +++ +++ +++ +++ + - +++ +++ 
3E6 + + ++++ +++ +++ - +++ +++ 
5D5 ++ +++ +++ +++ ++ NS +++ +++ 
5E7 +++ +++ +++ +++ +++ - ++ +++ 
5G12 +++ +++ +++ +++ +++ - ++ +++ 
5H4 -/+ + ++ +/++ -/+ - +++ +++ 
6D9 -/+ + ++ ++ + - +++ +++ 
9H1 + ++ +++ +++ + - +++ +++ 
9H4 ++ +++ +++ +++ ++ - +++ +++ 
13E1 ++ +++ ++++ +++ ++ - +++ +++ 
10B1 +++ +++ +++ +++ ++ NS +++ +++ 
12A12 ₋ - ++++ ++ -/+ - ++ +++ 
12C9 ++ +++ ++++ +++ +++ - ++ +++ 
12D10 +++ ++ ++++ ++ + NS +++ +++ 
15E11 ++ +++ +++ +++ ++ - +++ +++ 
15G3 + +++ +++ ++ ++ - ++ +++ 
16A4 -/+ + ++++ +++ ++ - +++ +++ 
16C11 + ++ ++++ +++ +++ NS + ++ 
16F6 ++ ++ ++++ +++ + - ++ +++ 
16H3 +++ ++ ++++ ++++ +++ NS +++ +++ 
Cell staining was performed using NIH3T3 cells transfected with constructs expressing c-Met or Met-V5. 
Recognition of purified c-Met α-chain and full length human c-Met (from whole cell extract of NIH3T3 
transfected with c-Met plasmid, U-87MG and T47D cells) by the antibodies were analysed by Western 
blotting. NS refers to recognition of non-specific bands observed in T47D samples. Ig production by the 
hybridoma cell lines and antibody reactivity to α-chain were analysed by dot blot. Transf.: Transfected. 
NS: Non-specific binding. Ig: Immunoglobulin. Antibody screening results were graded accordingly: (-): 
no reactivity; (+): slight reactivity; (++): intermediate reactivity; (+++): strong reactivity. 
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21 hybridoma clones were selected from the secondary hybridoma screen and were 
single-cell cloned to obtain cell lines expressing single monoclonal antibodies by 
Moravian Biotechnology. Monoclonal antibodies (Mab) were renamed for convenience 
and to avoid confusion. Reference to the original hybridoma clone names could be 
found in Table 3.4 at the end of this section. Cell supernatants were harvested from 
single-cell cloned cells and were re-tested their reactivity against c-Met to ensure they 
retained their anti-α-chain antibody producing capability (Figures 3.19A and B). 
3.2.5: Monoclonal antibody production and screening 
As mentioned, antibodies produced from a single hybridoma clone are monoclonal and 
thus it is assumed that the results observed are caused by a single antibody, specific to a 
single epitope. Consistent with the previous screening results, all monoclonal antibodies 
successfully detected both transfected and endogenous c-Met precursor from whole cell 
lysates in Western blots (Figures 3.19A and B). None of the anti-α-chain monoclonal 
antibodies were able to detect mature c-Met α-chain at its predicted molecular weight of 
50 kD in cell lysates. The commercial AF276 antibody, which was raised against the 
extracellular domain of human c-Met, should be able to detect the mature α-chain of c-
Met. From Figures 3.19, AF276 detected purified α-chain weakly but failed to detect 
endogenous and transfected α-chain from cell extracts. SC-10 was raised against a 
peptide in the C-terminal tail of c-Met and therefore, it did not recognise the α-chain. 
Due to the lack of antibodies that recognise the α-chain in cell lysates, there is no 
positive control to compare the protein bands observed in our anti-α-chain blots. It is 
difficult to conclude if the 40-70 kD protein bands observed, is genuinely representing 
the α-chain on Western blots. It is unclear why mature α-chain could not be detected on 
Western blots. Differential glycosylation of the α-chain could result in various sizes of 
α-chain observed on a Western blot. The mature α-chain could be rapidly degraded 
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upon cell lysis. In addition, the presence of non-specific protein bands observed on 
some of the Western blots probed with the monoclonal antibodies, could also obscure 
the faint mature c-Met α-chain.  Several protein bands observed on the Western blots 
could be explained by: 1) antibodies present in the FCS from cell media, 2) genuine 
recognition of the antibodies to its epitope which is present in other proteins, 3) high 
antibody concentration in the cell supernatants, and 4) degradation or processing of c-
Met protein.  
Finally, it is observed that the band profile produced by a group of monoclonal 
antibodies (Mab 6.1, 9.1, 10.1, 11.1, 12.1, 14.1, 20.1 and 21.1) on Western blots are 
highly similar. Mab 17.1, 18.1 and 19.1, also make up another group of antibodies that 
share a very similar band profile to this large group of antibodies. Mab 8.1 also shares a 
similar band profile to the large group of antibodies except for the presence of some 
non-specific bands. In contrast, Mab 13.1 recognises precursor c-Met and β-chain but 
also recognises a range of protein bands throughout the blot. This suggests that Mab 
13.1 does not work well on Western blotting as it detects many non-specific bands. 
Western blot band profiles are dependent on an antibody recognising its epitope. 
Monoclonal antibodies that share the same band profile could be recognising the same 
epitope while antibodies with different band profile will most probably recognise a 
different epitope. More assays are required to further characterise the monoclonal 
antibodies and allow us to select the appropriate antibody to be used in human therapy. 
A more detailed comparison of the Western blot band profiles will be discussed in the 
later part of this section. 
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Figure 3.19A: Screening of monoclonal antibodies following single cell cloning of hybridoma cell lines (Mab 1.1 to Mab 10.1) by Western blotting. 
21 hybridoma clones were selected for monoclonal antibody production and tested again for reactivity against full length c-Met in whole cell lysates. Monoclonal antibodies 
(Mab) were renamed to avoid confusion. 50 μg of whole cell lysates were obtained from untransfected NIH3T3 cells (UT), NIH3T3 cells transfected with full length human 
c-Met (Met) construct, U-87 MG cell lines and T47D cell lines. Hybridoma supernatants were diluted 1:1. 10 ng of purified α-chain and AF276 antibody were controls. 
Upper blue arrows indicate c-Met precursor. Lower blue arrows indicate β-chain detected in AF276 and SC-10 blots. Red arrows indicate purified α-chain. Mab: Monoclonal 
antibody. Molecular weights are noted aside, in kilodaltons.     
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Figure 3.19B: Screening of monoclonal antibodies (Mab 11.1 to Mab 21.1) by Western blotting. 
21 hybridoma clones were selected for monoclonal antibody production and tested again for reactivity against full length c-Met in whole cell lysates. Monoclonal antibodies 
(Mab) were renamed to avoid confusion. 50 μg of whole cell lysate were obtained from untransfected NIH3T3 cells (UT), NIH3T3 cells transfected with full length human c-
Met (Met) construct, U-87 MG cell lines and T47D cell lines. Hybridoma supernatants were diluted 1:1. 10 ng of purified α-chain and AF276 antibody were controls. Upper 
blue arrows indicate c-Met precursor. Lower blue arrows indicate β-chain detected in AF276 blot. Red arrows indicate purified α-chain. Mab: Monoclonal antibody. 
Molecular weights are noted aside, in kilodaltons.     
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Antibody isotype determines both antibody purification technique and ability of the 
antibody to recruit effector functions. Antibody isotyping was performed by dipping 
commercially available isotyping strips into cell supernatant. These strips can 
differentiate between IgG subclasses and antibody light chain subclasses (examples 
shown in Figure 3.20). A test line will develop on the strip specific to the antibody 
isotype. The appearance of several test lines indicates the presence of other antibodies in 
the cell supernatant. 
3.2.6: Monoclonal antibody isotyping 
All 21 monoclonal antibodies contain the IgG class and a single test line was observed 
for each antibody tested. This is an indication that the monoclonal antibodies are 
obtained from a single hybridoma clone. IgG subclass antibodies form dimers, are 
bivalent molecules and play an important role in antibody-dependent cell-mediated 
cytotoxicity (ADCC). Not all the antibodies share the same IgG subclass. 19 
monoclonal antibodies were IgG1. Mab 4.1 and 16.1 were IgG2A while Mab 19.1 was 
IgG2B. All 21 monoclonal antibodies contain the kappa light chain and these results are 
summarised in Table 3.4 at the end of this section. 
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Figure 3.20: Examples of monoclonal antibody isotyping strips.  
Commercially isotyping strips are individually available for characterising an antibody’s IgG subclass 
and light chain. Isotyping strips are dipped in cell supernatant containing monoclonal antibodies. A red 
band would appear which corresponds to the type of IgG subclass and light chain present in the cell 
supernatant. Control band ensures that the test strips are functional. If no IgG subclass or light chain is 
present in the cell supernatant, only the control band will appear. Figure is adapted from Sigma-Aldrich. 
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Monoclonal antibodies were further characterised by mapping the region of their 
epitope by pepscan. Identifying the region of c-Met bound by the antibody is important 
in determining whether the antibody might be able to block c-Met from binding to its 
ligand, HGF. Consecutive overlapping peptides that span the entire α-chain were 
synthesised in vitro (Mimotopes). Each peptide, made up of 15 amino acid residues, 
overlaps each neighbouring peptide by 10 amino acids. These peptides were tagged with 
biotin at the N-terminus through an SGSG linker sequence. Peptides were added to 
individual wells in a 96-well plate and unbound peptides were removed by extensive 
washing. To determine the region of antibody binding on the α-chain, hybridoma cell 
supernatants were added to each peptide. Binding of the antibody was detected by 
colorimetric assay and analysed by absorbance reading at 450 nM. The region of 
antibody binding was then mapped to a crystal structure of the c-Met extracellular 
domain binding to the β-chain of HGF which contains full length α-chain and partial β-
chain (Figure 3.24). This crystal structure was obtained from Protein Data Base, 
accession number 1SHY. In total, 10 different regions from the α-chain were identified 
from the 21 monoclonal cell supernatants tested, indicating that this is no one main 
region that is highly immunogenic. To avoid confusion, the regions identified were 
labelled 1 to 10 according to their position on the α-chain. Region 1 is closest to the N-
terminus while region 10 is the most C-terminal region. A simplified diagram of the 
antibody binding domain on c-Met α-chain is shown in Figure 3.21 and the amino acid 
sequence is shown in Figure 3.22. 
3.2.7: Mapping of monoclonal antibody binding regions 
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Figure 3.21: Schema of antibody binding regions.  
Pepscan was used to determine the binding region of 21 monoclonal supernatants. Consecutive overlapping peptides that span the entire α-chain were synthesised in vitro. 
Each peptide, made up of 15 amino acid residues, overlaps each neighbouring peptide by 10 amino acids. To determine the region of antibody binding on the α-chain, 
monoclonal cell supernatants were added to each peptide. Binding of the antibody was detected by colorimetric assay and analysed by absorbance reading at 450 nM. The 
epitope of the antibodies were categorised into regions. Region 1 is closest to the N-terminus while region 10 is the most C-terminal region. Antibodies that share the same 
binding region are indicated. The peptide sequence of the binding regions, in reference to the full length α-chain sequence, is shown in Figure 3.22. Figure not drawn to scale. 
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Figure 3.22: Antibody binding regions highlighted in the amino acid sequence of c-Met α-chain.  
10 binding region were identified among 21 monoclonal antibody developed against the α-chain of c-Met. The full length amino acid sequence of c-Met α-chain, excluding 
the N-terminal signalling peptide, is indicated above. This sequence was expressed in bacteria and purified for mouse immunisation. Antibody binding regions are indicated. 
Predicted glycosylation sites on asparagines (N) are highlighted in red. Region 1 is closest to the N-terminus while region 10 is the most C-terminal region. N’-: N-terminus 
of the protein sequence. –C’: C-terminus of the protein sequence.   
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Region 1  
Mab 16.1 binds to both peptides 11 and 12 (Figure 3.23A). The epitope of Mab16.1 
must therefore reside within the overlapping 10 amino acid residues of these peptides. 
This region is labelled as region 1. Peptide 12 developed a stronger colorimetric 
reaction compared to peptide 11. It is probable that the last five amino acid residues in 
peptide 12 contribute to the antibody-antigen interaction. Finally, it is observed that the 
epitope of Mab 16.1 does not lie within the region of the α-chain which interacts 
directly with HGF. 
Region 2 
Mab 12.1 and 20.1 bind only to one peptide, peptide 14 (Figure 3.23B). This indicates 
that residues on both sides of the central five amino acid region (amino acid residues 
‘CFPCQ’) must be essential for epitope recognition (amino acid residues ‘LEHPD’ and 
‘DCSSK’). It is likely that the central five amino acids (amino acid residues ‘CFPCQ’) 
are required. Alternatively, the main epitope could be a discontinuous sequence that is 
made up amino acids flanking the central region at peptide 14. Therefore, only one 
peptide is being detected. Alanine scan analysis would be required to define the specific 
residues more clearly.  
The epitopes of Mab 12.1 and 20.1 are mapped to region 2, suggesting that both 
epitopes could be the same. This is consistent that both of these antibodies were 
observed to produce similar Western blot band profiles (Figure 3.23B). Alternatively, it 
is possible that Mab 12.1 and 20.1 are different antibodies that bind to different epitopes 
within region 2. Further analysis, using techniques such as phage display, could be 
performed to verify this issue. Finally, it is observed that region 2 does not lie within the 
region of the α-chain which interacts directly with HGF. 
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Region 3 
The epitopes of Mab 11.1 and 21.1 (region 3) lie within a similar region to region 2 
(recognised by Mab 12.1 and 20.1), though a smaller region of 10 amino acid residues 
is required for antibody recognition. Mab 11.1 and 21.1 bind to peptide 14 and 15 
(Figure 3.23C), indicating that the main epitope is located within the overlapping 
residues ‘CFPCQDCSSK’. Similarly to Mab 16.1, one peptide (peptide 14) developed a 
stronger colorimetric reaction then the other (peptide 15), indicating that the residues 
outside this region may contribute to antibody-antigen binding. 
As region 2 and 3 overlap each other, the Western blotting analysed by Mab 11.1, 12.1, 
20.1 and 21.1 are being compared. All four antibodies produced very similar Western 
blot band profiles although the epitopes for these antibodies might be quite distinct from 
each other. Mab 16.1 recognises region 1 of c-Met (Figure 3.23A) and clearly, its 
epitope is distinct from Mab 11.1, 12.1, 20.1 and 21.1. Interestingly, Mab 16.1 shares 
similar band profiles with this group of antibodies suggesting that the bands observed 
on the Western blots are various sizes c-Met. These bands could be degradation 
products of c-Met or c-Met α-chain. 
Region 4 
Region 4 contains the epitopes of 14.1, 18.1 and 19.1, which is located in the 
overlapping residues of peptide 19 and 20 (Figure 3.23D). Both peptides show similar 
antibody binding intensity demonstrating that both peptides contain the essential 
residues that make up the epitope. Region 4 lies within the region of the α-chain which 
interacts directly with HGF.  
Mab 18.1 and 19.1 produced identical Western blots while Mab 14.1 produced a 
slightly different blot. This suggests that Mab 14.1 do not recognise the same epitope as 
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Mab 18.1 and 19.1, although they share the same binding region. Mab 17.1 also binds to 
region 8 which will be discussed below.  
Region 5 and 6 
Mab 3.1 and 5.1 bind to peptides 21 and 22 showing a similar intensity indicating that 
they bind to the overlapping region of these peptides (Figure 3.23E). Region 5 is tucked 
inside c-Met so would not be available for antibody binding to the native protein. It is 
not surprising that the epitopes of Mab 3.1 and 5.1 lie inside c-Met because denatured α-
chain was used as immunogen. Mab 4.1 bound only to peptide 22, here referred as 
region 6 (Figure 3.23F). Similar to region 5, region 6 is tucked inside c-Met and is 
unlikely to be involved in receptor-ligand binding. Mab 3.1, 4.1 and 5.1 bind within the 
same region, but may not necessarily recognise the same epitope. However, comparison 
of their Western blots profiles suggests that they do recognise similar epitopes. 
Region 7 
The epitopes of Mab 1.1, 2.1 and 9.1 are located within peptides 28 and 29 (Figure 
3.23G). Since both peptides have similar colour intensity, the overlapping amino acid 
residues (region 7) must contain the binding regions for these antibodies. Antibodies 
binding to region 7 might be capable of blocking receptor-ligand binding as this region 
lies on the surface of the c-Met extracellular domain, close to the binding region of the 
HGF β-chain. 
Mab 9.1 was observed to have different Western blot band profiles compared to Mab 
1.1 and 2.1. Although the antibodies share the same binding region, it is likely that they 
recognise different epitopes. High background and non-specific bands were observed in 
Mab 1.1 and 2.1. Lowering the antibody concentration for Mab 1.1 and 2.1 on Western 
blot could help reduce the non-specificity and produce a clearer blot. 
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Region 8 
The pepscan analysis of Mab 6.1, 10.1 and 13.1 yielded surprising results. Unlike other 
monoclonal antibodies that bound only a maximum of two peptides, these antibodies 
bound four peptides: peptide 36, 42, 43 and 44 (Figure 3.23H). Peptides 42, 43 and 44 
share the sequence ‘EFRDS’, but have no shared sequence with peptide 36. Various 
explanations are possible for the observed binding to peptide 36: 1) non-specific 
antibody binding, 2) contamination of the monoclonal antibody with other antibodies, 3) 
antibodies were not produced from a single hybridoma clone, 4) the paratope 
(antibody’s antigen binding site) of monoclonal antibodies bind to discontinuous 
epitopes, or 5) the antibodies are polyreactive antibodies (an antibody molecule 
recognising two epitope). Interestingly, peptide 36 contains a sequence ‘FPDH’ which 
is similar to the ‘FRDS’ sequence within the shared region of peptides 42, 43 and 44. 
Therefore ‘FxDx’, whereby x means any amino acid residue, could be the main epitope. 
If this is true, many proteins do contain the ‘FxDx’ sequence which will be recognised 
by these antibodies by Western blotting. Consistent with this theory, Mab 13.1 detected 
numerous protein band on Western blotting (Figure 3.23H panel c), suggesting that its 
epitope could be ‘FxDx’. Amino acid point mutations could be performed to confirm 
this hypothesis. Mab 6.1 and 10.1 produced identical band profile when Western 
blotting for c-Met, which is different from Mab 13.1 (Figure 3.23H). Fewer protein 
bands were observed on Mab 6.1 and 10.1 blots compared to Mab 13.1 suggesting that 
the Mab 6.1 and 10.1 epitopes are not ‘FxDx’. Mab 6.1 and 10.1 may share the same 
epitope within region 8 however, further analysis is required to determine the exact 
epitope. 
Region 9   
Mab 8.1 was the only monoclonal antibody that bound to region 9 defined by the 
overlap of peptides 39 and 40 (Figure 3.23I). Interestingly, region 9 lies in the 
132 
 
interacting surface of c-Met extracellular domain and HGF β-chain. It would be 
interesting to test if Mab 8.1 would be able to block c-Met from binding to HGF in vivo. 
The Western blot profile of Mab 8.1 shares some similarities with other antibodies, 
however, it also recognises a set of non-specific protein bands (Figure 3.19A). 
Region 10 
Lastly, the epitopes for Mab 7.1 and 15.1 lie in region 10. Both antibodies bound to 
peptides 52 and 53 with equal affinity (Figure 3.23J). Region 10 lies on the surface of 
the c-Met extracellular domain, close to the binding domain of the HGF β-chain. Mab 
7.1 and 15.1 may be capable of disrupting receptor-ligand interactions. The Western 
blot band profile of Mab 7.1 is different from Mab 15.1. This suggests that Mab 7.1 and 
15.1 have different epitopes that both lie within region 10. 
Mab 17.1 
To our surprise, Mab 17.1 bound to six peptides, peptide 19, 20, 36, 42, 43 and 44, 
simultaneously (Figure 3.23K). No common peptide sequence was observed among 
these six peptides. In addition, these peptides are not in proximity to each other when 
mapped on the c-Met α-chain crystal structure. Peptides 19 and 20 contain the epitope 
of Mab 14.1, 18.1 and 19.1 (region 4) while peptides 36, 42, 43 and 44 contain the 
epitope Mab 6.1, 10.1 and 13.1 (region 8). It is highly possible that Mab 17.1 is not 
produced from a single clone i.e. there is more than one hybridoma clone in the pool of 
cells producing IgG1 antibodies. One clone could be producing antibodies against 
region 4 while the other could be producing antibodies against region 8. Interestingly, 
the Western blot band profile of Mab 17.1 was highly similar to Mab 18.1 and 19.1 
(Figure 3.23D). Mab 18.1 and 19.1 recognise region 4 which is one of the regions that 
Mab 17.1 recognises. Although Mab 17.1 also recognises region 8, the band profile 
suggest that its epitope is more similar to region 4 than to region 8. 
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To investigate whether Mab 17.1 is produced from a single clone, hybridoma clone 2H8 
was single cell cloned again. Eleven colonies were obtained. Cell supernatants were 
harvested and analysed by pepscan. Pepscan results for the Mab 17.1 re-cloned lines are 
tabulated in Table 3.3. Interestingly, seven clones bound to both regions 4 and 8, four 
clones bound to region 4 specifically and none bound to region 8 specifically. It is 
unclear why the majority of the clones still bound to both regions despite being single-
cell cloned for the second time. One explanation is that Mab 17.1 is a polyreactive 
antibody. Normally, an IgG antibody molecule contains two similar antigen binding 
sites which recognise and bind to the same epitope (homotypic bivalent binding). 
Homotypic bivalent binding can only occur when the antigen is in abundance i.e. when 
epitopes are in close proximity. This is, however, not possible when the antigens are 
scarce such as in the case of the gp140 glycoprotein displayed on the surface of the 
human immunodeficiency virus (HIV).  Mouquet et al. (2010) reported the production 
of anti-HIV polyreactive antibodies in humans. Polyreactive antibodies have two 
different antigen binding sites thus allowing the antibody to recognise two epitopes in 
the same antigen molecule (bivalent heteroligomerisation). This allows antibodies to 
bind foreign molecules in situations whereby the antigen is scarce, and homotypic 
bivalent binding is not possible. Mab 17.1 could be a polyreactive monoclonal antibody, 
binding to two different regions of c-Met. Nonetheless, the results from Table 3.3 
suggest that the original Mab 17.1 clone could contain a mixture of poly-reactive 
monoclonal antibodies and monoclonal antibodies that recognises region 4. Since the 
results of Mab 17.1 re-clones are not interpretable, and it would be interesting to test the 
effect of blocking two regions of c-Met in functional assays, future experiments were 
performed with the parental Mab 17.1 clone.  
134 
 
It should be noted that we have only narrowed down the monoclonal antibody binding 
region and not identified the actual epitopes. As mentioned earlier, although some 
monoclonal antibodies share the same region of binding, it does not necessarily mean 
that they share the same epitope. In addition, although most of the antibody binding 
regions do not coincide with the region of c-Met interaction with HGF β-chain, does not 
mean that the antibodies would not be able to block the receptor-ligand interaction. 
1SHY is the crystal structure of a partial extracellular c-Met domain binding to the β-
chain of HGF. The crystal structure of full length c-Met (or at least full length c-Met 
extracellular domain) binding to full length HGF has not been solved. Our monoclonal 
antibodies binding to c-Met might block the HGF α-chain interaction with c-Met, 
prevent c-Met dimerisation or affect global protein conformation (Figure 3.24). The 
antibodies might also block other protein interactions, such as α6β4 integrin and CD44 
(Trusolino et al., 2001; van der Voort et al., 1999) which have been reported to interact 
with c-Met.  
A list of monoclonal antibody names, clone names, region of binding, sequence of 
binding region and isotype group can be found in Table 3.4. In the same table, is the 
comparison of the sequence of antibody binding region on human c-Met to its mouse 
homologue. The full length sequence alignment of human and mouse c-Met can be 
found in Appendix 2. The mapping of the epitope binding regions on the sequence 
alignment of human and mouse c-Met α-chain is shown in Figure 3.25. The alignment 
of the human and mouse c-Met sequences implies that it should be possible to raise 
antibodies that are both species specific- and cross-reactive (Table 3.4). As self-
tolerance to low abundance proteins is held in the T cell compartment, immunisation 
with the human protein can be predicted to induce antibodies that are human specific 
and are cross-reactive between the mouse and human proteins. Our results confirm this 
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completely (epitope mapping regions 5 and 6). Notably a single amino acid difference 
in an epitope is sufficient to define complete species specificity (Table 3.4). In a well-
studied example, the anti-p53 antibody recognises the DLW motif in the TFSDLW 
sequence at the N terminus of human p53. The same antibody is completely unreactive 
with the mouse p53 protein which has the sequence TFSGLW at this site. Thus the G to 
D substitution defines the species specificity of this very potent antibody. Interestingly 
in phage display peptide mapping all DO-1 binding phage peptide sequences contained 
the DLW motif (Lane, D.P. et al., 1996). 
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Figure 3.23A: Region 1 contains the epitope of Mab 16.1. 
a) Crystal structure of c-Met extracellular domain (amino acid residues 25 – 567), binding to HGF β-
chain. Crystal structure was obtained from Protein Data Bank (PDB), accession number 1SHY. c-Met is 
highlighted in green, HGF in blue and region 1 in red. The sequence of region 1 is also noted in red.  b) 
Pepscan of Mab 16.1. Cell supernatant was added to wells coated with various peptides (peptide 1 to 55) 
as shown. Binding of monoclonal antibodies to their epitope will produce a yellow colorimetric reaction. 
Sequence of peptide 11 and 12, and region 1 (overlapping region of both peptides) is noted in a). P56 (no 
peptide) is the negative control. c) Mab 16.1 Western blot analysis of c-Met in cell extracts obtained from 
untransfected (UT) NIH3T3 cells, NIH3T3 cells transiently expressing human c-Met (Met), U-87MG 
cells and T47D cells. Western blots are shown for comparison and are the same as those in Figures 3.19. 
Blue arrows and red arrows indicate c-Met precursor and c-Met purified α-chain respectively. Molecular 
weights are noted aside, in kilodaltons. P: Peptide (example P1 = Peptide 1). 
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Figure 3.23B: Region 2 contains the epitope of Mab 12.1 and 20.1. 
a) Crystal structure of c-Met extracellular domain (amino acid residues 25 – 567), binding to HGF β-
chain. Crystal structure was obtained from Protein Data Bank (PDB), accession number 1SHY. c-Met is 
highlighted in green, HGF in blue and region 2 in red. The sequence of region 2 is also noted in red. b) A 
pepscan example of Mab 12.1 and 20.1. Cell supernatants were added to wells coated with various 
peptides (peptide 1 to 55) as shown. Binding of monoclonal antibodies to their epitope will produce a 
yellow colorimetric reaction. Sequence of peptide 14/region 2 is noted in a). P56 (no peptide) is the 
negative control. c) Western blot analysis of c-Met in cell extracts obtained from untransfected (UT) 
NIH3T3 cells, NIH3T3 cells transiently expressing human c-Met (Met), U-87MG cells and T47D cells. 
Western blots were individually analysed by Mab 11.1, 12.1, 20.1 and 21.1. Western blots were grouped 
according to the binding region the antibody recognises, thus allowing the comparison of Western blot 
band profile among antibodies that bind within the same region. Antibodies from region 2 (Mab 12.1 and 
21.1) and 3 (Mab 11.1 and 20.1) were grouped together as their binding region are overlapping. Western 
blots are the same as those in Figures 3.19. Blue arrows and red arrows indicate c-Met precursor and c-
Met purified α-chain respectively. Molecular weights are noted aside, in kilodaltons. P: Peptide (example 
P1 = Peptide 1). 
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Figure 3.23C: Region 3 contains the epitope of Mab 11.1 and 21.1. 
a) Crystal structure of c-Met extracellular domain (amino acid residues 25 – 567), binding to HGF β-
chain. Crystal structure was obtained from Protein Data Bank (PDB), accession number 1SHY. c-Met is 
highlighted in green, HGF in blue and region 3 in red. The sequence of region 3 is also noted in red. b) A 
pepscan example of Mab 11.1 and 21.1. Cell supernatants were added to wells coated with various 
peptides (peptide 1 to 55) as shown. Binding of monoclonal antibodies to their epitope will produce a 
yellow colorimetric reaction. Sequence of peptide 14 and 15, and region 3 (overlapping region of both 
peptides) is noted in a). P56 (no peptide) is the negative control. c) Western blot analysis of c-Met in cell 
extracts obtained from untransfected (UT) NIH3T3 cells, NIH3T3 cells transiently expressing human c-
Met (Met), U-87MG cells and T47D cells. Western blots were individually analysed by Mab 11.1, 12.1, 
20.1 and 21.1. Western blots were grouped according to the binding region the antibody recognises, thus 
allowing the comparison of Western blot band profile among antibodies that bind within the same region. 
Antibodies from region 2 (Mab 12.1 and 21.1) and 3 (Mab 11.1 and 20.1) were grouped together as their 
binding region are overlapping. Western blots are the same as those in Figures 3.19. Blue arrows and red 
arrows indicate c-Met precursor and c-Met purified α-chain respectively. Molecular weights are noted 
aside, in kilodaltons. P: Peptide (example P1 = Peptide 1). 
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Figure 3.23D: Region 4 contains the epitope of Mab 14.1, 18.1 and 19.1. 
a) Crystal structure of c-Met extracellular domain (amino acid residues 25 – 567), binding to HGF β-
chain. Crystal structure was obtained from Protein Data Bank (PDB), accession number 1SHY. c-Met is 
highlighted in green, HGF in blue and region 4 in red. The sequence of region 4 is also noted in red. b) A 
pepscan example of Mab 14.1, 18.1 and 19.1. Cell supernatants were added to wells coated with various 
peptides (peptide 1 to 55) as shown. Binding of monoclonal antibodies to their epitope will produce a 
yellow colorimetric reaction. Sequence of peptide 19 and 20, and region 4 (overlapping region of both 
peptides) is noted in a). P56 (no peptide) is the negative control. c) Western blot analysis of c-Met in cell 
extracts obtained from untransfected (UT) NIH3T3 cells, NIH3T3 cells transiently expressing human c-
Met (Met), U-87MG cells and T47D cells. Western blots were individually analysed by Mab 14.1, 17.1, 
18.1 and 19.1. Western blots were grouped according to the binding region the antibodies recognises, thus 
allowing the comparison of Western blot band profile among antibodies that bind within the same region. 
Mab 17.1 recognises regions 4 and 8. Western blots are the same as those in Figures 3.19. Blue arrows 
and red arrows indicate c-Met precursor and c-Met purified α-chain respectively. Molecular weights are 
noted aside, in kilodaltons. P: Peptide (example P1 = Peptide 1). 
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Figure 3.23E: Region 5 contains the epitope of Mab 3.1 and 5.1. 
a) Crystal structure of c-Met extracellular domain (amino acid residues 25 – 567), binding to HGF β-
chain. Crystal structure was obtained from Protein Data Bank (PDB), accession number 1SHY. c-Met is 
highlighted in green, HGF in blue and region 5 in red. The sequence of region 5 is also noted in red. b) A 
pepscan example of Mab 3.1 and 5.1. Cell supernatants were added to wells coated with various peptides 
(peptide 1 to 55) as shown. Binding of monoclonal antibodies to their epitope will produce a yellow 
colorimetric reaction. Sequence of peptide 21 and 22, and region 5 (overlapping region of both peptides) 
is noted in a). P56 (no peptide) is the negative control. c) Western blot analysis of c-Met in cell extracts 
obtained from untransfected (UT) NIH3T3 cells, NIH3T3 cells transiently expressing human c-Met 
(Met), U-87MG cells and T47D cells. Western blots were individually analysed by Mab 3.1, 4.1 and 5.1. 
Western blots were grouped according to the binding region the antibody recognises, thus allowing the 
comparison of Western blot band profile among antibodies that bind within the same region. Antibodies 
from region 5 (Mab 3.1 and 5.1) and 6 (Mab 4.1) were grouped together as their binding region are 
overlapping. Western blots are the same as those in Figures 3.19. Blue arrows and red arrows indicate c-
Met precursor and c-Met purified α-chain respectively. Molecular weights are noted aside, in kilodaltons. 
P: Peptide (example P1 = Peptide 1). 
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Figure 3.23F: Region 6 contains the epitope of Mab 4.1. 
a) Crystal structure of c-Met extracellular domain (amino acid residues 25 – 567), binding to HGF β-
chain. Crystal structure was obtained from Protein Data Bank (PDB), accession number 1SHY. c-Met is 
highlighted in green, HGF in blue and region 6 in red. The sequence of region 6 is also noted in red.  b) 
Pepscan of Mab 41. Cell supernatant was added to wells coated with various peptides (peptide 1 to 55) as 
shown. Binding of monoclonal antibodies to their epitope will produce a yellow colorimetric reaction. 
Sequence of peptide 22/region 6 is noted in a). P56 (no peptide) is the negative control. c) Western blot 
analysis of c-Met in cell extracts obtained from untransfected (UT) NIH3T3 cells, NIH3T3 cells 
transiently expressing human c-Met (Met), U-87MG cells and T47D cells. Western blots were 
individually analysed by Mab 3.1, 4.1 and 5.1. Western blots were grouped according to the binding 
region the antibody recognises, thus allowing the comparison of Western blot band profile among 
antibodies that bind within the same region. Antibodies from region 5 (Mab 3.1 and 5.1) and 6 (Mab 4.1) 
were grouped together as their binding region are overlapping. Western blots are the same as those in 
Figures 3.19. Blue arrows and red arrows indicate c-Met precursor and c-Met purified α-chain 
respectively. Molecular weights are noted aside, in kilodaltons. P: Peptide (example P1 = Peptide 1). 
 
142 
 
 
Figure 3.23G: Region 7 contains the epitope of Mab 1.1, 2.1 and 9.1. 
a) Crystal structure of c-Met extracellular domain (amino acid residues 25 – 567), binding to HGF β-
chain. Crystal structure was obtained from Protein Data Bank (PDB), accession number 1SHY. c-Met is 
highlighted in green, HGF in blue and region 7 in red. The sequence of region 7 is also noted in red. b) A 
pepscan example of Mab 1.1, 2.1 and 9.1. Cell supernatants were added to wells coated with various 
peptides (peptide 1 to 55) as shown. Binding of monoclonal antibodies to their epitope will produce a 
yellow colorimetric reaction. Sequence of peptide 28 and 29, and region 7 (overlapping region of both 
peptides) is noted in a). P56 (no peptide) is the negative control. c) Western blot analysis of c-Met in cell 
extracts obtained from untransfected (UT) NIH3T3 cells, NIH3T3 cells transiently expressing human c-
Met (Met), U-87MG cells and T47D cells. Western blots were individually analysed by Mab 1.1, 2.1 and 
9.1. Western blots were grouped according to the binding region the antibody recognises, thus allowing 
the comparison of Western blot band profile among antibodies that bind within the same region. Western 
blots are the same as those in Figures 3.19. Blue arrows and red arrows indicate c-Met precursor and c-
Met purified α-chain respectively. Molecular weights are noted aside, in kilodaltons. P: Peptide (example 
P1 = Peptide 1). 
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Figure 3.23H: Region 8 contains the epitope of Mab 6.1, 10.1 and 13.1. 
a) Crystal structure of c-Met extracellular domain (amino acid residues 25 – 567), binding to HGF β-
chain. Crystal structure was obtained from Protein Data Bank (PDB), accession number 1SHY. c-Met is 
highlighted in green, HGF in blue and region 8 in red. The sequence of region 8 is also noted in red. b) A 
pepscan example of Mab 6.1, 10.1 and 13.1. Cell supernatants were added to wells coated with various 
peptides (peptide 1 to 55) as shown. Binding of monoclonal antibodies to their epitope will produce a 
yellow colorimetric reaction. Sequence of peptide 36, 42, 43 and 44, and region 8 (overlapping region of 
both peptides) is noted in a). P56 (no peptide) is the negative control. c) Western blot analysis of c-Met in 
cell extracts obtained from untransfected (UT) NIH3T3 cells, NIH3T3 cells transiently expressing human 
c-Met (Met), U-87MG cells and T47D cells. Western blots were individually analysed by Mab 6.1, 10.1, 
13.1 and 17.1. Western blots were grouped according to the binding region the antibodies recognises, thus 
allowing the comparison of Western blot band profile among antibodies that bind within the same region. 
Mab 17.1 recognises regions 4 and 8. Western blots are the same as those in Figures 3.19. Blue arrows 
and red arrows indicate c-Met precursor and c-Met purified α-chain respectively. Molecular weights are 
noted aside, in kilodaltons. P: Peptide (example P1 = Peptide 1). 
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Figure 3.23I: Region 9 contains the epitope of Mab 8.1. 
a) Crystal structure of c-Met extracellular domain (amino acid residues 25 – 567), binding to HGF β-
chain. Crystal structure was obtained from Protein Data Bank (PDB), accession number 1SHY. c-Met is 
highlighted in green, HGF in blue and region 9 in red. The sequence of region 9 is also noted in red. b) 
Pepscan of Mab 8.1. Cell supernatant was added to wells coated with various peptides (peptide 1 to 55) as 
shown. Binding of monoclonal antibodies to their epitope will produce a yellow colorimetric reaction. 
Sequence of peptide 39 and 40, and region 9 (overlapping region of both peptides) is noted in a). P56 (no 
peptide) is the negative control. c) Mab 8.1 Western blot analysis of c-Met in cell extracts obtained from 
untransfected (UT) NIH3T3 cells, NIH3T3 cells transiently expressing human c-Met (Met), U-87MG 
cells and T47D cells. Western blots are shown for comparison and are the same as those in Figures 3.19. 
Blue arrows and red arrows indicate c-Met precursor and c-Met purified α-chain respectively. Molecular 
weights are noted aside, in kilodaltons. P: Peptide (example P1 = Peptide 1). 
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Figure 3.23J: Region 10 contains the epitope of Mab 7.1 and 15.1. 
a) Crystal structure of c-Met extracellular domain (amino acid residues 25 – 567), binding to HGF β-
chain. Crystal structure was obtained from Protein Data Bank (PDB), accession number 1SHY. c-Met is 
highlighted in green, HGF in blue and region 10 in red. The sequence of region 10 is also noted in red. b) 
A pepscan example of Mab 7.1 and 15.1. Cell supernatants were added to wells coated with various 
peptides (peptide 1 to 55) as shown. Binding of monoclonal antibodies to their epitope will produce a 
yellow colorimetric reaction. Sequence of peptide 52 and 53, and region 10 (overlapping region of both 
peptides) is noted in a). P56 (no peptide) is the negative control. c) Western blot analysis of c-Met in cell 
extracts obtained from untransfected (UT) NIH3T3 cells, NIH3T3 cells transiently expressing human c-
Met (Met), U-87MG cells and T47D cells. Western blots were individually analysed by Mab 7.1 and 
15.1. Western blots were grouped according to the binding region the antibody recognises, thus allowing 
the comparison of Western blot band profile among antibodies that bind within the same region. Western 
blots are the same as those in Figures 3.19. Blue arrows and red arrows indicate c-Met precursor and c-
Met purified α-chain respectively. Molecular weights are noted aside, in kilodaltons. P: Peptide (example 
P1 = Peptide 1). 
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Figure 3.23K: Pepscan analysis of Mab 17.1. 
a) Crystal structure of c-Met extracellular domain (amino acid residues 25 – 567) with Mab 17.1 binding 
regions highlighted. Crystal structure was obtained from Protein Data Bank (PDB), accession number 
1SHY. Mab 17.1 binds to region 4 (in red) and region 8 (in blue). The protein complex is shown from 
two different viewpoints to allow visualisation of both regions. b) Pepscan of Mab 17.1. Monoclonal cell 
supernatant were added to wells coated with various peptides (peptide 1 to 55) as shown. Binding of 
monoclonal antibodies to their epitope will produce a yellow colorimetric reaction. Mab 17.1 binds to 
both regions 4 and 8. The sequence of region 4 and 8 are noted. The sequences of region 4 and region 8 
are in blue and red respectively. P56 (no peptide) is the negative control. P: Peptide (example P1 = 
Peptide 1). 
 
 
147 
 
Table 3.3: Pepscan results of Mab 17.1 re-clones 
Antibody 17.1 clones 
Region  
4 8 
E1 X   
E2 X x 
F1 X x 
F2 X x 
F3 X x 
F4 X x 
F6 X   
H2 X   
H3 X   
G2 X x 
G12 X x 
Parental 17.1 clone  X x 
 (x) indicate region of binding 
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Figure 3.24: Mapping of antibody binding regions to the crystal structure of c-Met. 
Crystal structure of c-Met extracellular domain (amino acid residues 25 – 567), binding to HGF β-chain. Crystal structure was obtained from Protein Data Bank (PDB), 
accession number 1SHY. c-Met is highlighted in green and HGF in blue. The protein complex is shown from two different viewpoints (a) and b)) to allow visualisation of the 
different antibody binding regions in relation to ligand-receptor interaction site. 
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Figure 3.25: Alignment of human and mouse c-Met α-chain. 
The sequence alignment of human and mouse c-Met, Swiss-Prot number P08581 and P16056 respectively, was performed and the α-chain sequence is shown only. The 
regions of antibody binding were mapped on to the sequence alignment to identify conserved residues. Detailed information on the antibody and its corresponding binding 
region is listed in Table 3.4. (*): residues identical in the alignment. (:): conserved residues subsitutions. (.): semi-conserved residues substitutions. 
Sequence alignment was performed with the Clustal series of programs. (2003)  
Chenna, Ramu, Sugawara, Hideaki, Koike,Tadashi, Lopez, Rodrigo, Gibson, Toby J, Higgins, Desmond G, Thompson, Julie D. 
Nucleic Acids Res 31 (13):3497-500 PubMedID: 12824352 
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Table 3.4: Characterisation of monoclonal antibodies 
Binding 
region Antibody 
Clone 
number 
IgG 
subclass 
Light 
chain  
Protein sequence 
of region 
Alignment* 
(human / mouse) 
1 16.1 12D10 IgG2A Kappa KVAEYKTGPV 
  
KVAEYKTGPV 
KVSEFKTGPV 
  
2 
    
IgG1 Kappa LEHPDCFPCQDCSSK 
  
12.1 5E7 LEHPDCFPCQDCSSK 
20.1 5G12 LEHPDCLPCRDCSSK 
      
3 
    
IgG1 Kappa CFPCQDCSSK 
  
11.1 9H1 CFPCQDCSSK 
21.1 12C9 CLPCRDCSSK 
      
4 
14.1 3E6 
IgG1 
Kappa LVVDTYYDDQ 
  
18.1 16H3 LVVDTYYDDQ 
17.1 2H8 LLVDTYYDDQ 
19.1 12A12 IgG2B   
5 
    
IgG1 Kappa LISCGSVNRG 
  
3.1 9H4 LISCGSVNRG 
5.1 16A4 LISCGSVNRG 
      
6 4.1 15E11 IgG2A Kappa LISCGSVNRGTCQRH 
  
LISCGSVNRGTCQRH 
LISCGSVNRGTCQRH 
  
7 
1.1 13E1 
IgG1 Kappa QIEEPSQCPD 
  
2.1 16F6 QIEEPSQCPD 
9.1 16C11 E-EESGQCPD 
      
8 
6.1 10B1 
IgG1 Kappa FRDS 
  
10.1 15G3 FRDS 
13.1 5H4 FLDS 
17.1 2H8   
9 8.1 2C6 IgG1 Kappa KETKDGFMFL 
  
KETKDGFMFL 
KETQDGFKFL 
  
10 
    
IgG1 Kappa NSGLHSYMEM 
  
7.1 6D9 NSGLHSYMEM 
15.1 5D5 DSGLHSYMEM 
      
*Top sequence: Human c-Met protein sequence. Bottom sequence: Murine c-Met protein sequence. Red: 
Differences in amino acid sequences.  
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3.3: Further characterisation of monoclonal hybridoma supernatant  
HGF is the only known ligand for c-Met. Upon ligand binding, c-Met dimerises and 
undergoes autophosphorylation. c-Met is then activated and phosphorylates cytoplasmic 
proteins involved in signalling pathways, leading to activation of various signalling 
cascades such as the ERK and AKT pathways. Previously, we have single-cell cloned 
21 hybridoma clones to obtain cell supernatant containing monoclonal antibodies. The 
monoclonal antibody’s isotype and binding region on c-Met were characterised. In this 
Section, we characterise the functional activity of the monoclonal antibodies by 
analysing the effects of the monoclonal antibodies were analysed on HGF-induced ERK 
phosphorylation and cell scatter.  
3.3.1: Activation of endogenous c-Met by recombinant HGF 
Before characterising the functional activity of the monoclonal antibodies, appropriate 
cell lines and experimental setups were required. In Section 3.1.4, we demonstrated that 
U-87MG, HaCaT and SNU-5 cells were positive for c-Met expression while T47D cells 
were negative for c-Met expression. Here, we test the experimental setup on these cell 
lines by analysing the effects of recombinant HGF (purchased from R&D Systems) on 
activation of c-Met, ERK and AKT. SNU-5 cells were not tested due to their high levels 
of phosphorylated c-Met, in the absence of added HGF (Figure 3.6).  
Cells were grown to 90% confluency and were then subjected to serum starvation for 24 
hrs to switch off growth signalling pathways. Recombinant HGF was then added to the 
cells for 30 mins and the cells were immediately harvested in hot sample loading buffer. 
U-87MG cells are a human glioblastoma cell line that expresses both c-Met and HGF, 
thus is it autocrine for c-Met activation (Martens et al., 2006). In serum-free media 
containing no added HGF, c-Met was observed to be phosphorylated (Figure 3.26), 
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which is consistent with the observation that U-87MG cells are autocrine for c-Met 
signalling. Interestingly, both c-Met precursor and mature β-chain were observed to be 
phosphorylated. Phosphorylation of c-Met correlates with increasing concentration of 
HGF, while the levels of total c-Met protein remained constant. Total levels of AKT 
protein remained constant with increasing HGF concentration. Increasing 
phosphorylation of AKT at threonine 308 (T308) correlated with increasing 
concentration of HGF, however, AKT phosphorylation at serine 473 (S473) was 
observed to remain constant. T308 and S473 lies in the kinase domain and C-terminal 
tail of AKT respectively. Activation of AKT results in the phosphorylation of T308 in 
the kinase domain. However, for full kinase activity, phosphorylation at a second site, 
S472, is required (Fresno Vara et al., 2004). Similarly to c-Met, ERK phosphorylation 
correlated with increasing HGF concentration while total ERK protein levels stayed the 
same. Activation of c-Met has been reported to lead to ERK and AKT phosphorylation 
(Bellon et al., 2008; Birchmeier et al., 2003; Smolen et al., 2006). It is not surprising 
that both ERK and AKT are phosphorylated with no added HGF because U-87MG cells 
are PTEN (phosphatase and tensin homolog) null cells. PTEN is a tumour suppressor 
protein that is a negative regulator of the AKT signalling pathway. AKT is thus 
constantly phosphorylated in U-87MG cells, even in the absence of added HGF.  
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Figure 3.26: Activation of endogenous c-Met by recombinant HGF in U-87MG cells. 
Western blotting of U-87MG cell extracts from cells treated with 0, 20, 40 and 80 ng/ml of recombinant 
HGF. Cells were serum-starved for 24 hrs. HGF was added to the cells, in serum-free media, for 30 mins 
before harvesting in sample buffer. 40 μg of total cell lysate was analysed in each sample. Activation of 
c-Met was examined by detecting phosphorylated c-Met (pMet). Arrows on the pMet blot indicate 
phosphorylated c-Met precursor (170 kD) and phosphorylated c-Met β-chain (145 kD). Activation of 
ERK and AKT signalling pathways were also examined by detecting phosphorylated ERK and AKT (at 
either S473 or T308). Anti-ERK and anti-phospho ERK antibodies detected 2 bands at 44 kD and 42 kD, 
which correspond to ERK1 and ERK2 respectively. PCNA was used as loading control. pERK: 
Phosphorylated ERK. pAKT: Phosphorylated AKT. 
 
HaCaT are derived from human keratinocyte cells and were shown to express c-Met in 
Figure 3.6. In this cell line, phosphorylation of c-Met was found to correlate with HGF 
concentration (Figure 3.27). In contrast to U-87MG cells, only c-Met mature β-chain 
was phosphorylated. HaCaT cells could not be grown to very high densities, therefore 
production of sufficient cell lysate to load 40 μg protein per well would have required 
prohibitive amounts of commercially bought HGF. As commercially available 
antibodies (AF276 and SC-10 antibodies) failed to detect total levels of c-Met analysed 
in 10 μg of cell lysates, the anti-α-chain antibody Mab 18.1, developed in this project, 
was used to detect precursor c-Met. An increase in c-Met precursor protein was detected 
when 20 and 40 ng/ml of HGF was added to the cells. A decrease of c-Met precursor 
levels was observed when 80 ng/ml of HGF was added, but due to time constraints, it 
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was not possible to show if this was a reproducible result. Interestingly, HGF resulted in 
an increase of total ERK levels in HaCaT cell but not in U-87MG cells.  
 
Figure 3.27: Activation of endogenous c-Met by recombinant HGF in HaCaT cells. 
Western blotting of HaCaT cell extracts treated with 0, 20, 40 and 80 ng/ml of recombinant HGF. Cells 
were serum-starved for 24 hrs. HGF was added to the cells, from cells in serum-free media, for 30 mins 
before harvesting in sample buffer. 10 μg of total cell lysate was analysed in each sample. Activation of 
c-Met was examined by detecting phosphorylated c-Met (pMet). Arrows on pMet blot indicate 
phosphorylated c-Met β-chain (145 kD). Activation of ERK and AKT signalling pathways were also 
examined by detecting phosphorylated ERK and AKT (at either S473 or T308) respectively. Anti-ERK 
and anti-phospho-ERK antibodies detected 2 bands at 44 kD and 42 kD, which correspond to ERK1 and 
ERK2 respectively. PCNA was used as loading control.  pERK: Phosphorylated ERK. pAKT: 
Phosphorylated AKT. 
 
Increased phosphorylation of AKT S473 should have been observed in HaCaT cells 
treated with increasing HGF concentrations as the cells were presumed to not produce 
HGF. Interestingly, increased HGF concentration did not affect total AKT protein levels 
or phosphorylation of AKT at S473. Constant levels of AKT phosphorylation at S473 is 
also observed in U-87MG cells treated with increasing HGF concentrations. U-87MG 
cells, which are HGF self-producing, are thus constantly phosphorylated at AKT S473, 
and added HGF would not have caused further increase in phosphorylation. As 
phosphorylation of AKT S473 indicates full AKT activation (Nicholson and Anderson, 
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2002), it is probable that the increased HGF concentrations were not sufficient to induce 
full AKT activation or a longer time point is required for full AKT activation i.e. HGF-
induced phosphorylation of AKT at S473 occurs after 30 mins. Finally, AKT 
phosphorylation at T308, ERK phosphorylation and total protein levels of ERK, 
correlated with increased HGF concentration in HaCaT cells.  
 
Figure 3.28: Activation of ERK and AKT signalling pathways by recombinant HGF in T47D cells. 
Western blotting of T47D cell extract from cells treated with 0, 20, 40, 80 ng/ml of recombinant HGF. 
T47D cells express very low levels of c-Met. Cells were serum-starved for 24 hrs. HGF was added to the 
cells for 30 mins before harvesting in sample buffer. 10 μg of total cell lysate was analysed in each 
sample. Activation of c-Met was examined by detecting for phosphorylated c-Met (pMet). c-Met and 
phosphorylated c-Met protein band were absent in the precursor c-Met and pMet blot. Activation of ERK 
and AKT signalling pathways determined by examining phosphorylation of ERK and AKT (at either 
S473 or T308) respectively. Anti-ERK and anti-phospho-ERK antibodies detected 2 bands at 44 kD and 
42 kD, which correspond to ERK1 and ERK2 respectively. PCNA was used as loading control. pERK: 
Phosphorylated ERK. pAKT: Phosphorylated AKT. 
 
As a control to determine if HGF has non-specific effects, ERK and AKT 
phosphorylation were examined in T47D cells. T47D cells are human breast cancer 
cells that were reported to express very low levels of c-Met protein (Shen et al., 2000) 
and we have conclusively shown that endogenous c-Met could not be 
immunoprecipitated from these cells (Figure 3.6). As expected, Mab 18.1 and anti-
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phospho-Met antibodies failed to detect total c-Met protein levels and phosphorylated c-
Met, respectively, by Western blotting (Figure 3.28). There were also no changes in 
AKT phosphorylation upon treatment with HGF. Interestingly, a slight increase in total 
ERK was observed across all levels of HGF, but mainly in samples treated with 20 
ng/ml of HGF. At this level, an increase in ERK phosphorylation was also observed. It 
should be noted that the increased ERK phosphorylation could be due to the increased 
levels of total ERK, rather than increased phosphorylation of ERK. This result is 
unexpected and could be due to the low level of c-Met activation in T47D cells. 
 
Figure 3.29: Activation of ERK pathway by increasing concentration of HGF in HaCaT cells. 
Western blotting of HaCaT cell extracts treated with increasing concentration of recombinant HGF. Cells 
were serum-starved for 24 hrs. Indicated concentrations of HGF were added to the cells and then they 
were incubated for 30 mins before harvesting in sample buffer. 10 μg of total cell lysate was analysed in 
each sample. Phosphorylation of ERK is used as an indicator of c-Met activation by HGF. Anti-ERK and 
anti-phospho-ERK antibodies detected 2 bands at 44 kD and 42 kD, which correspond to ERK1 and 
ERK2 respectively. Tubulin was used as loading control. pERK: Phosphorylated ERK. Molecular 
weights are noted aside, in kilodaltons.  
 
Comparing the activation of ERK and AKT pathways in U-87MG cells and HaCaT 
cells through activation of c-Met by HGF, ERK phosphorylation in HaCaT cells was the 
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most distinct and obvious. We therefore chose to examine ERK phosphorylation in 
HaCaT cells as an indicator of c-Met activation in our functional assays.  To determine 
the minimum concentration of HGF required to induce activation of endogenous c-Met, 
recombinant HGF was added to HaCaT cells in gradually increasing concentrations. 
Cells were harvested and analysed for ERK phosphorylation by Western blotting. ERK 
phosphorylation correlated with increased HGF concentration while total ERK protein 
levels remained constant (Figure 3.29). 10 ng/ml of HGF was the minimum 
concentration required to activate c-Met in HaCaT cells.  In our antibody functional 
assay, 10 ng/ml of HGF was thus used to compete with the monoclonal antibodies for 
binding to c-Met.       
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3.3.2: Preliminary analysis of the effect of treatment with monoclonal antibodies on 
ERK phosphorylation  
The overall aim of this project was to produce and screen for therapeutic antibodies 
against c-Met. Section 3.1 and 3.2 of this report have: 1) described the production of 
monoclonal antibodies against c-Met, 2) shown that the antibodies recognise denatured 
protein on Western blots, 3) identified the isotype of each antibody and 4) delineated the 
region of antibody binding on human c-Met. We now examine whether these 21 
monoclonal antibodies are functionally active by analysing the effects of the antibodies 
on HGF-induced ERK phosphorylation. Structural analysis of antibody binding regions 
in Section 3.2.7 suggests that some of the antibodies (Mab 1.1, 2.1, 7.1, 8.1, 9.1 and 
15.1) may be able to compete with HGF for c-Met binding, thus inhibiting c-Met 
activation by ligand binding. 
HaCaT cells were grown to approximately 90% confluency and then grown in serum-
free medium for 24 hrs. Hybridoma cell supernatants were then diluted in serum-free 
media and incubated with the cells for 1 hr. 10 ng/ml of HGF was added to the cells and 
incubated for 30 mins. Cells were immediately harvested in hot sample loading buffer 
and 10 μg of total cell lysate were analysed by Western blotting. It should be noted that 
hybridoma cell supernatants are being tested and not purified antibodies. FCS contains 
growth factors, antibodies and other various proteins. Therefore, due to the presence of 
FCS in hybridoma cell supernatant, it is not possible to measure antibody concentration. 
Each hybridoma clone has an individual rate of antibody secretion and so antibody 
concentration is different in each hybridoma supernatant sample. In addition, it is also 
not possible to determine how much FCS remains in the media. Due to the various 
issues mentioned above, it is difficult to standardise this assay. Varying antibody 
concentrations were therefore tested by diluting cell supernatant in 1:10, 1:5 and 1:1 
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with serum-free media. It is assumed that the cell supernatant contained 10% FCS and 
the amount of growth factors in each batch of FCS, between Moravian Biotechnology 
and our lab, is identical but this assay should be seen as a preliminary screening test 
designed to help prioritise antibodies for further study.  
As mentioned earlier, activation of c-Met by HGF results in activation of intracellular 
signalling pathways, one of which is the ERK pathway (Figure 3.27). HaCaT cells were 
used in this study due to their low basal level of ERK phosphorylation after serum 
starvation (Figure 3.27). Cells were serum-starved to switch off growth signalling 
pathways. Activation of c-Met, induced by HGF or by our monoclonal antibodies, after 
serum starvation would result in phosphorylation of ERK. Inhibition of HGF-induced c-
Met activation, by commercial inhibitors or our monoclonal antibodies, would result in 
very low basal levels of ERK phosphorylation.  
Due to the presence of FCS in antibody containing cell supernatant, various controls 
were carried out to determine the effect of FCS on ERK phosphorylation (Figure 3.30). 
Without serum starvation, untreated cells were harvested to determine the basal level of 
ERK phosphorylation. Only ERK2 (lower band, 42 kD) was detectably phosphorylated. 
Following serum starvation, and in the absence of FCS, added HGF resulted in 
increased ERK protein levels and an increased phosphorylation of both ERK1 and 
ERK2. In order to mimic the effects of adding hybridoma cell supernatant (containing 
FCS) at 1:1 dilution to serum-starved cells, media containing final concentrations of 5% 
FCS was used as control. Adding media containing 5% FCS to serum-starved cells was 
sufficient to induce an increase in total ERK levels as well as an increase in 
phosphorylation of both ERK1 and ERK2. This indicates that the levels of FCS proteins 
in the cell supernatant would have an effect on the outcome of this assay. Serum-starved 
cells treated with HGF, in the presence of 5% FCS, produced similar increased in total 
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ERK levels and phosphorylated ERK as compared to serum-starved cells treated with 
HGF, in the absence of FCS. This indicates that HGF alone was capable of increasing 
total ERK levels and inducing ERK phosphorylation without FCS. As a control to block 
HGF from binding to c-Met, an anti-HGF antibody was incubated with HGF for an hour 
prior its addition to serum-starved cells, at a final concentration of 5 μg/ml (from Jiao et 
al. (2005) and Somlen et al. (2006)), in media containing 5% FCS. In the presence of 
the anti-HGF antibody, the addition of HGF did not affect the levels of ERK protein or 
levels of ERK phosphorylation. These levels of total ERK and ERK phosphorylation 
were similar to serum-starved cells treated with media containing 5% FCS. This 
suggests that anti-HGF antibody completely inhibits the ability of HGF to activate the 
ERK pathway through c-Met and the constituents of FCS are evidently acting to 
activate the ERK pathway. 
Prat et al. (1998) reported work aimed at developing inhibitory monoclonal antibodies 
against c-Met. These anti-Met antibodies turned out to be agonistic instead of 
antagonist. It was thus hypothesised that bivalent binding of an antibody molecule is 
capable of dimerising c-Met molecules which leads to c-Met activation. Martens et al. 
(2006) developed a one-armed anti-Met antibody that consists of only one epitope 
binding site. This one-arm antibody was reported to successfully block tumour growth 
in mouse models.  Anti-α-chain antibodies developed here were thus tested for their 
ability activate c-Met or block HGF binding to c-Met. Due to the presence of FCS in the 
hybridoma cell supernatant, which also caused ERK phosphorylation, it was difficult to 
interpret these results.  
Hybridoma cell supernatants were diluted 1:1 in serum-free media. Total ERK levels 
and phosphorylated ERK levels were analysed from cells treated with hybridoma cell 
supernatant and either with or without HGF (Figure 3.30). Results were compared to 
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control cells treated in media containing 5% FCS, and tabulated in Table 3.5. Any 
decreases in ERK phosphorylation levels suggest that these antibodies are inhibiting 
HGF-induced activation of c-Met. Based on the results on Table 3.5, the effects of 
monoclonal antibodies on total ERK levels and ERK phosphorylation could be 
classified into several groups. The majority of antibodies (highlighted in green) fell into 
a group in which a decrease of total ERK and phosphorylated ERK were observed in 
both HGF induced and un-induced samples. It is likely that the treatment with these 
antibodies caused a reduction in total ERK levels, resulting in a reduction in the 
observed levels of phosphorylated ERK. Alternatively, serum levels or the ERK-inducer 
present in the serum is reduced, thus resulting in the reduced ERK levels.  Mab 1.1, 2.1 
and 13.1 together fell into another distinct group (highlighted in red). In this group, an 
increase in total ERK levels was observed in the absence of HGF and there was no 
change in phosphorylated ERK compared to the no-antibody control. No changes in 
total ERK levels and phosphorylated ERK levels were observed in HGF-induced 
samples. These results suggest that Mab 1.1, 2.1 and 13.1 do not have an effect on ERK 
phosphorylation but are affecting ERK levels by an unknown mechanism. Total ERK 
levels were observed to remain constant in HGF-induced and un-induced samples 
treated with either Mab 3.1, 7.1 or 8.1 (highlighted in purple). Interestingly, although 
total ERK levels remained constant, a decrease in ERK phosphorylation levels was 
observed in these samples. These antibodies are of interest as the results suggest that 
these antibodies have the ability to inhibit c-Met activation thus resulting in the decrease 
of ERK phosphorylation observed. With Mab 14.1 and 15.1, total ERK levels and ERK 
phosphorylation levels remained constant in the different treatments tested indicating 
that these antibodies do not have any effect on c-Met. Finally, Mab 9.1 was the only 
antibody whose total ERK levels and phosphorylated ERK levels stayed the same upon 
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HGF induction but decreased in un-induced samples. It is possible that Mab 9.1 is able 
to reduce total ERK and phosphorylated ERK levels in the absence of HGF. However, 
in the presence of HGF, the reduced effect of Mab 9.1 is being cancelled out by HGF-
induction resulting in the constant levels of ERK and phosphorylated ERK observed. 
The ERK pathway clearly plays a role in the biological changes, such as cell 
proliferation and cell motility, induced by c-Met activation (Birchmeier et al., 2003; Li 
et al., 2005; Rosario and Birchmeier, 2003). However, the mechanism by which c-Met 
or anti-Met antibodies affect ERK levels is still unclear. The observed changes in ERK 
levels within one hour of antibody incubation, followed by 30 mins of HGF treatment, 
could possibility be due to the effects of antibody treatment or FCS effects.  
The results of antibody binding regions in Section 3.2.7 suggested that the epitopes of 
Mab 1.1, 2.1, 7.1, 8.1, 9.1 and 15.1 lie within Met-HGF interaction site. Competition 
binding of these antibodies to c-Met would disrupt the receptor-ligand interaction, 
prevent c-Met activation and activation of the ERK pathway. Consistent with the 
structural analysis, reduced ERK phosphorylation was observed in Mab 7.1 and 8.1 
treated samples suggesting that these antibodies are inhibiting c-Met activation by 
competing with HGF for c-Met. 
Hybridoma cell supernatant tested at 1:10 dilution (data not shown) failed to produce 
significant ERK responses. Subtle differences in ERK responses were observed in 
samples treated with hybridoma supernatant diluted 1:5 in serum-free media (Appendix 
3). In this assay, some effects of monoclonal antibody on ERK levels and 
phosphorylation levels were observed. However, the presence of FCS makes it difficult 
to differentiate the effects of the monoclonal antibodies and the effect of FCS. Purified 
monoclonal antibodies, which will be discuss in the next section, will be required to 
eliminate this FCS issue. 
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Figure 3.30: Mab (diluted 1:1) effects on ERK phosphorylation in HaCaT cells. 
HaCaT cells were treated with anti-α-chain c-Met antibodies. HaCaT cells were grown to 90% confluency before serum starvation. Monoclonal antibody cell supernatants 
were diluted 1:1 in serum-free media and incubated with HaCaT cells for an hour. 10 ng/ml of HGF was added to the cells for 30 mins before harvesting in hot sample buffer. 
10 μg of total cell lysate was analysed in each sample by SDS-PAGE. Western blotting was performed using anti-phospho-ERK, anti-ERK and PC10 antibodies to detect 
phosphorylated ERK, total ERK and PCNA levels respectively. Activation of c-Met was determined by phosphorylation of ERK. PCNA levels were used as loading control. 
All controls were serum-starved, except for untreated (UT) samples. Controls with media containing 0% and 5% FCS were performed to examine the effect of FCS on ERK 
phosphorylation. Antibody against HGF (5 μg/ml) was used as a control to block HGF from binding to c-Met. pERK: Phosphorylated ERK. Anti-HGF: Antibody against 
HGF. 
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Table 3.5: Mab effects on total ERK and phosphorylated ERK levels. 
 Mab Total ERK Phosphorylated ERK 
No HGF HGF No HGF HGF 
1.1 ↑ S S S 
2.1 ↑ S S S 
3.1 S S ↓ ↓ 
4.1 ↓ ↓ ↓ ↓ 
5.1 ↓ ↓ ↓ ↓ 
6.1 ↓ ↓ ↓ ↓ 
7.1 S S ↓ ↓ 
8.1 S S ↓ ↓ 
9.1 ↓ S ↓ S 
10.1 ↓ ↓ ↓ ↓ 
11.1 ↓ ↓ ↓ ↓ 
12.1 ↓ ↓ ↓ ↓ 
13.1 ↑ S S S 
14.1 S S S S 
15.1 S S S S 
16.1 ↓ ↓ ↓ ↓ 
17.1 ↓ ↓ ↓ ↓ 
18.1 ↓ ↓ ↓ ↓ 
19.1 ↓ ↓ ↓ ↓ 
20.1 ↓ ↓ ↓ ↓ 
21.1 ↓ ↓ ↓ ↓ 
Summary of results from Figure 3.30. Levels of ERK and phosphorylated ERK from HaCaT cells treated 
with monoclonal antibody supernatant, in the presence or absence of HGF. Results were compared to 
control cells treated in 5% FCS and tabulated. Hybridoma cell supernatant that have the same effects on 
ERK levels are highlighted in the same colour. (↑): increased levels compared to control; (↓): decreased 
levels compared to control; (S): levels remain the same as control. 
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The activation/inhibition effects of monoclonal antibodies on ERK phosphorylation do 
not necessary induce the same effects on other hallmarks of c-Met activation (Prat et al., 
1998). We thus investigated the effects of the antibodies on HGF-induced changes in 
cell motility or scattering. Cell scattering is one of the biological effects of c-Met 
activation upon HGF stimulation (Birchmeier et al., 2003). HaCaT cells are cuboidal-
shaped cells that form tight circular colonies under normal tissue culture growth 
conditions. In the presence of HGF, HaCaT cells become spindle-shape cells and 
scatter, which is a hallmark of the epithelial-mesenchymal transition (EMT). 
3.3.3: Preliminary analysis of monoclonal antibodies effects on cell scattering 
 
Figure 3.31: HGF induction causes cell scattering in HaCaT cells. 
Crystal violet staining of HaCaT cells. Un-induced HaCaT cells form tight, circular colonies. However, 
upon HGF stimulation, HaCaT cells change shape and spread out (scatter), no longer retaining their tight, 
circular colonies. Scattering of HaCaT cells by HGF induction could be blocked by anti-HGF antibodies. 
HaCaT cells were seeded at low cell density and allowed to grow until colonies formed. HGF and anti-
HGF antibody were used at a final concentration of 10 ng/ml and 5 μg/ml respectively. Anti-HGF 
antibody was pre-incubated with HGF, in media containing 2% FCS, for 1 hr before adding to the cells. 
Cells were treated, as indicated in media containing 2% FCS, for 24 hrs before fixing in methanol and 
staining with crystal violet. Results were shown in duplicates for each set of conditions. 
    
HaCaT cells were seeded at low cell density and allowed to grow until colonies were 
formed. Cells were serum-starved for 24 hrs following which, hybridoma cell 
supernatants containing monoclonal antibodies were added to the cells for 1 hr. HGF 
was then added and the cells incubated for 24 hrs. Cells were then fixed with methanol 
and stained with crystal violet for easy visualisation of cell colonies (Figures 3.31 and 
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3.28). Percentage of cell scatter is not available. Magnitude of cell scatter was observed 
by eye. Pictures of cell colonies taken represent the majority phenotype observed for 
each indicated treatment. It is assumed that the hybridoma supernatants contained 10% 
FCS and as a rough guide, a final concentration of 2% of FCS was used in controls 
(Figure 3.31). As observed, HaCaT cells only scatter in the presence of HGF. HaCaT 
cells failed to scatter under normal conditions (no treatment control), treatment with a 
combination of HGF and anti-HGF antibody and with anti-HGF antibody alone. Failure 
to scatter under the combination of HGF and anti-HGF antibody is due to anti-HGF 
antibody competition binding with c-Met for HGF, thus preventing c-Met activation by 
added HGF.   
To test whether our anti-α-chain antibodies were capable of blocking the effects of HGF 
on HaCaT cells, varying antibody concentrations were tested by diluting cell 
supernatant in 1:10, 1:5 and 1:1 with serum-free media. The anti-α-chain antibodies did 
not induce cell scattering in the absence of HGF (Figure 3.32). The one exception was 
Mab 6.1, which induced a slight scattering effect, suggesting that Mab 6.1 has an 
activating effect on c-Met-induced cell scatter. In the presence of added HGF, Mab 4.1, 
8.1, 11.1, 14.1 and 17.1 showed discernable inhibition of cell scatter, indicating that 
these antibodies are inhibitory towards HGF-induced cell motility. The inhibitory effect 
of cell scatter by the remaining antibodies is not obvious as the colonies were observed 
to scatter less than the HGF control and were not as tight at the combination of HGF 
and anti-HGF antibody control.  
The effects of the hybridoma monoclonal antibodies in functional assays (ERK 
phosphorylation and cell scatter) are compiled in Table 3.6. From this table, it is 
observed that Mab 4.1, 8.1, 11.1, 14.1 and 17.1 are able to inhibit cell scatter and 
reduce/remain ERK phosphorylation levels. The next stage is to analyse the effects of 
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the antibodies without the presence of FCS to confirm their effect on ERK 
phosphorylation and cell scatter.     
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Figure 3.32A: Mab 
1.1, 2.1 and 3.1 
effects on cell 
scattering in HaCaT 
cells. 
Crystal violet staining 
of HaCaT cells. 
HaCatTcells were 
seeded at low cell 
density and allowed to 
grow until colonies 
were formed. Cells 
were serum-starved for 
24 hrs before 
incubating with cell 
supernatant containing 
monoclonal antibodies 
for an hour. Cell 
supernatants were 
diluted 1:10, 1:5 and 
1:1 in serum-free 
media. HGF was 
added to the cells for 
24 hrs before fixation 
in methanol and 
staining in crystal 
violet. Two fields are 
shown for each cell 
treatment condition.  
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Figure 3.32B: Mab 
4.1, 5.1 and 6.1 
effects on cell 
scattering in HaCaT 
cells. 
Crystal violet staining 
of HaCaT cells. 
HaCaT cells were 
seeded at low cell 
density and allowed to 
grow until colonies 
were formed. Cells 
were serum-starved for 
24 hrs before 
incubating with cell 
supernatant containing 
monoclonal antibodies 
for an hour. Cell 
supernatants were 
diluted 1:10, 1:5 and 
1:1 in serum-free 
media. HGF was 
added to the cells for 
24 hrs before fixation 
in methanol and 
staining in crystal 
violet. Two fields are 
shown for each cell 
treatment condition.  
 
170 
 
 
Figure 3.32C: Mab 
7.1, 8.1 and 9.1 
effects on cell 
scattering in HaCaT 
cells. 
Crystal violet staining 
of HaCaT cells. 
HaCaT cells were 
seeded at low cell 
density and allowed to 
grow until colonies 
were formed. Cells 
were serum-starved for 
24 hrs before 
incubating with cell 
supernatant containing 
monoclonal antibodies 
for an hour. Cell 
supernatants were 
diluted 1:10, 1:5 and 
1:1 in serum-free 
media. HGF was 
added to the cells for 
24 hrs before fixation 
in methanol and 
staining in crystal 
violet. Two fields are 
shown for each cell 
treatment condition.  
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Figure 3.32D: Mab 
10.1, 11.1 and 12.1 
effects on cell 
scattering in 
HaCatTcells. 
Crystal violet staining 
of HaCaT cells. 
HaCatTcells were 
seeded at low cell 
density and allowed to 
grow until colonies 
were formed. Cells 
were serum-starved for 
24 hrs before 
incubating with cell 
supernatant containing 
monoclonal antibodies 
for an hour. Cell 
supernatants were 
diluted 1:10, 1:5 and 
1:1 in serum-free 
media. HGF was 
added to the cells for 
24 hrs before fixation 
in methanol and 
staining in crystal 
violet. Two fields are 
shown for each cell 
treatment condition.  
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Figure 3.32E: Mab 
13.1, 14.1 and 15.1 
effects on cell 
scattering in HaCaT 
cells. 
Crystal violet staining 
of HaCaT cells. 
HaCatTcells were 
seeded at low cell 
density and allowed to 
grow until colonies 
were formed. Cells 
were serum-starved for 
24 hrs before 
incubating with cell 
supernatant containing 
monoclonal antibodies 
for an hour. Cell 
supernatants were 
diluted 1:10, 1:5 and 
1:1 in serum-free 
media. HGF was 
added to the cells for 
24 hrs before fixation 
in methanol and 
staining in crystal 
violet. Two fields are 
shown for each cell 
treatment condition.  
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Figure 3.32F: Mab 
16.1, 17.1 and 18.1 
effects on cell 
scattering in HaCatT 
cells. 
Crystal violet staining 
of HaCaT cells. 
HaCaT cells were 
seeded at low cell 
density and allowed to 
grow until colonies 
were formed. Cells 
were serum-starved for 
24 hrs before 
incubating with cell 
supernatant containing 
monoclonal antibodies 
for an hour. Cell 
supernatants were 
diluted 1:10, 1:5 and 
1:1 in serum-free 
media. HGF was 
added to the cells for 
24 hrs before fixation 
in methanol and 
staining in crystal 
violet. Two fields are 
shown for each cell 
treatment condition.  
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Figure 3.32G: Mab 
19.1, 20.1 and 21.1 
effects on cell 
scattering in HaCaT 
cells. 
Crystal violet staining 
of HaCaT cells. 
HaCaT cells were 
seeded at low cell 
density and allowed to 
grow until colonies 
were formed. Cells 
were serum-starved for 
24 hrs before 
incubating with cell 
supernatant containing 
monoclonal antibodies 
for an hour. Cell 
supernatants were 
diluted 1:10, 1:5 and 
1:1 in serum-free 
media. HGF was 
added to the cells for 
24 hrs before fixation 
in methanol and 
staining in crystal 
violet. Two fields are 
shown for each cell 
treatment condition.  
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Table 3.6: Result summary of monoclonal hybridoma cell supernatants in functional assays. 
Monoclonal 
antibody 
c-Met 
binding 
region 
Total 
ERK/phosphorylated 
ERKa 
Cell scatterb 
1.1 7 S/S − 
2.1 7 S/S − 
3.1 5 S/↓ − 
4.1 6 ↓/↓ Inhibit 
5.1 5 ↓/↓ − 
6.1 8 ↓/↓ Activate 
7.1 10 S/↓ − 
8.1 9 S/↓ Inhibit 
9.1 7 S/S − 
10.1 8 ↓/↓ − 
11.1 3 ↓/↓ Inhibit 
12.1 2 ↓/↓ − 
13.1 8 S/S − 
14.1 4 S/S Inhibit 
15.1 10 S/S − 
16.1 1 ↓/↓ − 
17.1 4 & 8 ↓/↓ Inhibit 
18.1 4 ↓/↓ − 
19.1 4 ↓/↓ − 
20.1 2 ↓/↓ − 
21.1 3 ↓/↓ − 
Results of hybridoma cell supernatant effects on ERK phosphorylation and cell scatter are compiled 
together. Antibody binding region are shown for comparison.  
a) Levels of total ERK compared to levels of ERK phosphorylation, in the presence of HGF. Results were 
obtained from Table 3.5 where the levels of total ERK and phosphorylated ERK, in the presence of HGF, 
were compared to control cells treated in media containing 5% FCS. Hybridoma cell supernatant that 
have the same effects on ERK levels are highlighted in the same colour (i.e. colour coding was directly 
obtained from Table 3.5 whereby the hybridoma cell supernatants that were observed to give the same 
effects on total ERK and phosphorylated ERK levels were grouped according to colour.). For further 
details, refer to Table 3.5. (↑): increased levels compared to control; (↓): decreased levels compared to 
control; (S): levels remain the same as control.  
b) Results of hybridoma cell supernatant on cell scatter (reference to Figures 3.32A to G in section 3.3.3). 
(Inhibit): antibodies have an inhibitory effect on cell scattering; (Activate): antibodies have an activating 
effect on cell scattering; (-): no clear effect.  
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It was demonstrated that the recognition of monoclonal antibodies directed against 
surface protein causes cell clustering (Zhang. et al., 1998, Choo A.B. et al., 2008). To 
examine the ability of our monoclonal antibodies to recognise and bind native c-Met, 
and cause cell clumping, c-Met expressing cells, growing in suspension culture were 
required (Figure 3.6). SNU-5 suspension cells were thus incubated in hybridoma cell 
supernatant, diluted 1:20, 1:10, 1:5 and 1:1 dilution in RPMI cell media, for 4 – 24 hrs 
before examining for cell clusters (Figures 3.33). As an antibody control, cell 
supernatant from 4B2 hybridoma cells was used which produce an anti-Mdm2 
monoclonal antibody.  
3.3.4: Monoclonal antibodies effects on clustering of cells  
Results of cell cluster are summarised in Table 3.7. Cell clustering was only observed in 
hybridoma supernatants diluted at 1:1 (Figures 3.33). Mab 3.1, 5.1, 6.1, 16.1, 17.1 and 
19.1 had no response, suggesting that they do not bind native c-Met. Mab 2.1, 11.1, 
12.1, 13.1, and 8.1 were observed to induce a strong cell cluster response (more than 30 
cells in a cluster). Mab 1.1, 10.1, 14.1 and 17.1 induced intermediate responses (20 – 30 
cells in a cluster) and Mab 9.1, 18.1 and 20.1 induced weak response (10 – 20 cells in a 
cluster).  
There is little understanding of the clustering of cells induced by monoclonal antibody 
recognition of cell surface proteins. Cell cluster induced by anti-Porimin (Pro-oncosis 
receptor inducing membrane injury) monoclonal antibody results in lethal damage to 
cell membrane which eventually led to cell death (Zhang et al., 1998). Interestingly, the 
mAb 84 antibody directed against PDOXL (Podocalyxin-Like Protein-1), is able to bind 
to PDOXL on undifferentiated human embryonic stem cells and cause cell killing in a 
similar fashion as the anti-Porimin antibodies. This form of cell killing is independent 
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of complement and shares no characteristic with apoptosis (no DNA fragmentation or 
apoptotic bodies observed). Cell killing induced by anti-Porimin and anti-PDOXL 
monoclonal antibodies, however, share similar characteristic with oncosis – initially 
proposed by von Reckling-hausen in 1910 to describe cell death caused by swelling 
(Majno and Joris, 1995). Beers et al. (2008) reported the classification of type I and II 
therapeutic monoclonal antibodies against the CD20 antigen. Type II antibodies are able 
to cause cell clustering (also known as homotypic adhesion) and were found to be more 
efficient in the elimination of malignant B-cells by programme cell (PCD) (Alduaji et 
al., 2011, Beers et al., 2008). Alduaji et al. (2011) also reported that the induction of 
PCD is not mediated by effector functions of the anti-CD20 monoclonal antibody. It is 
intriguing that the clustering of cells, induced by antibody treatment, eventually led to 
cell death. Antibody-induced cell death is still debatable (whether oncosis is considered 
as PCD or it is two different cell death mechanisms) and more studies are required as 
apoptosis is clearly not the cause of cell death.  
The ability to cause cell cluster may only reflect the ability of our antibodies to 
recognise native c-Met and the size of the cell cluster might not provide much 
information of our antibodies. However, it would be interesting to test if our antibodies, 
like the above mentioned antibodies, are able to induce cell death. In our study, 
although the use of an anti-Mdm2 monoclonal antibody was used to demonstrate that 
the cell clustering was mediated through c-Met, knocking down c-Met expression via 
siRNA in SNU-5 cells would have provided stronger evidence.  
In this section, we attempted to characterise the functional activities of 21 monoclonal 
antibodies in the form of cell supernatants by ERK phosphorylation and cell scattering. 
It is observed that the presence of FCS in the cell media have an effect on the functional 
activities of the antibodies, resulting in contradictory results. Functional analysis of the 
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monoclonal antibodies could be more explicit if purified monoclonal antibodies were 
used. However, these tests were being carried out as a preliminary screen to identify 
potential therapeutic antibodies. Purification of all the monoclonal antibodies would be 
time-consuming and unnecessary. Since it was not possible to quantify the antibody 
concentration in these experiments, steps were therefore taken to test varying antibody 
concentration in each case, which can be viewed as no more than a preliminary 
screening process. In the next section, potential antibodies identified from this 
preliminary screen were selected for ascites production followed by antibody 
purification. Purified monoclonal antibodies were then subjected to further 
characterisation and analysis.   
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Figure 3.33A: Homotypic 
adhesion of SNU-5 cells. 
SNU-5 suspension cells were 
incubated with hybridoma cell 
supernatants (Mab 1.1 to 6.1). 
Cell supernatants were diluted 
1:1 in RPMI cell media. 
Untreated (UT) cells were 
incubated in media containing 
1:1 DMEM/RPMI. A 
hybridoma, clone 4B2, 
producing antibody to Mdm2 
was used as a control. Cells 
were incubated for 4-24 hrs 
before examining for cell 
clusters. Arrows indicate cell 
clusters.  
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Figure 3.33B: Homotypic 
adhesion of SNU-5 cells. 
SNU-5 suspension cells were 
incubated with hybridoma cell 
supernatants (Mab 7.1 to 
15.1). Cell supernatants were 
diluted 1:1 in RPMI cell 
media. Untreated (UT) cells 
were incubated in media 
containing 1:1 DMEM/RPMI. 
A hybridoma, clone 4B2, 
producing antibody to Mdm2 
was used as a control. Cells 
were incubated for 4-24 hrs 
before examining for cell 
clusters. Arrows indicate cell 
clusters.  
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Figure 3.33C: Homotypic 
adhesion of SNU-5 cells. 
SNU-5 suspension cells were 
incubated with hybridoma cell 
supernatants (Mab 16.1 to 
21.1). Cell supernatants were 
diluted 1:1 in RPMI cell 
media. Untreated (UT) cells 
were incubated in media 
containing 1:1 DMEM/RPMI. 
A hybridoma, clone 4B2, 
producing antibody to Mdm2 
was used as a control. Cells 
were incubated for 4-24 hrs 
before examining for cell 
clusters. Arrows indicate cell 
clusters.  
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Table 3.7: Summary of hybridoma cell supernatant results obtained from ERK phosphorylation, 
cell scattering and cell clustering assays. 
Binding 
regiona 
Monoclonal 
Antibody 
IgG 
subclassa 
Total 
ERK/phosphorylated 
ERKb 
HaCaT cell 
scatterc 
Cell 
clusteringd 
1 16.1 IgG2A ↓/↓ - - 
2 12.1 IgG1 ↓/↓ 
- +++ 
20.1 ↓/↓ - + 
3 11.1 IgG1 ↓/↓ 
Inhibit +++ 
21.1 ↓/↓ - ++ 
4 
14.1 
IgG1 
S/S Inhibit ++ 
18.1 ↓/↓ - + 
17.1 ↓/↓ Inhibit ++ 
19.1 IgG2B ↓/↓ - - 
5 3.1 IgG1 S/↓ 
- - 
5.1 ↓/↓ - - 
6 4.1 IgG2A ↓/↓ Inhibit - 
7 
1.1 
IgG1 
S/S - ++ 
2.1 S/S - +++ 
9.1 S/S - + 
8 
6.1 
IgG1 
↓/↓ Activate - 
10.1 ↓/↓ - ++ 
13.1 S/S - +++ 
17.1 ↓/↓ - ++ 
9 8.1 IgG1 S/↓ Inhibit +++ 
10 7.1 IgG1 S/↓ 
- - 
15.1 S/S - - 
Monoclonal hybridoma cell supernatants are being grouped according to their epitope binding region. 
Highlighted in blue are hybridoma clones selected for ascites production and antibody purification.  
a) Characterisation of antibody binding regions and isotypes were obtained from Table 3.4.  
b) Levels of total ERK levels were compared to levels of phosphorylated ERK in the presence of HGF 
(refer to Table 3.5 or 3.6 for further details). (↑): increased levels compared to no treatment control; (↓): 
decreased levels compared to no treatment control; (S): levels remain the same as no treatment control.  
c) Effects of monoclonal hybridoma cell supernatants on cell scatter (refer to Table 3.6 or Figures 3.32A 
to G). (Inhibit): antibodies in cell supernatant have an inhibitory effect on cell scattering; (Activate): 
antibodies in cell supernatant have an activating effect on cell scattering; (-): no clear effect.  
d) Results of cell clustering, in reference to Figures 3.33A to C, are scored accordingly. (-): no response; 
(+): weak response; (++): intermediate response; (+++): strong response.  
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3.4: Characterisation of purified monoclonal antibodies 
21 hybridoma clones were single cell cloned and the antibody they produce was 
characterised for their region of binding, recognition of c-Met on Western blotting, 
isotype and ability to block/activate c-Met in functional assays. Hybridoma clones 
expressing monoclonal antibodies in tissue culture produce approximately 0.05 mg/ml 
of antibodies when grown to confluence (Harlow and Lane, 1999). In order to 
characterise further the monoclonal antibodies describe here, a more efficient way of 
producing monoclonal antibodies was required. Hybridoma clones were therefore 
selected for ascites production which was performed by Moravian Biotechnology. 
3.4.1: Ascites production and purification of monoclonal antibodies 
From the 21 hybridoma cell clones tested, eleven were selected for ascites production. 
Selection was based on several criteria: 1) Results from functional assays: monoclonal 
antibodies that inhibited c-Met activation were selected. 2)  monoclonal antibodies that 
induced a strong cell cluster response were selected. 3) Analysis of antibody binding 
region (Section 3.2.7). Antibodies were grouped according to their binding region on c-
Met. One antibody was selected from each binding region (except region 5) to represent 
the binding region. Region 5 is not repeated, but this lies within region 6. The eleven 
clones selected for ascites production were: Mab 2.1, 4.1, 8.1, 11.1, 12.1, 13.1, 14.1, 
15.1, 16.1, 17.1 and 18.1. Ascites fluids, obtained from the peritoneal cavity of mice 
that were injected with hybridoma cells, were produced by Moravian Biotechnology. 
We purified monoclonal antibodies from ascites fluid using protein A beads. Depending 
on the isotype of the monoclonal antibody (characterised in Section 3.2.6), high salt or 
low salt purification was performed. Purified monoclonal antibodies were dialysed in 
phosphate-buffered saline (PBS) except for Mab 4.1 which precipitated in PBS. 2 μg of 
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purified antibody was resolved on a SDS-PAGE gel and stained with Coomassie blue 
dye (Figure 3.34). Commercially-bought mouse IgG was used as a control. 
An IgG antibody molecule is made up of two heavy and two light polypeptide chains 
held together by disulphide bonds. Two bands of approximately 51 kD and 25 kD were 
observed in each antibody sample (Figure 3.34). The bands correspond to an antibody’s 
heavy chain (51 kD) and light chain (25 kD). The variations in molecular weight of the 
light chains observed in different antibodies samples were due to the different amino 
acid composition that makes up the antigen binding site in each antibody. Interestingly, 
two bands corresponding to the light chain were observed in Mab 17.1, suggesting that 
the Mab 17.1 molecule contains two different epitope binding sites. This is consistent 
with Mab 17.1 being a polyreactive monoclonal antibody, and binds to regions 4 and 8 
of c-Met. Similarly, the variations in molecular weight of the heavy chains is due to 
differing amino acid composition of the antigen binding site and sequences specific to 
the antibody isotype. No other protein bands were observed in the Coomassie-stained 
gel, suggesting that the purification of the monoclonal antibodies was successful and the 
antibody samples have a high level of purity. 
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Figure 3.34: Purification of monoclonal antibodies from mouse ascites. 
Coomassie-stained SDS-PAGE gel of monoclonal antibodies purified from mouse ascites. Monoclonal 
antibodies obtained from mouse ascites were purified using protein A beads. 2 μg of antibody was 
resolved on a SDS-PAGE gel and stained with Coomassie blue dye. Commercially-obtained mouse IgG 
(2 μg) was used as a control. Antibody heavy and light chain are indicated. Molecular weights are noted 
aside, in kilodaltons. 
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To ensure that the monoclonal antibodies retained their anti-α-chain activity after ascites 
production and purification, purified monoclonal antibodies were characterised again by 
Western blotting (Figure 3.35). 1 μg/ml of purified monoclonal antibodies was used to 
detect purified c-Met α-chain, transfected and endogenous c-Met from whole cell 
lysates of NIH3T3 transfected cells and U-87MG cells respectively. All monoclonal 
antibodies, except Mab 13.1 and 15.1, successfully detected purified c-Met α-chain, 
transfected and endogenous human c-Met. Mab 13.1 and 15.1 had low specificity 
towards c-Met. Mab 13.1 only detected purified α-chain weakly and showed little or no 
reaction with endogenous or transfected c-Met samples. Mab 15.1 was able to detect 
purified α-chain but detected full length c-Met precursor weakly. Mab 2.1 and 14.1 
were observed to have higher affinity towards c-Met, compared to Mab 13.1 and 15.1, 
however they also recognise other non-specific protein bands. Mab 4.1, 8.1, 16.1, 17.1 
and 18.1 have affinity towards c-Met and fewer non-specific bands. Despite having 
different epitopes, most of the anti-α-chain monoclonal antibodies share the same 
patterns of band recognition with Mab 11.1 and 12.1. This suggests that the band 
profiles of Mab 11.1 and 12.1 are completely specific. Mab 11.1 and 12.1 are thus the 
best monoclonal antibodies to use on Western blots as they detected c-Met with good 
affinity and specificity. NIH3T3 cells transfected samples were observed to have more 
protein bands. This could be due to degradation of c-Met since the cell was expressing 
high levels of transfected protein. For some antibodies, non-specific binding was 
observed even though purified monoclonal antibodies were used. Lastly, protein bands 
observed at approximately 50 kD could possibility be the α-chain of c-Met. 
3.4.2: Purified monoclonal antibodies on Western blotting 
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Figure 3.35: Purified 
monoclonal antibodies on 
Western blotting. 
11 hybridoma clones were 
selected for ascites 
production. Monoclonal 
antibodies were purified 
from ascites and tested 
again for reactivity against 
full length c-Met in whole 
cell lysates. 50 μg of whole 
cell lysate was obtained 
from untransfected NIH3T3 
cells (UT), NIH3T3 cells 
transfected with full length 
human c-Met (Met), U-87 
MG cell lines and T47D cell 
lines. Monoclonal 
antibodies are used at 
concentration of 1 μg/ml. 10 
ng of purified α-chain was 
used as positive control. 
AF276 antibody was used as 
control. Blue arrows 
indicate c-Met precursor 
(170 kD). Red arrows 
indicate purified α-chain. 
Mab: Monoclonal antibody. 
Molecular weights are noted 
aside, in kilodaltons.     
188 
 
Purified monoclonal antibodies were tested if they could be utilised as biological tools 
for the investigation of endogenous c-Met by immunofluorescence. SNU-5 cells were 
selected in this assay because it is a c-Met expressing cell line and gave the clearest 
staining, compared to HaCaT and U-87MG cells, when tested with AF276 antibody 
(data not shown). T47D, a low c-Met expressing cell line, was used in this assay as a 
control. Cells were fixed in methanol/acetone before incubation with 1 μg/ml of 
monoclonal antibody. FITC-conjugated anti-mouse secondary antibody was used to 
detect the bound monoclonal antibody. DAPI was used as a counterstain. Table 3.8 is a 
summary of the results obtained from immunofluorescence assay.  
3.4.3: Characterisation of purified monoclonal antibodies by immunofluorescence 
c-Met is a tyrosine receptor kinase expressed on the cell membrane. 
Immunofluorescence staining of endogenous c-Met would therefore localise to the 
plasma membrane of cells. We attempted to use phalloidin conjugated-rhodamine as a 
control for cell membrane staining. However, phalloidin, which stains F-actin, only 
worked on paraformaldehyde-fixed cells. Under methanol/acetone fixation conditions, 
phalloidin staining only worked in areas where cell densities were extremely high (data 
not shown). In these areas, staining of c-Met on the plasma membrane becomes unclear 
as the cells were overlapping. We therefore could not use phalloidin as a control to 
counterstain the plasma membrane. The lack of a plasma membrane control to use in 
both suspension (SNU-5 cells) and adherent (T47D cells) cell lines needs to be 
addressed in future.  
Although the commercial antibody AF276 stained the cytoplasm, predominant staining 
was observed on the cell membrane (Figure 3.36). Mab 2.1, 8.1, 11.1 and 12.1 were 
observed to produce identical staining to AF276 antibody, thus it is assumed that these 
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antibodies are staining for c-Met localised on the cell membrane (Figures 3.36A and B). 
Weak staining localised to the plasma membrane was observed by Mab 13.1, 14.1, 16.1, 
17.1 and 18.1 which suggests that these antibodies are not strong enough to detect c-
Met by immunofluorescence (Figures 3.36B to D). Mab 15.1 detectably recognised 
transfected and endogenous c-Met by Western blotting (Figure 3.35) but failed to stain 
for endogenous c-Met by immunofluorescence (Figure 3.36C). Mab 4.1 worked well in 
Western blotting, but showed diffused cytoplasmic staining, suggesting that Mab 4.1 
can be used as a biological tool for Western blotting but not in immunofluorescence 
assays (Figure 3.36A). Weak cytoplasmic staining was also observed in the SNU-5 cell 
treated controls (AF276 antibody and secondary-only antibody). The diffused 
cytoplasmic staining observed in our monoclonal antibody-treated samples in SNU-5 
cells could be due to the antibody detecting precursor c-Met in the cytoplasm, as 
suggested by the AF276 antibody. Cytoplasmic staining could also be due to the non-
specific effects of the secondary antibody. Background staining was observed in T47D 
cells stained with Mab 2.1, 12.1 and 17.1 which could be attributed to the antibodies 
recognising non-specific proteins in the cytoplasm. Antibody concentration was only 
tested at 1 μg/ml as this was only a preliminary test aimed to investigate if the anti-α-
chain monoclonal antibodies function in immunofluorescence assays. As each antibody 
has an optimum working condition, an optimisation of antibody concentration is 
required for each monoclonal antibody. Exposure time varied in each sample. Stained 
cells were exposed until a signal was observed. 
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Table 3.8: Summary of immunofluorescence results using purified monoclonal antibodies. 
Monoclonal 
antibody 
Immunofluorescence staining of SNU-5 
cells 
Immunofluorescence 
staining of T47D cells 
(background 
staining) 
Membrane 
staining 
Cytoplasmic 
staining 
2.1 +++  ++ ++ 
4.1 -  + - 
8.1 +++ ++ - 
11.1 +++  + - 
12.1 +++ + + 
13.1 + + - 
14.1 ++ + - 
15.1 - - - 
16.1 ++ ++ - 
17.1 + ++ + 
18.1 ++ ++ - 
Secondary alone - + - 
 (-): no staining; (+): slight staining; (++): intermediate staining; (+++): intense staining. 
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Figure 3.36A: Immunofluorescence of endogenous c-Met in SNU-5 and T47D cells. 
Detection of endogenous c-Met in SNU-5 and T47D cells by immunofluorescence using purified anti-α-chain monoclonal antibodies. 1 μg/ml of monoclonal antibody was 
used. Bound monoclonal antibodies were detected by anti-mouse FITC-conjugated secondary antibody. AF276 antibody and secondary-only were used as controls. Cells 
were counterstained with DAPI.  
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Figure 3.36B: Immunofluorescence of endogenous c-Met in SNU-5 and T47D cells. 
Detection of endogenous c-Met in SNU-5 and T47D cells by immunofluorescence using purified anti-α-chain monoclonal antibodies. 1 μg/ml of monoclonal antibody was 
used. Bound monoclonal antibodies were detected by anti-mouse FITC-conjugated secondary antibody. AF276 antibody and secondary-only were used as controls. Cells 
were counterstained with DAPI.  
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Figure 3.36C: Immunofluorescence of endogenous c-Met in SNU-5 and T47D cells. 
Detection of endogenous c-Met in SNU-5 and T47D cells by immunofluorescence using purified anti-α-chain monoclonal antibodies. 1 μg/ml of monoclonal antibody was 
used. Bound monoclonal antibodies were detected by anti-mouse FITC-conjugated secondary antibody. AF276 antibody and secondary-only were used as controls. Cells 
were counterstained with DAPI. 
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Figure 3.36D: Immunofluorescence of endogenous c-Met in SNU-5 and T47D cells. 
Detection of endogenous c-Met in SNU-5 and T47D cells by immunofluorescence using purified anti-α-chain monoclonal antibodies. 1 μg/ml of monoclonal antibody was 
used. Bound monoclonal antibodies were detected by anti-mouse FITC-conjugated secondary antibody. AF276 antibody and secondary-only were used as controls. Cells 
were counterstained with DAPI.  
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3.4.4: Purified monoclonal antibody effects on ERK phosphorylation 
In Section 3.3.2, ERK phosphorylation was used as an indicator to examine the effects 
of monoclonal hybridoma supernatant on HGF-induced c-Met activation. Due to the 
presence of FCS in cell supernatant, antibody concentration determination was not 
possible and it was difficult to differentiate between the effects of the antibodies and 
those of FCS. To avoid this issue, the effects of purified monoclonal antibody on c-Met 
activation were tested on HaCaT cells in serum-free media. HaCaT cells were serum-
starved for 24 hrs before treatment with 1 μg/ml of monoclonal antibodies in serum-free 
media. The cells were incubated 1 hr with monoclonal antibodies before HGF was 
added to the cells. Cells were harvested in sample loading buffer and cell lysates were 
analysed by Western blotting (Figure 3.37). Commercially-obtained IgG, anti-HGF 
antibody and a small molecule inhibitor of c-Met (SU11274) were controls. Similarly to 
the ERK analysis in Section 3.3.2, phosphorylation of ERK was used as an indicator of 
c-Met activation status. 
As previously, phosphorylation of ERK would indicate activation of c-Met by HGF or 
by the monoclonal antibodies. Untreated cells after serum starvation were observed to 
have undetectable phosphorylation of ERK even though total ERK levels were 
detectable. Increased ERK phosphorylation, particularly in ERK2 (lower band), was 
observed in serum-starved cells treated with 10 ng/ml of HGF alone, indicating the 
activation of c-Met. Total ERK levels were also observed to increase in these cells, 
suggesting that c-Met activation by HGF increases or stabilises ERK protein levels. The 
mechanism in which how c-Met activation affects ERK protein levels is unknown. To 
ensure that the antibodies do not have non-specific effects on ERK phosphorylation, 
cells were treated with mouse IgG. In the absence of HGF, these mouse IgG-treated 
cells were observed to have no ERK phosphorylation and total ERK levels were similar 
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to untreated cells. In the presence of HGF, these cells showed significant increase in 
ERK phosphorylation and protein levels. The c-Met small molecule inhibitor, SU11274, 
and the commercially-obtained anti-HGF antibody were used as controls to inhibit c-
Met activation by HGF. While SU11274 prevents c-Met downstream signalling by 
binding to the catalytic domain of c-Met (Bellon et al., 2008), anti-HGF antibody 
sequesters HGF present in the cell media and prevents HGF from binding to c-Met. As 
shown in Figure 3.37, SU11274 completely inhibited ERK phosphorylation while a 
slight phosphorylation of ERK2 was still observed in cells treated with the combination 
of anti-HGF antibody and HGF. SU11274 is a better c-Met inhibitor compared to anti-
HGF antibody. Interestingly, regardless of the presence of HGF, total ERK levels in 
anti-HGF treated samples were identical to untreated cells while a decrease was 
observed in SU11274-treated samples. The SU11274 inhibitor showed constant levels 
of total ERK protein in both HGF induced and un-induced samples. 
Purified monoclonal antibody treatment of HaCaT cells were compared to the mouse 
IgG control and results were tabulated in Table 3.9. As in the previous ERK assay 
(Section 3.3.2), our monoclonal antibodies fell into groups according to the levels of 
total ERK and phosphorylated ERK compared to mouse IgG. After induction with 
HGF, treatment with Mab 13.1, 14.1, 15.1 and 16.1 (Table 3.9, highlighted in green) 
resulted in a decrease in ERK phosphorylation while total ERK levels remained 
constant. This suggests that these antibodies are inhibiting ERK phosphorylation 
without affecting the total levels of ERK, thus are antagonist towards HGF-induced 
ERK phosphorylation. Mab 2.1 and 4.1 were observed to show an increase in ERK 
levels and ERK phosphorylation levels, in the absence of HGF. This suggests that Mab 
2.1 and 4.1 could be inducing c-Met activation by dimerising c-Met molecules on the 
cell surface. Mab 12.1 and 17.1 did not affect the status of ERK and phosphorylated 
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ERK in the absence of HGF but they were able to decrease ERK and phosphorylated 
ERK levels in the presence of HGF. Mab 12.1 and 17.1 may affect ERK 
phosphorylation levels by decreasing ERK levels via an unknown pathway. Treatment 
with Mab 18.1 without HGF induction had no effect on ERK and phosphorylated ERK 
levels indicating that Mab 18.1 is not an activator of c-Met. No change was observed in 
the levels of ERK and phosphorylated ERK in samples treated with Mab 18.1 and HGF. 
Mab 18.1 might be blocking c-Met activation by HGF thus resulting in the constant 
levels of ERK protein and ERK phosphorylation levels. Finally, Mab 8.1 and 11.1 do 
not fall into any group and the results were unexpected. In the presence of HGF, total 
ERK levels and phosphorylation levels remained constant in Mab 8.1 treated cells. Mab 
8.1 caused an unexplainable decrease in total ERK levels but an increase in 
phosphorylation levels in the absence of HGF. Similarly, Mab 11.1 caused an increase 
in ERK phosphorylation in the absence of HGF while total ERK and ERK 
phosphorylation levels remain constant in other treatment.   
Table 3.9: Effects of purified monoclonal antibody on total ERK and phosphorylated ERK levels.  
Mab 
Total ERK Phosphorylated ERK 
No HGF HGF No HGF HGF 
2.1 ↑ S ↑ ↑ 
4.1 ↑ S ↑ ↑ 
8.1 ↓ S ↑ S 
11.1 S S ↑ S 
12.1 S ↓ S ↓ 
13.1 S S S ↓ 
14.1 S S S ↓ 
15.1 S S S ↓ 
16.1 S S S ↓ 
17.1 S ↓ S ↓ 
18.1 S S S S 
HaCaT cells were treated with 1 μg/ml of purified monoclonal antibody, in the presence or absence of 
HGF. Levels of ERK and phosphorylated ERK from these cells were compared to control cells treated 
with mouse IgG and tabulated. Antibodies that share the same results are highlighted. (↑): increased levels  
compared to control; (↓): decreased levels compared to control; (S): levels remain the same as control. 
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The effects of our purified anti-α-chain monoclonal antibodies were also tested at 
concentrations of 0.1 μg/ml, 0.5 μg/ml, 5 μg/ml, 10 μg/ml and 50 μg/ml (results not 
shown). Due to time constraints, these results were not reproduced and thus not 
discussed here. However, an in depth analysis of the antibodies effects on ERK 
activation has to be pursued in future. As ERK is involved in many signalling pathways, 
a slight change in growth condition might affect the outcome of this assay. Therefore, it 
would be ideal to determine c-Met activation by directly observing c-Met 
phosphorylation status. To do this, an antibody with better affinity toward 
phosphorylated c-Met than the commercial antibody is required. Moravian 
Biotechnology is presently developing this antibody.         
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Figure 3.37: Western blot analysis of HaCaT cells treated with purified monoclonal antibodies. 
HaCaT cells were serum-starved for 24 hrs. 1 μg/ml of purified monoclonal antibodies were added to cells and incubated for 1 hr before 10 ng/ml of HGF were added to the 
cells. Cells were incubated in the presence of HGF for 30 mins before the cells were directly lysed in sample buffer. 5 μg of cell lysate were analysed in each sample. 
Detection of phosphorylated ERK (pERK) was used to determine the effects of monoclonal antibodies on c-Met activation. The molecular weights of ERK1 (top band) and 
ERK2 (bottom band) are 44 kD and 42 kD respectively. Total ERK and PCNA were used as controls. Anti-HGF antibody (anti-HGF), commercial mouse immunoglobulin G 
(IgG) and the small molecule c-Met inhibitor SU11274 were used as controls at a final concentration of 5 μg/ml, 1 μg/ml and 5 μM. UT: Untreated.    
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3.4.5: Effects of purified monoclonal antibodies on cell scatter 
Monoclonal antibodies produced in tissue culture were tested for their ability to 
block/induce cell scatter in Section 3.3.3. As discussed above, the presence of FCS and 
undetermined antibody concentration made these results difficult to interpret. Here, we 
examine the effects of purified monoclonal antibodies on cell scatter. HaCaT cells were 
seeded at low density and allowed to grow until colonies formed. Cells were serum-
starved for 24 hrs before incubating with 1 μg/ml monoclonal antibodies. HGF was 
added, at a final concentration of 10 ng/ml, to the cells and cells were incubated for a 
further 24 hrs before fixing and crystal violet staining. 
Cell scattering is one of the biological hallmarks of c-Met activation. Inhibition of 
HGF-induced c-Met activation by our purified monoclonal antibodies would result in 
the inhibition of cell scatter. Agonist monoclonal antibodies would activate c-Met and 
cause cells to become motile and disperse. As expected, cell scatter of HaCaT cells was 
induced by HGF (Figure 3.38). Presence of non-specific IgG (mouse IgG) did not affect 
scattering. Anti-HGF antibody and SU11274 were used as controls to inhibit HGF-
induced cell scatter. Similarly to the results from the analysis of ERK phosphorylation, 
SU11274 was a better antagonist as compared to anti-HGF antibody. In the presence of 
HGF, SU11274-treated cell colonies remained circular while a slight scattering was 
observed in anti-HGF antibody-treated cell colonies. The differences observed between 
anti-HGF antibody and SU11274 may be due to their mechanism of action. SU11274 is 
c-Met kinase inhibitor that binds tightly and specifically to c-Met catalytic domain. It 
was identified as a competitive inhibitor of ATP. SU11274 competes with ATP for the 
c-Met catalytic domain, prevents c-Met from phosphorylating cytoplasmic proteins, 
thus blocking the downstream signalling cascade. Anti-HGF antibody, on the other 
hand, competes with c-Met from binding to HGF and prevents c-Met activation. The 
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binding of an antibody to its antigen is a dynamic process whereby the antibody, antigen 
and antibody-antigen complex is in equilibrium i.e. constantly associating and 
dissociating together. It is thus possible that when HGF is released from this interaction, 
it is free to bind and activate c-Met. This result in the slight scattering observed in cells 
treated with anti-HGF antibody and HGF combination.  
Cell colonies treated with Mab 2.1 and 16.1 seems to scatter in the absence of HGF. 
However, increased magnification on these cell colonies indicate that the cells remain in 
tight clusters and this effect is due to variation in staining intensity. No cell scatter was 
thus observed in cells treated with monoclonal antibodies alone (Figure 3.39). This 
suggests that the monoclonal antibodies are not agonist towards c-Met activated cell 
scatter.  
All monoclonal antibodies failed to completely inhibit HGF-induced cell scattering. To 
our surprise, Mab 12.1 which was observed to inhibit ERK phosphorylation in HGF-
induced cells (Figure 3.37), failed to inhibit cell scattering. Binding of Mab 12.1 to c-
Met might force c-Met into a structural conformation that resulted in inhibition of ERK 
phosphorylation only. For Mab 4.1, 8.1, 14.1, 15.1 and 17.1, it is clear that these 
antibodies do not inhibit HGF-induced cell scatter. Cell colonies treated with Mab 2.1, 
11.1, 13.1, 16.1 and 18.1 were observed to scatter less as compared to the HGF-induced 
control. This suggests that these antibodies may be partially inhibiting c-Met and it 
would interestingly to test if a combination of these antibodies would be able to 
completely inhibit cell scatter. Cao et al. (2001) described the production of monoclonal 
antibodies against HGF and tested their ability to block HGF from binding to c-Met. 
None of the antibodies alone were capable of blocking c-Met activity. However, c-Met 
activity was blocked by combining three different monoclonal antibodies against HGF. 
van der Horst et al. (2009) reported that the ability of a combination of two anti-Met 
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Fab molecules to disrupt HGF-cMet binding was more potent than treatment with a 
single Fab on its own. 
It should be noted that cell scatter was performed in media containing 1% FCS. It is 
ideal that no FCS should be used as FCS might contain motility stimulating or 
inhibitory factors. However in this assay, HGF-induced scattering failed in the absence 
of FCS (data not shown). Failure to induce cell motility in the absence of HGF was not 
seen during the initial optimisation process of cell scattering. Variations in batches of 
HGF might be the cause of this problem and further work is required to verify this issue. 
Cell scattering was also tested on antibody concentrations of 0.5 μg/ml, 5 μg/ml and 10 
μg/ml. The results for cell scatter at these concentrations were extremely unclear due to 
the varied effects of HGF. Cell scattering tested at these antibody concentrations needs 
to be repeated. 
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Figure 3.38: Analysis of effects of antibodies and a c-Met inhibitor on cell scatter in HaCaT cells. 
HaCaT cells were serum-starved for 24 hrs before treatment. Monoclonal antibodies (1 μg/ml), HGF (10 
ng/ml), anti-HGF antibody (5 μg/ml) and SU11274 (5 μM) were added to the cells and incubated for 24 
hrs before fixation. Cells were then stained with crystal violet for visualisation. Anti-HGF antibody (anti-
HGF), commercially-obtained mouse immunoglobulin G (IgG), and c-Met small molecule inhibitor 
SU11274 were used as controls. UT: Untreated. 
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Figure 3.39: Effects of purified monoclonal antibodies on cell scatter. 
HaCaT cells were serum-starved for 24 hrs before treatment. Monoclonal antibodies (1 μg/ml) and HGF 
(10 ng/ml) were added to the cells and incubated for 24 hrs before fixation. Cells were then stained with 
crystal violet for visualisation. Commercially-obtained mouse immunoglobulin G (IgG) was used as a 
control. UT: Untreated. 
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3.4.6: Purified monoclonal antibodies in flow cytometry 
Failure to inhibit ERK phosphorylation and cell scattering could be due to the inability 
of monoclonal antibodies to recognise c-Met in its native conformation. We therefore 
decided to use flow cytometry to determine whether the antibodies described here could 
bind to c-Met in its native form using live cells. The cells chosen for this analysis were 
SNU-5 cells because they express high levels of c-Met (Section 3.1.4) and grow in 
suspension, making them ideal for flow cytometry analysis. Binding of anti-α-chain 
antibodies to native c-Met expressed on the cell surface of SNU-5 cells was detected 
using anti-mouse secondary antibody conjugated with Alexa Fluor® 488 dye. T47D, 
which expresses very low levels of c-Met, was used as a control to determine if the 
antibodies bind non-specifically to the cell surface. 
The flow cytometry results of purified monoclonal antibody treated-T47D cells were 
indistinguishable from the negative control (secondary antibody only), indicating that 
monoclonal antibodies do not bind non-specifically to the cell surface (Figure 3.40). 
Flow cytometry results obtained with SNU-5 cells showed that the antibodies fell into 
three distinct groups with different fluorescence intensity towards native c-Met: strong 
fluorescence intensity, intermediate fluorescence intensity and weak fluorescence 
intensity (Figure 3.41). Mab 2.1 and 13.1 showed the strongest fluorescence intensity in 
this assay. Surprisingly, they both showed poor binding for c-Met by Western blotting 
(Figure 3.35). Mapping of the Mab 13.1 binding region (Section 3.2.7) suggests that 
Mab 13.1 may recognise small denatured regions in a peptide screen in vitro, but its 
epitope could be influenced by secondary structures making it able to recognise native 
c-Met. Mab 8.1, 11.1, 12.1 and 17.1 showed intermediate fluorescence intensity while 
Mab 4.1, 14.1, 15.1, 16.1 and 18.1 showed weak fluorescence intensity (as 
demonstrated by the small peak shift in Figure 3.41). Weak fluorescence intensity to 
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native c-Met might explain why some of the antibodies were unsuccessful in inhibiting 
HGF-induced ERK phosphorylation and/or cell scattering. However, analysis of the 
characterisation of the purified monoclonal antibodies listed in Table 3.10 indicates that 
there is no obvious correlation between the results obtained from the ERK 
phosphorylation assay, cell scatter assay and flow cytometry assay. Despite the use of 
T47D as a negative cell line to demonstrate the monoclonal non-specificity, it would be 
more appropriate to use the same cell line in both the negative and positive controls. It 
is thus possible to knock down the expression of c-Met in SNU-5 cells using siRNA to 
determine the non-specificities of the antibodies. Alternatively, we can use transiently 
express c-Met in T47D cells using other expression system (i.e. Lentiviral expression). 
Finally, the difference in antibody subclasses will affect the binding of the anti-mouse 
secondary antibody, thus affecting the fluorescence intensity in this assay. Other 
methods such as labelling of the antibodies with FITC (or other fluorescence molecules) 
will circumvent this issue. These are only preliminary findings and optimisation of 
antibody concentration is required to fully understand an antibody’s functional activity.  
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Figure 3.40: Flow cytometry analysis of T47D cells treated with monoclonal antibodies. 
Purified monoclonal antibodies (1 μg/ml) were incubated with live T47D cells. Bound antibodies were 
detected using FITC-conjugated secondary antibodies before the cells were passed through a flow 
cytometer. A shift in FITC intensity would indicate monoclonal antibodies binding to T47D cells. Data 
analysis was assisted by Daniel Klotz. 
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Figure 3.41: Flow cytometry analysis of SNU-5 cells treated with monoclonal antibodies. 
Purified monoclonal antibodies (1 μg/ml) were incubated with live SNU-5 cells. Bound antibodies were 
detected using FITC-conjugated secondary antibodies before the cells were passed through a flow 
cytometer. A shift in FITC intensity indicates monoclonal antibodies binding to SNU-5 cells. Data 
analysis was assisted by Daniel Klotz. 
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Table 3.10: Summary of monoclonal antibody characterisation. 
Monoclonal 
antibody 
Western blottinga Total 
ERK/Phosphorylated 
ERKb 
Inhibition of 
cell scatterc 
Flow 
cytometryd 
Immunofluorescence 
staininge Cell cluster
f 
Affinity Specificity 
2.1 ++ + S/↑ Partial Strong +++  +++ 
4.1 +++ ++ S/↑ ND Weak -  -  
8.1 +++ ++ S/S ND Intermediate +++ +++ 
11.1 ++ +++ S/S Partial Intermediate +++  +++ 
12.1 +++ +++ ↓/↓ ND Intermediate +++ +++ 
13.1 -/+ + S/↓ Partial Strong + +++ 
14.1 ++ + S/↓ ND Weak ++ ++ 
15.1 + + S/↓ ND Weak - -  
16.1 ++ ++ S/↓ Partial Weak ++ -  
17.1 +++ ++ ↓/↓ ND Intermediate + ++ 
18.1 +++ ++ S/S Partial Weak ++ + 
*Table legends are noted on next page. 
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Table 3.10 summarises the results obtained using purified monoclonal antibodies in Western blotting, effect on ERK phosphorylation, ability to 
inhibit cell scatter, flow cytometry, immunofluorescence staining. Results of cell cluster using monoclonal antibody from cell supernatants have 
been included.   
 
a) Affinity and specificity of monoclonal antibodies against c-Met in Western blots. Results were based on Figure 3.35. Highlighted in red are 
antibodies that work well in Western blotting. (-): no binding; (+): Low affinity/specificity; (++): intermediate affinity/specificity; (+++): strong 
affinity/specificity. 
 
b) Effects of antibody treatment on ERK protein and phosphorylation levels following treatment with HGF. Results were obtained from Table 
3.9, where the levels of total ERK and phosphorylated ERK, in the presence of HGF, were compared to mouse Ig-treated control cells. For 
further details, refer to Table 3.9 and Figure 3.37. (↑): increased levels compared to control; (↓): decreased levels compared to control; (S): levels 
remain the same as control. 
 
c) Ability of monoclonal antibody to block HGF-induced c-Met cell scatter (Figure 3.39). (Partial): monoclonal antibody caused partial blockage 
of cell scatter; (ND): not determined as the effects of cell scatter was not clear. 
 
d) Ability of monoclonal antibodies to bind to native c-Met was tested by flow cytometry. Refer to Figure 3.41. ‘Strong’, ‘intermediate’ and 
‘weak’ was used to categorise the antibodies binding ability to native c-Met on cell surface. 
  
e) Ability of monoclonal antibodies to stain the cell membrane of SNU-5 cells in immunofluorescence (IF). (-): no membrane staining; (+): weak 
membrane staining; (++): intermediate membrane staining; (+++): strong membrane staining. 
 
f) Ability of monoclonal antibodies (from hybridoma cell supernatant) to cause cell cluster. Refer to Figures 3.33A to C. (-): no response; (+): 
weak response; (++): intermediate response; (+++): strong response.  
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CHAPTER 4: DISCUSSION AND FUTURE WORK 
c-Met is a tyrosine kinase receptor involved in a wide spectrum of cellular activities 
such as cell proliferation, tubulogenesis, cell motility, angiogenesis and morphogenesis. 
The only known ligand for c-Met is the soluble cytokine, HGF. While c-Met is 
expressed in epithelial cells, HGF is differentially expressed in cells of mesenchymal 
origin. Together, signalling between c-Met and HGF form a cell-to-cell communication 
between epithelial cells and their neighbouring stromal cells. Activation of c-Met by 
HGF results in the activation of several signal transduction pathways, eventually 
leading to the various biological activities. The role of the c-Met/HGF axis in cancer 
development has been well documented: 1) expression of c-Met/HGF correlates with 
tumour grade, aggression and disease prognosis (Birchmeier et al., 2003), 2) mutation 
in the kinase domain of c-Met was found in patients with sporadic and hereditary 
papillary renal tumours (Jeffers et al., 1997), 3) gastric cell lines harbouring c-Met gene 
amplification demonstrated sensitivity to the c-Met small molecule inhibitor PHA-
665752 (Smolen et al., 2006), and 4) in xenograft models, tumours with abnormal c-
Met active expression show inhibition of tumour growth and invasion upon treatment 
with anti-Met molecules such as the OA-5D5 antibody (Martens et al., 2006), the c-Met 
small molecule inhibitor SU11274 (Sattler et al., 2003) and  the c-Met competitor 
decoy-Met (Michieli et al., 2004).   
c-Met is essential for embryonic and placental development. In adult tissues, c-Met is 
only required for wound healing and liver regeneration (Knudsen and Vande Woude, 
2008). The dispensable nature of c-Met in adult tissues and the involvement of c-
Met/HGF in tumourigenesis and tumour cell-acquired resistance towards EGFR drugs 
makes c-Met/HGF an attractive target for drug therapy. Many groups have used various 
mechanisms to inhibit c-Met activation. Small molecule kinase inhibitors such as the 
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PHA-665752, AM7 and SU11274 were extremely successful in inhibiting c-Met 
activation (Bellon et al., 2008; Sattler et al., 2003). However, toxicity issues due to off-
target effects of the small molecule inhibitors are of major concern. In addition, 
SU11274 was reported to be ineffective against specific c-Met mutations (Berthou et 
al., 2004). Abounader et al. (2001) reported the use of U1snRNA/ribozyme to 
downregulate the expression levels of c-Met/HGF. Although this method is novel and 
intriguing, at present it is not feasible to use this method for cancer treatment due to 
drug delivery issues. U1snRNA/ribozyme has to be efficiently delivered into every 
tumour cell to be expressed in order to be effective. The process of delivery will be a 
challenging problem. The use of HGF and c-Met fragments, such as NK4 and decoy-
Met respectively, to compete for Met-HGF interactions has been examined. These 
competitive inhibitors show efficient inhibition of c-Met activation in vivo xenograft 
models, however, their clinical utility has yet to be determined (Brockmann et al., 2003; 
Michieli et al., 2004). Successful anti-cancer drugs in the field are largely represented 
by small molecule inhibitors and therapeutic antibodies (Ma and Adjei, 2009).   
The success of using therapeutic monoclonal antibodies for cancer treatment is evident. 
Herceptin (Trastuzamab), a humanised IgG1 antibody targeted against the human 
epidermal growth factor receptor (Her2), is widely used for the treatment of breast 
cancer. Rituxan (Rituximab) targeting CD20 and Avastin (Bevaciumab) targeting 
vascular endothelial growth factor receptor (VEGFR), both chimeric IgG1 antibodies, 
have been successful in treatment of lymphomas and of colorectal and lung cancer 
respectively (Adams and Weiner, 2005). Therapeutic antibodies success in disease 
treatment can be attributed to their high affinity and specificity towards their target 
antigen. Antibody stability in vivo and their ability to recruit the host immune system to 
destroy tumour cells make this form of therapy clinically advantageous over other types 
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of c-Met/HGF inhibitors (De Souza et al., 2009). In addition, advances in antibody 
engineering can improve the pharmacokinetiecs of a therapeutic antibody molecule.   
The aims of this project is to develop monoclonal antibodies against c-Met and to use 
the antibodies as therapeutic molecules in cancer treatment/diagnostics. The first phase 
of this project was to develop and build bio-tools required for the screening and 
development of anti-Met antibodies. The commercial antibodies used in the thesis fall 
into two classes, those raised against synthetic peptides and those raised against 
recombinant protein fragments (AF276 was raised against the extracellular domain of c-
Met which recognises endogenous c-Met precursor and c-Met β-chain while SC-10 was 
raised against a synthetic peptide in the C-terminal tail of c-Met). AF276 was shown to 
be the most reliable antibody to use as an antibody control as compared to other 
commercial anti-Met antibodies (SC-10 and EP1454Y) tested. We have shown that 
AF276 antibody detected purified α-chain weakly, but not endogenous α-chain. Both 
AF276 and SC-10 are polyclonal antibodies. While the epitope recognised by the SC-10 
antibody is essentially defined by the immunogen (anti-peptide antibody) this is not the 
case for the AF276 antibody. It would have been possible to map the epitopes 
recognised by these antibodies using the pepscan library but this would not have 
provided information of much value. The antibodies will recognise both complex, 
conformational, and linear epitopes and the mapping data would therefore be 
incomplete. The results might have indentified dominant epitopes but this would not 
have affected our analysis. We used a new immunogen different from those used by the 
commercial suppliers and we used a complete scan of the protein fragment we 
immunised with successfully mapping all of the epitopes recognised by our large set of 
antibodies. How knowing what epitopes a commercial antibody recognises would help 
in this analysis is not clear. The key issue that comparison with the commercial 
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antibodies has revealed is the superior performance of our new reagents in both 
immunoblotting and immunoprecipitation analysis. 
In order to characterise the monoclonal antibodies, expressing and non-expressing c-
Met cell lines were required. The expression and phosphorylation status of endogenous 
c-Met was thus examined in a range of cell lines and SNU-5, U-87MG, HaCaT and 
T47D cells were chosen for further study. We have also exploited the adenoviral system 
and used various high-expression mammalian vectors in attempt to increase human c-
Met transient expression in cell lines. By using the same c-Met expression vectors, it is 
also possible to in-vitro translating c-Met as a positive control for antibody 
characterisation. We developed the use of the novel SBP tag to purify c-Met from cell 
lines to a high purity, which could be used for future c-Met high-throughput processes. 
To develop antibodies against c-Met, the α-chain of c-Met was expressed in bacteria, 
purified and used as an immunogen for mouse immunisation. The α-chain of c-Met was 
expressed as inclusion bodies in bacteria and re-folding in 6M urea was required. 
Prokaryotic expression system allows for low cost, simple and high yield protein 
expression but lacks in eukaryotic post-translational medication and proper protein 
folding of eukaryotic proteins (e.g. proper formation of disulphide bonds). Other types 
of expression systems such as mammalian cells or insect cells could be utilise to 
produce soluble c-Met in the correct conformation for antibody immunisation. The 
mammalian cells and insect cell expression system have proper eukaryotic post-
translational modification and are able to express protein in the right conformation but 
compromising on the yield of the expressed protein.     
The second phase of this project was the production and screening of mouse 
monoclonal antibodies against the α-chain of c-Met. In total, 39 hybridoma cell lines 
were identified which stably express anti-α-chain antibodies. It is unusual to obtain such 
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large numbers of positive cell lines in antibody hybridoma fusion. The α-chain of c-Met 
must be highly immunogenic and the hybridoma cell fusion must have been extremely 
successful. 21 hybridoma cells lines were selected for single cell cloning and 
monoclonal antibody production. Monoclonal antibodies were characterised by 
identifying their epitope binding region as well as their isotype subclasses (Table 3.4). 
All 21 monoclonal antibodies were IgG antibodies, with a majority of them being IgG1. 
As a preliminary screen, the functional effects of the antibodies were characterised by 
analysing their effects on ERK phosphorylation and cell scatter. As the antibodies were 
produced as tissue culture supernatants, the presence of FCS interfered with these 
analyses. The antibodies were also analysed for their ability to cause cell clustering. 
Finally, eleven monoclonal antibodies were selected for ascites production and antibody 
purification. These antibodies were characterised in their pure form again by Western 
blotting, immunofluorescence staining, functional assays (ERK phosphorylation and 
cell scatter) and for their ability to recognise native c-Met by flow cytometry (Table 
3.10). 
Our antibodies are the first anti-α-chain c-Met antibodies developed. We have shown 
that our purified monoclonal antibodies are able to detect endogenous human c-Met by 
Western blotting and immunofluorescence staining. This is extremely beneficial to the 
research field of c-Met because we have shown that our antibodies have higher affinity 
and specificity compared to the currently available commercial antibodies in both 
Western blotting and immunofluorescence staining. Presently, we are optimising the use 
of our monoclonal antibodies in immunohistochemistry for the diagnostic purposes of 
examining c-Met expression in human tumour samples. Mab 11.1 and 12.1 were the 
best antibodies for Western blotting as they demonstrated good affinity and high 
specificity towards c-Met. Despite other anti-α-chain antibodies having different 
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epitopes, nearly all the anti-α-chain antibodies share similar band profiles with Mab 
11.1 and 12.1, indicating that the protein bands observed between 40 kD and 70 kD 
genuinely represent the α-chain of c-Met. In addition, the absence of these bands in the 
T47D samples (low c-Met expressing cell line) further reinforces this hypothesis. No 
groups have specifically examined the expression of endogenous c-Met α-chain 
therefore there is no literature we could make reference to. There are many possibilities 
that could result in the varied molecular weight of c-Met α-chain. The α-chain is heavily 
glycosylated and differential glycosylation could lead to the varied molecular weight 
observed. The α-chain forms part of c-Met sema domain (Figure 1.1) which is an 
elliptical structure and could result in the α-chain running at a higher molecular weight 
on SDS-PAGE gels (Tolbert et al., 2007). There have also been various reports of 
truncated forms of c-Met (Deheuninck et al., 2008; Petrelli et al., 2006; Prat et al., 
1998) which might also led to the variations in the molecular weight of c-Met α-chain. 
There has not been much study on the truncated forms of c-Met and it seems that the 
lack of good biological tools has hindered our further understanding of c-Met. 
Presently, we have yet to characterise how our antibodies are able to function in 
immunoprecipitation and ELISA. Having antibodies that are well-characterised in 
various biochemical techniques would be highly advantageous. Our antibodies will be 
valuable tools for c-Met further studies. 
Our antibodies, in particular Mab 11.1 and 12.1, were shown to work well in detecting 
endogenous c-Met in immunofluorescence. This is an assumption based on comparisons 
with the immunofluorescence staining observed by AF276 antibody. A membrane 
marker will be an ideal control to ensure that the immunofluorescence staining was 
indeed localised to the cell membrane. However, because T47D cells are adherent cells 
and SNU-5 cells are suspension cells, it was difficult to select an appropriate membrane 
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marker to use in both cell types. In addition, our antibodies only work on 
methanol/acetone-fixed cells and not on paraformaldehyde-fixed cells. This makes the 
selection for an appropriate membrane marker harder. E-cadherin could be used as a 
marker for T47D cells and, since suspension cells would probably lose E-cadherin 
expression, carcinoembryonic antigen (CEA) could be used for SNU-5 cells. 
Alternatively, by designing siRNA against c-Met, expression of c-Met can be knock 
down in SNU-5 cells. This serves as a control to determine the specificity of our 
antibodies when compared to siRNA un-treated cells. Knock down of c-Met expression 
via siRNA could also be used as a control in other assays such as Western blotting and 
flow cytometry.  
The alignment of the human and mouse c-Met sequences indicate that epitope binding 
regions 5 and 6 share exact amino acid sequence. This indicating that the antibodies in 
these regions might cross react with the mouse c-Met. It is possible to raise antibodies 
against self protein as immune tolerance to low abundant antigen lies at the T helper cell 
level. The autoreactive B cells are readily stimulated by injection across species. The 
most dramatic example of this derives from Silver and Lane (1975) where it was 
demonstrated that autoantibodies to the liver-specific F antigen could not be raised by 
autoimmunisation but by cross strain immunisation. The resulting antibodies however 
cannot distinguish between the F antigen of different strains. This is because self 
tolerance to this antigen rests entirely in the T cell compartment (Silver and Lane, 
1975). Many other examples of this exist and closer to home, the extensive collection of 
murine monoclonal antibodies raised to human p53 that cross react with mouse p53 
might be mentioned.   
The epitope binding region of Mab 17.1 was the most interesting and unexpected as it 
recognises two binding regions (region 4 and 8) simultaneously. Although it is 
222 
 
 
 
theoretically not possible to obtain an antibody with two distinct paratopes, Monquet et 
al. (2010) reported the existence of polyreactive antibodies against HIV in humans. The 
genetic rearrangements of an antibody gene that occur when a naive B-cell differentiates 
into an antibody-producing cell would suggest that a hybridoma clone expressing 
polyreactive antibody is genetically unstable. This would explain the varied results of 
epitope binding analysis obtained from the second single-cell cloning of Mab 17.1. 
Colonies obtained from Mab 17.1 would continue to produce antibodies that recognise 
both regions. As the parental Mab 17.1 clone is unstable, some of these colonies might 
stabilise and produce antibodies recognising only one region. However, it is unclear 
why only antibodies that recognise region 4 was produced and not region 8. Mab 17.1, 
despite being able to bind to two epitopes, showed no significant inhibition/activation 
compared to the other antibodies in the functional assays tested. It is possible that 
binding to the two sites recognised by Mab 17.1 is not sufficient to block HGF from 
interacting with c-Met. 
There are various ways in which our antibodies might be able to block c-Met activation. 
Through epitope mapping, we were able to predict if the binding sites of our antibodies 
lie within the HGF-interacting region of c-Met, phosphotyrosine residues and 
glycosylated residues. No phosphorylation sites were predicted on c-Met alpha chain. 
Four residues (Asp45, Asp106, Asp149 and Asp202) were predicted to be glycosylated 
with N-acetylglucosamine (N-linked GlcNAc), however, epitope mapping indicate that 
the glycosylated residues do not lie in the region of our monoclonal antibodies epitopes 
(Figure 3.22). The inability of our antibodies to recognise native c-Met, which was 
developed using bacterially-expressed c-Met α-chain as an immunogen, was not due to 
the blockage by the sugar molecule. Antibody binding regions 4, 7, 9 and 10 were found 
to lie within the HGF-Met interacting region (Figure 3.24). Binding of these antibodies 
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(Mab 1, 2, 8, 7, 9, 14, 15, 18 and 19) to c-Met could therefore block c-Met interaction 
with HGF and this would be effective against tumours in which c-Met is abnormally 
activated by HGF. Our antibodies might also block c-Met dimerisation which would 
affect both wild-type c-Met and c-Met activating mutants as dimerisation is required for 
c-Met activation (Jeffers, 1999). Binding of our antibodies to c-Met might also lock c-
Met in an ‘inactive’ conformation thus preventing its interaction with HGF, or 
preventing c-Met dimerisation and activation. Alternatively, our antibodies could 
disrupt c-Met’s crosstalk with other cell surface molecules such as EGFR, α6β4 
integrin, plexins and CD44v6, thus affecting c-Met induced biological activity (Corso et 
al., 2005).  
The final aim of this project is to use the antibodies as therapeutic molecules in the 
treatment of human cancer. Since there is no clear understanding of how an antibody is 
able to efficiently recruit immune effector functions to destroy tumour cells, it is not 
possible to screen antibodies directly for this function. In vitro functional analysis of our 
antibodies is one of the best methods to identify antibodies that would exert their 
functional effects in vivo. We have chosen to test if our antibodies have an inhibitory 
effect on HGF-induced ERK phosphorylation and cell scatter. c-Met is known to be 
activated upon dimerisation. Due to the bivalent binding of an IgG antibody to its target 
antigen and based on several reports (Cioce et al., 1996; Michieli et al., 2004; Prat et 
al., 1998; Tolbert et al., 2007), we anticipated that some of our antibodies would be 
agonist towards c-Met activation. Although agonistic bivalent c-Met antibodies have 
little therapeutic use, we would know that these antibodies are eliciting their effects 
through c-Met binding. These antibodies can be used as bio-tools for further 
understanding of c-Met. Alternatively, these antibodies could also be engineered to be 
monovalent (scFv or Fab antibody fragments) for therapeutic purposes. An excellent 
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example is the anti-Met 5D5 antibody that was engineered to contain only a single Fab 
fragment is OA-5D5. OA-5D5 was shown to inhibit glioma growth in mouse models 
(Martens et al., 2006).  
To our surprise, some of our antibodies affected total ERK levels through an unknown 
pathway. This makes the analysis of the effects of our antibody on ERK 
phosphorylation difficult to interpret. Due to the subtle changes in ERK levels, it would 
be preferable to compare the changes in ERK levels/phosphorylation levels by 
quantifying the band intensity rather than by visual comparison. This can be done by 
densitometric scanning, or using the image analysis softwares such as Image J or 
Photoshop. We could also employ more sensitive assay such as the 
AlphaScreen®SureFire® p-ERK1/2(Thr202/Tyr204) from PerkinElmer to measure the 
phosphorylation of ERK. As ERK is central to many growth signalling pathways, minor 
changes in growth conditions will affect ERK levels/phosphorylation levels which, in 
turn, will affect antibody analysis. To overcome this problem, the analysis of the effect 
of our antibodies on ERK phosphorylation should be repeated more comprehensively. 
We could also analyse the functional effects of our antibodies through other signalling 
pathways such as AKT activation/phosphorylation. Analysing pathways downstream of 
c-Met may not be a good indicator of c-Met activation/inhibition because these 
pathways are usually shared by other tyrosine receptors/signal transduction pathways. 
Non-specific interactions of the antibodies or interactions of other inhibitors/activators 
might separately affect these downstream pathways and influence the analysis of the 
effects of our antibodies. Therefore, directly analysing the phosphorylation status of c-
Met by Western blotting will be the best method to determine c-Met 
activation/inhibition. However, this is presently not possible due to the poor affinity and 
specificity of current commercial anti-phospho-Met antibodies. Moravian 
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Biotechnology is presently developing anti-phospho-Met antibodies which were shown 
to have high affinity and specificity for phosphorylated c-Met in Western blotting. 
These anti-phospho-Met antibodies will be vital tools for c-Met analysis. Finally, the 
effects of our antibodies on ERK phosphorylation should be tested on other cells lines, 
such as SNU-5 and U-87MG cells, that have aberrant c-Met expression. This is because 
the biological activity induced by c-Met is dependent on the cell type and extracellular 
matrix, suggesting that different signalling pathways are activated in different cell lines 
to bring about the varied biological changes. HaCaT cells may not be the ideal cell line 
in which to study the effects of our antibodies on ERK phosphorylation as, in these 
cells, the major signal transduction pathway of c-Met activation may not be through 
ERK pathway. In addition, Christensen et al. (2003) demonstrated that the small 
molecule c-Met inhibitor PHA-665752 drastically inhibited c-Met activation in cells 
expressing high levels of c-Met, but had little effect on BxPC-3 cells which express 
moderate levels of c-Met. HaCaT cells used in our assay express lower levels of c-Met 
expression compared to SNU-5 and U-87MG cells and are not dependent on c-Met 
activation for survival. Therefore, similar to the BxPC-3 cells, inhibition of c-Met in 
HaCaT cells using our antibodies might have resulted in the subtle changes in ERK 
phosphorylation observed.  
Similarly to ERK phosphorylation, the effects of our antibodies on cell scatter were 
difficult to interpret. This was partly due to the inconsistent effects of varying batches of 
commercially-obtained HGF. In addition, each cell colony (in the same well) responded 
differently to the same treatment resulting in a variation of scatter response observed. 
Although the effects of the antibodies on cell scatter were analysed according to the 
majority effects, it is sometimes difficult to interpret the overall result. The varied 
response of the cell colonies could be due to the size of the colony where more cells 
226 
 
 
 
result in more complicated cell-to-cell communication among the colony. Presence of 
neighbouring cell colonies might also affect cell scatter as cell colonies can 
communicate with each other to grow closer together. Individually growing and treating 
a cell colony in a 96-well might be more ideal for analysing the effects of our antibodies 
on cell scatter.  
The results from flow cytometry provide the strongest and direct evidence that some of 
our antibodies bind and recognise native c-Met. These antibodies (especially Mab 2.1 
and 13.1) can be useful tools for the study of c-Met on the cell surface. It would also be 
tempting to further engineer and improve these antibodies for imaging of tumour cells 
in vivo. Interestingly, results from flow cytometry correlate with the ability of the cells 
to cause cell cluster; Mab 2.1, 8.1, 11.1, 12.1 and 13.1 were strongly positive for cell 
cluster and showed intense fluorescence staining in flow cytometry. These antibodies 
must be able to recognise native c-Met on the cell surface so as to cause cell cluster. 
This suggests that the result of cell cluster is real and could be used as a high-
throughput, quick and simple assay to screen for antibodies that bind to native protein 
on the cell surface.  
Interestingly, Mab 13.1, which showed very poor affinity and specificity to c-Met by 
Western blotting and immunofluorescence, was, along with Mab 2.1, produced the 
highest fluorescence staining determined by flow cytometry. Through the binding of 
Mab 2.1 or 13.1 to c-Met, these antibodies may be able to elicit a functional effect on c-
Met. It is interesting that the some antibodies affect ERK signalling but not cell scatter. 
This might be due to the binding of our antibodies to different epitopes on c-Met. Both 
Mab 2.1 and 13.1 could be partial antagonists of c-Met as Mab 2.1 causes ERK 
phosphorylation, but is able to partially inhibit cell scatter, while Mab 13.1 inhibits 
ERK phosphorylation and partially inhibit cell scatter. Partial inhibition of c-Met-
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induced biological activities using monoclonal anti-Met antibodies has also been 
described by Prat el al. (1998). The anti-Met antibody, DN-30, inhibits other c-Met-
induce biological activities, but not cell motility. In the same study, another monoclonal 
antibody (DO-24) developed from the same immunisation as DN-30, was a full agonist 
capable of eliciting full c-Met activity. From another study, it also demonstrated that 
more than three monoclonal antibodies are required to completely inhibit c-Met binding 
(Cao et al., (2001). The molecular mechanisms of c-Met activation by HGF are still 
unclear. This interaction is more complex than previously thought and from these 
antibodies studies, it is obvious that there are critical interaction sites that are 
responsible for eliciting various c-Met activities. It is possible that binding of our 
monoclonal antibodies to c-Met might interfere with c-Met conformation, thus affecting 
c-Met binding to downstream signalling molecules such as Gab1 and p85 (subunit of 
PI3K) and influencing the biological activity of the cell. As mentioned above, c-Met 
was demonstrated to cross talk with other receptors and cell surface molecules causing 
an amplification of downstream signals that led to cancer progression. Our antibodies 
could bind to c-Met, inhibit c-Met cross talk and shut down the signalling pathways 
responsible for abnormal growth.    
In contrast to Mab 2.1 and 13.1, Mab 11.1 and 12.1 demonstrated good affinity and high 
specificity towards c-Met in Western blotting and immunofluorescence staining, but 
only bound to native c-Met with intermediate affinity. The difference in the affinity of 
the antibodies to recognise native and denatured c-Met is likely due to the antibody’s 
epitope. Mab 2.1 and 13.1 epitope recognition is partially dependent upon secondary 
structure while for Mab 11.1 and 12.1 epitope can be denatured. Mab 2.1 and 13.1 are 
the most interesting antibodies as they have the most potential to be developed into 
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therapeutic antibodies while Mab 11.1 and 12.1 will be useful tools for c-Met 
expression studies that require the detection of antigen in Western blot methods. 
There is high potential for developing our panel of anti-α-chain antibodies for clinical 
purposes. However, at present, more work is required to further characterise our anti-α-
chain antibodies. As every antibody works differently, an antibody concentration will 
have a significant effect of the antibody’s ability to inhibit/activate c-Met. More work is 
thus required to optimise the antibody concentration in the functional assays for each 
antibody. We can also characterise the effects of our antibodies on other c-Met-induced 
functional assays such as Matrigel gel invasion assays and proliferation assays. As 
shown by Cao et al. (2001) and van der Horst et al. (2009), combinations of monoclonal 
antibodies demonstrated the best inhibition of c-Met interaction with HGF. It would be 
interesting to test the different combinations of our antibodies to determine if c-Met 
inhibition could be improved. We might also need to develop scFv or Fab fragments of 
our antibodies for therapeutic purposes. The next step would to bring the antibodies into 
xenograft models and to test if the antibodies are able to function in vivo. Humanising 
potential antibodies for therapeutic/diagnostic purposes and testing these engineered 
antibodies again for their functional activity will be the next step of developing 
therapeutic antibodies. Our humanised anti-Met antibodies will also be tested for 
effector functions such as binding abilities to various FcγR to mediate ADCC, binding 
abilities to C1q component to induce CDC or ability of antibodies to cause cell death in 
chromium pre-loaded cells. 
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c-Met and HGF relevance in human cancer. 
Appendix 1  
Adapted from adapted from Birchmeier et al., 2003. 
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Full length alignment of human (P08581) and mouse (P16056) c-Met. 
Appendix 2  
 
 
Human           MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAETPIQNVILHEH 60 
Mouse           MKAPTVLAPGILVLLLSLVQRSHGECKEALVKSEMNVNMKYQLPNFTAETPIQNVVLHGH 60 
                ****:**********::*****:*******.************************:** * 
 
Human           HIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNINMAL 120 
Mouse           HIYLGATNYIYVLNDKDLQKVSEFKTGPVLEHPDCLPCRDCSSKANSSGGVWKDNINMAL 120 
                **:***********::*****:*:***********:**:******* ************* 
 
Human           VVDTYYDDQLISCGSVNRGTCQRHVFPHNHTADIQSEVHCIFSPQIEEPSQCPDCVVSAL 180 
Mouse           LVDTYYDDQLISCGSVNRGTCQRHVLPPDNSADIQSEVHCMFSPE-EESGQCPDCVVSAL 179 
                :************************:* :::*********:***: **..********** 
 
Human           GAKVLSSVKDRFINFFVGNTINSSYFPDHPLHSISVRRLKETKDGFMFLTDQSYIDVLPE 240 
Mouse           GAKVLLSEKDRFINFFVGNTINSSYPPGYSLHSISVRRLKETQDGFKFLTDQSYIDVLPE 239 
                ***** * ***************** *.:.************:*** ************* 
 
Human           FRDSYPIKYVHAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMPLECIL 300 
Mouse           FLDSYPIKYIHAFESNHFIYFLTVQKETLDAQTFHTRIIRFCSVDSGLHSYMEMPLECIL 299 
                * *******:******:********:*****************::*************** 
 
Human           TEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSKPDSAEPMDRS 360 
Mouse           TEKRRKRSTREEVFNILQAAYVSKPGANLAKQIGASPSDDILFGVFAQSKPDSAEPVNRS 359 
                ****:****::****************:**:***** .******************::** 
 
Human           AMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNSSGCEARRDEYRTEF 420 
Mouse           AVCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNSSGCEARSDEYRTEF 419 
                *:************************************************** ******* 
 
Human           TTALQRVDLFMGQFSEVLLTSISTFIKGDLTIANLGTSEGRFMQVVVSRSGPSTPHVNFL 480 
Mouse           TTALQRVDLFMGRLNQVLLTSISTFIKGDLTIANLGTSEGRFMQVVLSRTAHLTPHVNFL 479 
                ************::.:******************************:**:.  ******* 
 
Human           LDSHPVSPEVIVEHTLNQNGYTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGW 540 
Mouse           LDSHPVSPEVIVEHPSNQNGYTLVVTGKKITKIPLNGLGCGHFQSCSQCLSAPYFIQCGW 539 
                **************. ********:*************** ************ *:**** 
 
Human           CHDKCVRSEECLSGTWTQQICLPAIYKVFPNSAPLEGGTRLTICGWDFGFRRNNKFDLKK 600 
Mouse           CHNQCVRFDECPSGTWTQEICLPAVYKVFPTSAPLEGGTVLTICGWDFGFRKNNKFDLRK 599 
                **::*** :** ******:*****:*****.******** ***********:******:* 
 
Human           TRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYSTFSYVDPVIT 660 
Mouse           TKVLLGNESCTLTLSESTTNTLKCTVGPAMSEHFNVSVIISNSRETTQYSAFSYVDPVIT 659 
                *:**************** ***********.:***:*:****.: *****:********* 
 
Human           SISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLKSVSNSILECYTPAQTISTEF 720 
Mouse           SISPRYGPQAGGTLLTLTGKYLNSGNSRHISIGGKTCTLKSVSDSILECYTPAQTTSDEF 719 
                ****:*** **********:***********************:*********** * ** 
 
Human           AVKLKIDLANRETSIFSYREDPIVYEIHPTKSFISGGSTITGVGKNLNSVSVPRMVINVH 780 
Mouse           PVKLKIDLANRETSSFSYREDPVVYEIHPTKSFISGGSTITGIGKTLNSVSLPKLVIDVH 779 
                .************* *******:*******************:**.*****:*::**:** 
 
Human           EAGRNFTVACQHRSNSEIICCTTPSLQQLNLQLPLKTKAFFMLDGILSKYFDLIYVHNPV 840 
Mouse           EVGVNYTVACQHRSNSEIICCTTPSLKQLGLQLPLKTKAFFLLDGILSKHFDLTYVHNPV 839 
                *.* *:********************:**.***********:*******:*** ****** 
 
Human           FKPFEKPVMISMGNENVLEIKGNDIDPEAVKGEVLKVGNKSCENIHLHSEAVLCTVPNDL 900 
Mouse           FEPFEKPVMISMGNENVVEIKGNNIDPEAVKGEVLKVGNQSCESLHWHSGAVLCTVPSDL 899 
                *:***************:*****:***************:***.:* ** *******.** 
 
Human           LKLNSELNIEWKQAISSTVLGKVIVQPDQNFTGLIAGVVSISTALLLLLGFFLWLKKRKQ 960 
Mouse           LKLNSELNIEWKQAVSSTVLGKVIVQPDQNFAGLIIGAVSISVVVLLLSGLFLWMRKRK- 958 
                **************:****************:*** *.****..:*** *:***::***  
 
Human           IKDLGSELVRYDARVHTPHLDRLVSARSVSPTTEMVSNESVDYRATFPEDQFPNSSQNGS 1020 
Mouse           HKDLGSELVRYDARVHTPHLDRLVSARSVSPTTEMVSNESVDYRATFPEDQFPNSSQNGA 1018 
                 **********************************************************: 
 
Human           CRQVQYPLTDMSPILTSGDSDISSPLLQNTVHIDLSALNPELVQAVQHVVIGPSSLIVHF 1080 
Mouse           CRQVQYPLTDLSPILTSGDSDISSPLLQNTVHIDLSALNPELVQAVQHVVIGPSSLIVHF 1078 
                **********:************************************************* 
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Human           NEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVL 1140 
Mouse           NEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIEEVSQFLTEGIIMKDFSHPNVL 1138 
                ************************************** ********************* 
 
Human           SLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKF 1200 
Mouse           SLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKF 1198 
                ************************************************************ 
 
Human           VHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKF 1260 
Mouse           VHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKF 1258 
                ************************************************************ 
 
Human           TTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCW 1320 
Mouse           TTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITIYLLQGRRLLQPEYCPDALYEVMLKCW 1318 
                *********************************:****************.********* 
 
Human           HPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNATYVNVKCVAPYPSLLSSEDNADDEVD 1380 
Mouse           HPKAEMRPSFSELVSRISSIFSTFIGEHYVHVNATYVNVKCVAPYPSLLPSQDNIDGEGN 1378 
                ******************:******************************.*:** *.* : 
 
Human           TRPASFWETS 1390 
Mouse           T--------- 1379 
                *          
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Mab (diluted 1:5) effects on ERK phosphorylation in HaCaT cells. 
Appendix 3  
 
 
HaCaT cells were treated with anti-α-chain c-Met antibodies. HaCaT cells were grown to 90% confluency before serum starvation. Monoclonal antibody cell supernatants 
were diluted 1:5 in serum-free media and incubated with HaCaT cells for an hour. 10 ng/ml of HGF was added to the cells for 30 mins before harvesting in hot sample buffer. 
10 μg of total cell lysate was analysed in each sample by SDS-PAGE. Western blotting was performed using anti-phospho-ERK, anti-ERK and PC10 antibodies to detect 
phosphorylated ERK, total ERK and PCNA levels respectively. Activation of c-Met was determined by phosphorylation of ERK. PCNA levels were used as loading control. 
All controls were serum-starved, except for untreated (UT) samples. Controls with media containing 0% and 5% FCS were performed to examine the effect of FCS on ERK 
phosphorylation. Antibody against HGF (5 μg/ml) was used as a control to block HGF from binding to c-Met. pERK: Phosphorylated ERK. Anti-HGF: Antibody against 
HGF. 
 
 
